Alternative splicing as a regulatory mechanism of the NLRP3 inflammasome by Hoß, Florian
  
Alternative splicing as a regulatory 
mechanism of the NLRP3 inflammasome 
 
 
 
 
 
 
Dissertation 
 
zur  
Erlangung des Doktorgrades (Dr. rer. nat.) 
der 
Mathematisch-Naturwissenschaftlichen Fakultät 
der 
Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
 
 
 
 
vorgelegt von 
Florian Hoß 
aus 
Neuwied 
 
 
Bonn, September 2018 
   
  
Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät 
der Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Gutachter: Prof. Dr. med Eicke Latz 
2. Gutachter: Prof. Dr. med. Joachim L. Schultze 
 
Tag der Promotion: 02.04.2019 
Erscheinungsjahr: 2019 
 
Table of Contents 
1 
Table of Contents 
Table of Contents ..................................................................................... 1	
1.	 Zusammenfassung ............................................................................ 4	
2.	 Summary ............................................................................................. 5	
3.	 Introduction ........................................................................................ 6	
3.1.	 The immune system .............................................................................. 6	
3.1.1.	 The innate IS ..................................................................................... 7	
3.1.2.	 Pattern recognition receptors ............................................................ 8	
3.1.3.	 Inflammasomes ............................................................................... 10	
3.1.4.	 Structure and assembly of the inflammasome ................................ 11	
3.1.5.	 Inflammatory caspases and cell death ............................................ 13	
3.1.6.	 Inflammasome Regulation .............................................................. 14	
3.1.7.	 NLRP3 ............................................................................................ 15	
3.1.8.	 NLRP3-associated diseases ........................................................... 19	
3.2.	 The leucine-rich repeat motif ............................................................. 21	
3.3.	 Splicing ................................................................................................. 22	
3.3.1.	 The splice reaction .......................................................................... 23	
3.3.2.	 The spliceosome and splice regulation ........................................... 23	
3.3.3.	 Alternative splicing .......................................................................... 25	
3.3.4.	 Splicing in immunity ........................................................................ 27	
3.4.	 Scope of this study ............................................................................. 28	
4.	 Materials and Methods .................................................................... 29	
4.1.	 Materials ............................................................................................... 29	
4.1.1.	 Devices ........................................................................................... 29	
4.1.2.	 Disposables .................................................................................... 30	
4.1.3.	 Reagents and Kits ........................................................................... 31	
4.1.4.	 Buffers and media ........................................................................... 35	
4.1.5.	 Antbodies ........................................................................................ 35	
4.1.6.	 Plasmids ......................................................................................... 36	
4.1.7.	 Cell lines ......................................................................................... 37	
4.1.8.	 Oligonucleotides ............................................................................. 38	
4.1.9.	 Software .......................................................................................... 39	
4.2.	 Methods ................................................................................................ 41	
Table of Contents 
 2 
4.2.1.	 Molecular Biology ............................................................................ 41	
4.2.2.	 Cell culture ...................................................................................... 49	
4.2.3.	 Microscopy and Flowcytometry assays .......................................... 54	
4.2.4.	 Biochemical Assays: ....................................................................... 55	
4.2.5.	 In silico analysis .............................................................................. 57	
4.2.6.	 Statistics .......................................................................................... 58	
4.2.7.	 Ethics .............................................................................................. 59	
5.	 Results .............................................................................................. 60	
5.1.	 The LRR domain of NLRs exhibits a highly conserved 
exon organization ..................................................................................... 60	
5.2.	 The splicing landscape of human NLRP3 ......................................... 63	
5.3.	 NLRP3 ∆ exon 5 is inactive ................................................................. 69	
5.3.1.	 NLRP3 ∆ exon 5 is not able to induce ASC speck 
formation in Flp-In 293 reporter cells ........................................................ 69	
5.3.2.	 NLRP3 ∆ exon 5 does not induce caspase-1 maturation 
and IL-1β secretion in macrophages ........................................................ 73	
5.3.3.	 Morpholinos can be used to alter splice patterns in 
primary human monocyte-derived macrophages ..................................... 75	
5.3.4.	 NLRP3 ∆ exon 5 has no inhibitory function on the NLRP3 
full-length variant ...................................................................................... 77	
5.4.	 NLRP3 splicing is regulated on a single-cell level ........................... 80	
5.5.	 NLRP3 ∆ exon 5 does not interact with NEK7 .................................. 82	
5.6.	 NLRP3 ∆ exon 5 regains activity after prolonged priming .............. 87	
6.	 Discussion ........................................................................................ 89	
6.1.	 LRR domains of the NLR family have a conserved multi-
exon organization suitable for AS ........................................................... 90	
6.2.	 Detection of AS by NGS ...................................................................... 92	
6.3.	 NLRP3 splice ratios are non-variable ................................................ 93	
6.4.	 NLRP3 ∆ exon 5 remains inactive after standard 
activation ................................................................................................... 94	
6.5.	 NLRP3 exon 5 is critical for the interaction with NEK7 ................... 95	
6.6.	 Single-cell gene expression of NLRP3 splice variants .................... 97	
6.7.	 Stochastic distribution of NLRP3 activity in human 
macrophages ............................................................................................. 98	
6.8.	 Delayed inflammasome assembly by NLRP3 ∆ exon 5 .................... 99	
6.9.	 Further implications of NLRP3 splicing .......................................... 100	
Table of Contents 
3 
6.10.	Conclusion ......................................................................................... 101	
7.	 List of abbreviations ...................................................................... 103	
8.	 List of figures ................................................................................. 106	
9.	 List of Tables .................................................................................. 107	
10.	 Bibliography ................................................................................. 108	
11.	 Acknowledgements ..................................................................... 127	
12.	 Appendix ....................................................................................... 128	
12.1.	NLR LRR alignments ......................................................................... 128	
12.2.	Mapping statistics of RNAseq reads ............................................... 134	
12.3.	Sashimi plots ..................................................................................... 135	
12.4.	Protein sequences of NLRP3 variants ............................................. 136	
12.4.1.	 NLRP3 full-length .......................................................................... 136	
12.4.2.	 NLRP3 ∆ exon 5 ........................................................................... 136	
12.4.3.	 NLRP3 2x exon 6 .......................................................................... 136	
12.4.4.	 NLRP3 exon 5 surface to exon 6 .................................................. 137	
12.4.5.	 NLRP3 2x exon 6 surface rescue ................................................. 137	
12.5.	Physico-chemical properties of NLRP3 isoforms and 
artificial variants ..................................................................................... 138	
Zusammenfassung 
 4 
1. Zusammenfassung 
Wesentlicher Bestandteil des angeborene Immunsystems sind vererbbare 
Rezeptoren, die pathogene Muster oder Veränderungen der Zell-Homöostase 
erkennen. Nach Aktivierung durch Pathogene oder sterile Gefahrensignale können 
einige intrazelluläre Rezeptoren des angeborenen Immunsystems (z. B. NLRP3) 
multimere Signalübertragungsplattformen, sogenannte Inflammasome, bilden. Diese 
führen zur Aktivierung von Caspase-1, die sowohl einen pyroptotischen Zelltod, als 
auch die Aktivierung der Zytokine IL-1β und IL-18 induziert. NLRP3 spielt eine 
zentrale Rolle in kardiovaskulären, neurodegenerativen und entzündlichen 
Erkrankungen. 
Ziel dieser Studie war es, zu erörtern, ob alternatives Splicing (AS) als regulatorische 
Instanz für die Aktivierung des NLRP3-Inflammasoms dient, ähnlich wie es für 
andere Immunrezeptoren oder pflanzliche Resistenzgene gezeigt wurde. Ich konnte 
zeigen, dass die NLRP3 LRR-Domäne von repetitiven, stark konservierten Exonen 
kodiert wird und dies eine Eigenschaft ist, die auch weitere LRR-kodierende 
Genfamilien besitzen. Diese strikte Modularität der LRR-Exone erlaubt AS, ohne 
strukturelle Schäden zu induzieren. Tatsächlich konnte ich AS mehrerer NOD-like 
Rezeptoren nachweisen, am prominentesten in NLRP3. Der häufigsten humanen 
alternativen NLRP3 Isoform fehlt Exon 5. In murinem NLRP3 konnte keine 
alternative Variante detektiert werden.  
Mit Hilfe verschiedener Modellsysteme und Testmethoden konnte ich zeigen, dass 
NLRP3 ∆ Exon 5 inert gegenüber gängigen Aktivatoren ist. Des Weiteren konnte ich 
aufzeigen, dass die Regulation der NLRP3 Isoformen auf Einzelzellebene 
stochastisch erfolgt. Die mechanistische Begründung der Inaktivität von NLRP3 ∆ 
Exon 5 liegt im Verlust der Interaktionsfähigkeit mit NEK7. Unerwarteterweise konnte 
die Aktivierbarkeit von NLRP3 ∆ Exon 5 durch eine Vorbehandlung von mehr als 10 
Stunden mit einem entzündungsfördernden Signal wiederhergestellt werden. In 
Zusammenhang mit der stochastischen Prävalenz der NLRP3 Isoformen ergibt sich 
dadurch eine Untergruppe von Zellen, die in einer ersten Welle der NLRP3-
Aktivierung nicht pyroptotisch wird und zu einem späteren Zeitpunkt unterstützend 
zum Entzündungsgeschehen beitragen kann. 
Zusammengefasst zeigen die hier dargelegten Daten eine noch nicht beschriebene 
Art der Regulation des NLRP3-Inflammasoms durch alternatives Splicing und 
erlauben Einblicke in speziesspezifische regulatorische Mechanismen mit 
therapeutischem Potenzial, die nicht in Mausmodellen gefunden werden könnten. 
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2. Summary 
The innate immune system relies on germ-line encoded pattern recognition receptors 
and is critically involved in the early sensing of pathogens and disturbances of cell 
homeostasis. Upon activation by pathogenic or sterile danger signals, several 
cytosolic receptors of the innate immune system (e.g. NLRP3) can recruit multi-
protein signaling platforms, so called inflammasomes. Inflammasome formation leads 
to the activation of caspase-1, causing pyroptosis as well as maturation and release 
of IL-1β and IL-18. NLRP3 is critically involved in several cardiovascular, 
neurodegenerative and inflammatory diseases.  
This study aimed to decipher whether alternative splicing (AS) might act as a 
regulator of NLRP3 inflammasome activation, similarly to what is described for other 
vertebrate immune receptors and plant R-proteins. I could show that the LRR of 
NLRP3 is encoded by multiple repetitive and highly conserved exons, a feature 
which is shared by other LRR encoding genes. This strict exonic modularity of LRR 
domains of several human gene families serves as a prerequisite for non-destructive 
AS. Indeed, I could show AS of the LRR of several NOD-like receptors, most 
prominently in NLRP3. Human NLRP3, but not mouse NLRP3, could be detected as 
two major isoforms: The fully active NLRP3 full-length variant and a variant lacking 
exon 5. By use of several different model systems and readouts, NLRP3 ∆ exon 5 
could be shown to be inert to common NLRP3 activators. Furthermore, I could show 
that alternative splicing is stochastically regulated on a single-cell level. 
Mechanistically, I could provide evidence that NLRP3 ∆ exon 5 is inactive due to the 
absence of a necessary interaction surface for NEK7 binding, required for NLRP3 
activation. Surprisingly, a prolonged priming for over 10 h rendered NLRP3 ∆ exon 5 
activatable. In combination with the stochastic isoform expression, this allows for a 
backup pool of cells, which do not become pyroptotic in the first round of NLRP3 
inflammasome activation, but rather enable a sustained inflammatory response. 
The data presented here provide evidence for a not yet described regulatory role of 
AS in NLRP3 inflammasome activation through differential utilization of highly 
conserved LRR modules. Moreover, the species differences described here might 
hold therapeutic potential that could not have been revealed in mouse models. 
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3. Introduction 
3.1. The immune system 
While the historic roots of modern medicine reach back several thousand years, 
immunology, the science of how an organism defeats infections, is relatively young. 
Although mankind always invented treatments against diseases, some of the biggest 
breakthroughs were based on immunological findings. At the end of the 18th century, 
Edward Jenner used cowpox to successfully vaccinate against smallpox. In the 19th 
century, Robert Koch proved microorganisms to be the cause of infectious diseases, 
and Pasteur and others extended the repertoire of available vaccinations. At the 
same time, two key findings already heralded the separation of the immune system 
(IS) into two branches, the adaptive and the innate IS: Kitasato, Ehrlich and von 
Behring discovered antibodies as specific circulating antitoxins, while Metchnikoff 
described macrophages as cells able to engulf and digest microbes. Since then, our 
knowledge of the IS has increased enormously and immunology has evolved into a 
flourishing field of research. 
The first line of defense is provided by epithelial and mucosal tissues, which prevent 
the entry of pathogens and harmful substances. Below that layer, different cell types 
of the innate and adaptive IS are located to recognize and fight invading pathogens. 
Besides, specialized immune cells, located in other organs, can be recruited to the 
site of infection, and different soluble factors, such as antibodies or the complement 
system, contribute to clearance of the infection and recovery to homeostasis. 
Simplistically, the innate IS constitutes a rather unspecific, but readily available task 
force, while the adaptive IS is composed of specialized immune cells which need to 
be educated before activation.  
The major cell types of the innate IS are macrophages, monocytes, dendritic cells 
(DCs), granulocytes and mast cells, which are all derived from the myeloid linage, as 
well as natural killer cells derived from the lymphoid linage. The adaptive IS consists 
predominantly of T- and B-lymphocytes, which are selected for their highly specific 
antigen receptors and are able to either specifically kill infected cells or secrete highly 
specific antibodies against pathogens, respectively. Moreover, they can provide a 
long-lasting memory against pathogens after a first encounter, a mechanism utilized 
by vaccinations. The huge variety of the receptors of the adaptive IS is achieved via 
a complex gene-rearrangement process 1. The two branches of the IS are highly 
dependent on each other. Mostly myeloid cells engulf and digest pathogens and 
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present the derived pathogen-specific peptides to T cells in order to educate them. 
Depending on an either pro- or anti-inflammatory environment so called T-helper 
cells can afterwards license B-lymphocytes for antibody production or cytotoxic T-
killer cells 1. 
The IS of higher vertebrates is a complex, non-spatial defined organ, which is 
distributed all over the body and does not act independently of other organs and 
tissues. Immune cells clear infections, remove harmful substances, play a role in 
wound healing and detect malignant tissue aberrations 2, but their function is fine-
tuned by a pleiotropy of positive and negative signals from other non-immune  
tissues 3. 
 
3.1.1. The innate IS 
Cells of the innate IS are often the first to detect a threat and to initiate an immune 
response. Tissue-resident innate cells such as macrophages, DCs or mast cells are 
enriched at likely sites of infection and upon activation, recruit further cells by 
secreting cytokines and chemokines. The first wave of recruited cells consists of 
neutrophils and monocytes, which support the tissue-resident cells in phagocytosis of 
pathogens, followed by the release of antimicrobial peptides, proteases and reactive 
oxygen species. Professional antigen-presenting cells such as DCs, provide co-
stimulatory interactions and secrete cytokines to induce a specific adaptive immune 
response. Following the immune response, cells of the IS are also responsible for the 
induction of tissue repair and re-establishment of homeostasis 1.  
Although eosinophils and basophils have been phenotypically described for a long 
time, relatively little is known about their exact functions except for their role in the 
defense against multicellular pathogens 4. Over the last years, it became evident that 
even platelets, which were previously only known for their role in coagulation, play a 
role in innate immunity 5. 
Beside the cellular components, the innate IS consists of secreted factors known as 
acute phase proteins. These include C-reactive protein and complement factors, 
which work as opsonins and lytic agents, ferritin and haptoglobin, which inhibit 
bacterial iron supply, and coagulation factors, which lead to the trapping of 
pathogens within blood clots 4,6. 
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3.1.2. Pattern recognition receptors 
Characteristically, innate immune cells, but also some non-immune cells express so-
called pattern recognition receptors (PRRs), which can be activated by pathogen-
associated molecular patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs) 7–9. In context of the discovered interplay between metabolism and 
immunity a new class of patterns was suggested to be added to the group of PRR 
activators, so-called homeostasis-altering molecular processes (HAMPs) 10. 
In contrast to the receptors of the adaptive IS, PRRs are typically germline-encoded 
and their specificity cannot be altered by genomic reshuffling. Therefore, they can 
only detect conserved patterns 11. To maximize their effectiveness PRRs mostly 
detect highly conserved pathogenic structures, which are very often integral to the 
pathogen’s survival, replication or infectivity 11 (Figure 3-1). 
PRRs can be subdivided into several sub-classes, of which the following represent 
the most prominent ones: Toll-like receptors (TLRs), retinoic acid inducible gene 1 
(RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs), nucleotide 
oligomerization domain (NOD)-like receptors (NLRs) and N-terminal pyrin domain 
(PYD) C-terminal DNA-binding hematopoietic interferon-inducible nuclear protein 
(HIN) domain containing (PYHIN) family of receptors. 
Vertebrate TLRs evolved to recognize mostly cell wall components and nucleic acids. 
Commonly used TLR agonists include Lipopolysaccharide (LPS) (TLR4), the 
triacylated lipopeptide Pam3CSK4 (TLR1/2) and the imidazoquinoline derivative 
resiquimod (R848, TLR7) 7. TLRs are located either on the cell surface or within 
endosomal compartments, where they form either homo- or heterodimers. Upon 
activation, they can either induce the secretion of interferons via the Toll/ IL-1R 
homologous domain-containing adapter-inducing interferon-β (TRIF)/ tumor necrosis 
factor (TNF) receptor-associated factor (TRAF) pathway or they signal via the 
myeloid differentiation primary-response protein 88 (MyD88)/ IL-1R-associated 
kinase 4 (IRAK4) complex, which leads to nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-kB) activation and the production of pro-inflammatory 
cytokines. Within the class of TLRs, TLR4 is unique, as it is able to induce both 
pathways 7,12. 
The cytosolic RLRs induce a general anti-viral state of the cell and the production of 
type-I interferon upon sensing viral double-stranded (ds) RNA 13. RIG-I, the 
namesake of this family, seems to mainly recognize the 5’triphospate signature of 
dsRNA 14.  
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CLRs are well known for their role in in anti-fungal immunity. However, they might 
also contribute to the defense of parasites, bacteria and viruses. Dectin-1, Mincle, 
mannose-receptor and DC-SIGN represent prominent members of the CLR family. 
Upon activation, they induce an antimicrobial response, pro- or anti-inflammatory 
cytokines and phagocytosis 4,15.  
 
Figure 3-1 Pattern recognition receptors of the innate immune system 
TLRs located on the cell surface mostly recognize components of bacterial cell walls and other directly 
extracellularly available microbial structures. Endosomal TLRs sense nucleic acids and molecules, 
which are only available after uptake and digestion. TLRs signal via MyD88 and TRIF to induce the NF-
κB or IRF-dependent transcription of pro-inflammatory cytokines and type I IFNs. RIG-I and MDA5 act 
as cytosolic nucleic acid sensors preferentially detecting RNA, while cGAS/STING is the default 
cytosolic DNA sensor, inducing a potent type-I IFN response. C-type lectin receptors bind to 
carbohydrates and are predominantly involved in anti-fungal immune responses. AIM2, NLRP3 and 
NLRC4 are all capable of inducing inflammasome formation. Key events in inflammasome activation are 
ASC speck formation, caspase-1 self-activation and IL-1β maturation. 
AP1: activator protein 1; AIM2: absent in melanoma 2; ASC: apoptosis-associated speck-like protein 
containing a caspase activation and recruitment domain; cGAS: cyclic GMP-AMP synthase; DC-SIGN: 
Dendritic cell-specific ICAM-grabbing non-integrin; IL: Interleukin; IRF: interferon regulatory factor; LPS: 
lipopolysaccharide; MAPK: mitogen-activated protein kinase; MAVS: mitochondrial antiviral signaling 
protein; MDA5: melanoma differentiation antigen 5; MyD88: myeloid differentiation primary-response 
protein 88; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NLRC: nucleotide-
binding oligomerization domain-containing protein with a caspase recruitment domain; NLRP: 
nucleotide-binding oligomerization domain -, leucine-rich repeat-, pyrin domain- containing; Pro-infl: pro-
inflammatory; RIG-I: retinoic acid inducible gene 1; STING: stimulator of interferon genes; TLR: Toll-Like 
receptor; TRIF: TIR domain-containing adaptor protein inducing IFN. 
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NLRs are cytosolic PRRs, which are characterized by their NOD and their leucine-
rich repeats (LRRs). Apart from the NLRs able to induce inflammasome formation 
(which I will describe in more detail below), NLRs can play multiple roles. NOD-1 and 
NOD-2 are able to activate the NF-kB and mitogen-activated protein kinase (MAPK) 
pathways similar to TLRs 16 and NLR family caspase activation and recruitment 
domain (CARD) containing 5 (NLRC5) and class II major histocompatibility complex 
(MHC) transactivator (CIITA) act as transcriptional regulators of the MHC class II 
complex 17. Absent in melanoma 2 (AIM2) and interferon gamma inducible protein 16 
(IFI-16), the two members of the PYHIN family of receptors, sense cytosolic DNA 
and were described to induce inflammasomes similar to NLRs 18. 
The most important sensor of cytosolic DNA, cyclic GMP-AMP (cGAMP) synthase 
(cGAS), is not a member of any of these subfamilies. Upon activation, cGAS 
produces the second messenger cGAMP, which triggers stimulator of interferon 
genes (STING) to induce an interferon response 19. 
 
3.1.3. Inflammasomes 
Inflammasomes are multimolecular signaling platforms that promote the cleavage of 
pro-caspase-1, and the maturation of the pro-inflammatory cytokines interleukin 
(IL)-1β and IL-18 in response to a range of danger signals derived from either 
pathogens or sterile cell damage 20. The IL-1 family cytokines are potent 
pro-inflammatory mediators implicated in numerous metabolic and autoimmune 
diseases.  
The inflammasome complex was discovered and named in 2002 21. However, there 
is not just one inflammasome, but several different receptors have been proposed to 
induce the assembly of an inflammasome complex. The most prominent 
inflammasome receptors include NLR family PYD containing 1 (NLRP1), NLRP3, 
NLRC4, AIM2 and Pyrin 22. NLRP1B recognizes anthrax lethal toxin, NLRP3 a huge 
variety of DAMPS and PAMPs, NLRC4 associates with different NLR family 
apoptosis inhibitory proteins (NAIPs) and detects components of the bacterial type-3 
secretion system and flagellin, AIM2 recognizes cytosolic DNA and Pyrin detects 
toxin-induced modifications of Rho GTPases 23. While most inflammasome 
components are conserved between mice and humans, the function of human 
NLRP1 is not as clear and humans only express one NAIP. Beside these sensors, 
others have been reported to induce inflammasome formation. Yet, the exact 
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pathways for RIG-I, IFI-16, NLRP6, NLRP7 and NLRP12 are controversial or not 
well-defined 24. 
Inflammasome assembly is organized in a hierarchy and requires, in most cases, a 
sensor protein, an adapter protein, and an effector protein 20,25. The activated 
receptor recruits the adaptor apoptosis associated speck-like protein containing a 
CARD (ASC), which oligomerizes and mediates the interaction with the effector 
caspase-1. Consequently, pro-caspase-1 undergoes auto-catalytic maturation. The 
active hetero-tetramer of caspase-1 cleaves pro-IL-1β and pro-IL-18 and induces the 
release of their mature forms, which exert potent pro-inflammatory effects 20,25,26. 
Furthermore, the activation of caspase-1 results in an inflammatory type of cell death 
termed pyroptosis, which requires gasdermin D (GSDMD) cleavage 27,28. Although 
the different inflammasome sensor proteins enable a response to a diverse spectrum 
of DAMPs and PAMPs, the classical inflammasome pathways converge already on 
the level of ASC 29. 
 
3.1.4. Structure and assembly of the inflammasome 
The central adapter of inflammasome assembly is ASC. It is composed of an 
N-terminal PYD and a C-terminal CARD, connected by an unstructured linker region. 
Each of these two domains promotes homotypic interactions and links the PYD of the 
receptor to the CARD of the effector caspase-1 30. However, NLRC4 constitutes an 
exception to the rule. It can either directly interact with pro-caspase-1 via its own 
CARD or recruit pro-caspase-1 via the adapter ASC 20,31. 
PYDs and CARDs both belong to the death-domain superfamily, one of the largest 
protein domain families. Death-domain family members participate in cell death and 
inflammation and characteristically form homotypic interactions. These interactions 
are typically not restricted to dimers, but rather give rise to oligomeric signaling 
platforms 32. Although the sequence similarities between death-domain family 
members are limited, ASC-PYD, AIM2-PYD, NLRP3-PYD and others were shown to 
fold into a classical six helix-bundle 33–39. 
Upon activation, the inflammasome receptor molecule either undergoes 
conformational changes enabling oligomeric self-interaction (e.g. NLRC4) 40 or 
several receptor molecules assemble in close proximity by binding to a common 
ligand (e.g. AIM2) 41. Both mechanisms lead to DD homo-interactions of several 
receptors and a oligomeric PYD cluster acts as a seed to promote ASC-PYD filament 
formation 41 (Figure 3-2 A). Under homeostatic conditions, a high energy barrier 
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keeps ASC in a soluble form and prevents spontaneous oligomerization. The 
preformed seed recruits ASC and lowers the threshold for ASC polymerization by a 
prion-like propagation of conformational changes 42. This process leads to the 
assembly of ASC PYDs into a hollow filament with a right-handed rotation, an inner 
diameter of 20 Å and an outer diameter of 90 Å 41,43. Since PYD and CARD of ASC 
are orientated in a back-to-back orientation and are stabilized by the linker region, 
they are structurally independent from each other and the CARD does not influence 
PYD filament formation 4443. Instead, the CARDs are located on the outside of the 
filaments and recruit pro-caspase-1 43,45. Similar to the PYDs, CARDs can assemble 
 
Figure 3-2 Inflammasome assembly 
A Upon activation, NLRP3 (green) recruits ASC via its PYD. The ASC PYDs (blue) polymerize into 
filaments with their corresponding CARDs (red) to the outside. ASC-CARDs can cluster and form seeds 
for caspase-1 (yellow) polymerization. The caspase-1 filaments act as a platform for caspase-1 self-
maturation. B Multiple ASC filaments can be cross-linked via CARD-CARD interactions. C High 
resolution stimulated emission depletion (STED) microscopic image of an ASC speck.  D All ASC 
molecules of a cell are recruited into one speck per cell. Confocal microscopy image of an activated 
macrophage, expressing ASC-mCherry (red). Nuclei (blue) and membrane (green) were counterstained. 
ASC: apoptosis- associated speck-like protein containing a CARD; CARD: caspase recruitment domain; 
NLRP3: nucleotide-binding oligomerization domain, leucine-rich repeat, PYD containing 3; PYD: pyrin 
domain. 
Modified from Hoss et al. 2016 29 
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filamentous structures which are mutually exclusive to PYD filaments 46,47 (Figure 3-2 
A, B).  
The overall inflammasome complex is assembled by multiple filaments, clustered 
together similarly to a bird’s nest with a condensed globular core and single filaments 
extending into the periphery 46 (Figure 3-2C). Blocking the CARD interaction interface 
disables the crosslinking of ASC filaments 48. This finding strongly supports the 
theory that ASC filaments are cross-linked via CARD-CARD interactions. Beside 
crosslinking ASC filaments, the CARDs can form seeds for further homotypic 
pro-caspase-1 CARD filaments 42,48,49. Analysis of full ternary inflammasome 
complexes containing a receptor, ASC and pro-caspase-1 showed that 
pro-caspase-1 is even over-stoichiometric to ASC 41. Taking the structure described 
above into account, this is not un-expected since the pro-caspase-1 filaments can 
emerge in a star shaped complex (seen from along the ASC filament) to all sides 
multiplying the number of involved pro-caspase-1 monomers. This architecture 
increases the local concentration of pro-caspase-1 and allows for caspase-1 
activation by auto-proteolysis 21,45,50,51.  
As soon as the inflammasome is activated, all ASC molecules from one cell are 
recruited into one speck following an energetic gradient (Figure 3-2D). The process 
is irreversible and once started no longer dependent on the initial starting signal, 
reminiscent of prionoid events 42. This guarantees extreme sensitivity, since prionoid 
filament formation results in a potent signal amplification cascade 42. 
 
3.1.5. Inflammatory caspases and cell death 
Upon activation and auto-proteolysis of pro-caspase-1, a C-terminal 10 kDa and a 20 
kDa fragment are released from the CARD domain forming the enzymatically active 
caspase-1 complex as a heterotetramer of two p10 and two p20 subunits 52,53. 
However, a more recent study suggested that a p33 (CARD+p20)/p10 tetramer, still 
attached to the ASC speck, represents the predominant active species 54. The active 
caspase-1 heterotetramer cleaves pro-IL-1β and pro-IL-18 into their active p17 and 
p18 forms, respectively 55–57. The other major target of caspase-1 is the pyroptosis 
mediator GSDMD. In homeostatic cells, the auto-inhibitory C-terminus of GSDMD 
folds back on the N-terminus and inhibits its lytic activity. Upon cleavage, the 
N-terminal p30 fragment is released, localizes to membranes and forms functional 
oligomeric pores 58–60. 
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Although the best known substrates for caspase-1 are the IL-1 family cytokines and 
the pyroptosis effector GSDMD, many more proteins can be processed by caspase-1 
61,62.  
Taking into account the tremendous effects of caspase-1 activation and the large 
number of activated caspase-1 molecules per cell 41, it is only reasonable that the 
active half-life of caspase-1 is restricted to a few minutes 62. According to the 
p33/p10 model, once released from the speck by cleavage of the CARD linker, the 
locally increased concentration of the tetramer is lost and drops below the 
dissociation concentration, rendering caspase-1 quickly inactive 54. 
 
3.1.6. Inflammasome Regulation 
The ability for immediate response is a key characteristic of the innate IS. Such rapid 
responses involve events that may cause excessive and self-amplifying 
inflammation, causing severe damage to the host. Therefore, a multitude of 
checkpoints exists within this response in order to fine-tune, reduce or terminate it. 
This includes positive and negative feedback loops, protein-protein interactions, 
regulation of gene expression, posttranslational modifications and autophagy 63. 
Furthermore, decoy receptors and programmed cell death are involved. 
One way to regulate the inflammasome are so called pyrin-only proteins (POPs) and 
CARD-only proteins (COPs), which can act as decoy interaction partners for different 
inflammasome components relying on PYD or CARD homo-interactions 29. Four 
different POPs were discovered in the human system, while there is no murine 
orthologous 64,65. While the role the role of POP1 is controversial 29 and POP4 seems 
not to be involved in inflammasome regulation 66, POP2 and POP3 are widely 
accepted as inhibitors of the inflammasome. POP2 is proposed to bind as a 
competitive inhibitor to the inflammasome receptors NLRP3, NLRP1 and NLRP12 
65,67,68. POP3 is genetically located within the same gene cluster as AIM2 and inhibits 
specifically AIM2 induced ASC speck formation 69. In addition, POP1, POP2 and 
POP4 also regulate NF-kB signaling and thereby indirectly the expression of 
inflammasome components 66,67,70,71. Additionally, some viruses express POP-like 
proteins in order to evade the recognition by the innate IS 29. 
Not only the inflammasome seed formation is inhibited, but also caspase-1 activation 
as the common downstream event with potentially detrimental outcomes. COPs are 
restricted to the genomes of primates 65, but it is speculated that a splice forms of 
ASC (ASC-c) adopts their function in mice 72. The COPs CARD16, CARD17 and 
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CARD18 are highly homologous to the CARD of pro-caspase-1 and have most likely 
derived from gene duplication events 65. CARD17 has been shown to bind to the tips 
of pro-caspase-1 filaments, preventing further polymerization and activation 73,74. The 
experimental evidence for the function of CARD16 and CARD18 is not as clear. Both 
have been shown to either promote or inhibit inflammasomes in different assays 29.  
A closely related mechanism of regulation is alternative splicing of ASC, resulting in 
up to 4 different isoforms of ASC. The role of ASC-b, which lacks the flexible linker, is 
controversial but most likely the stiff connection between PYD and CARD reduces 
the efficiency of inflammasome formation 72. ASC-c lacks most of the PYD and 
inhibits IL-1β maturation 72. ASC-b and ASC-c are both LPS-inducible and detectable 
in human macrophages 72. 
Remarkably, the effects of the released pro-inflammatory IL-1 cytokines are even 
regulated downstream of the inflammasome. The IL-1 receptor 2 acts as a decoy 
receptor without a signaling domain, the IL-1 receptor antagonist (IL-1Ra) binds the 
IL-1 receptor, but prevents its activation, and IL-18 binding protein is a secreted 
decoy interaction partner of IL-18 75. 
 
3.1.7. NLRP3 
NLRP3 consists of three functional domains, the N-terminal PYD, the NOD (also 
known as NACHT) and the C-terminal LRR. The exact overall structure of NLRP3 is 
not yet known. However, the structure of NLRP3 PYD was successfully solved by X-
ray crystallography 34 and the LRR of NLRP3 is highly canonical, which allows for a 
reliable modeling based on the structure of ribonuclease inhibitor [106, see as well 
Results]. Moreover, the crystal structure of a related inflammasome sensor, NLRC4, 
was solved 40. The LRR was shown to fold back onto the NOD and to sequester 
NLRC4 in the monomeric state. During activation, a dramatic conformational change 
opens up the self-inhibited NLRC4 and allows for its oligomerization 49,77. Similarly, 
NLRP3 is assumed to be kept inactive by its LRR. Upon activation, NLRP3 clusters 
via the NODs and brings the PYDs close enough together to act as a seed for ASC 
polymerization 41. 
Activation of the NLRP3 inflammasome is tightly regulated and requires at least two 
independent signals: in a first priming or licensing step, PRRs or cytokine receptors 
trigger the activation of NF-kB that induces the expression of NLRP3 and pro-IL-1β. 
A second stimulation step is required to induce the assembly of the inflammasome 78 
(Figure 3-3). 
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Some reports indicate, however, that NLRP3 cannot only be primed by de novo 
transcription, but also via post-translational modifications (PTMs). A fast licensing 
step of already translated NLRP3 protein via de-ubiquitination is dependent on 
BRCC3 79,80. In human monocytes, an extracellular signal-regulated kinase 1 
phosphorylation-dependent priming process, which takes place within minutes after 
stimulation with LPS, was postulated as well 81. Moreover, nitrosylation was reported 
to inhibit NLRP3 activation 82–84. 
PTMs can modulate protein function in diverse ways and their roles depend on the 
modified residue and on the type of PTM. Ser-5 phosphorylation within the PYD of 
NLRP3 can block inflammasome activation, most likely by blocking a PYD-PYD 
interaction surface 85. Other phosphorylation sites described to inhibit NLRP3 include 
Ser-295 and Tyr-861 86,87. 
Compared to other inflammasome receptor molecules, NLRP3 has a special role. It 
senses a range of very diverse stimuli, such as bacterial toxins, ATP, crystals and 
metabolic changes. Thus, it seems inconceivable that they would all bind directly to 
NLRP3 and therefore the term sensor should be preferred over receptor. The 
best-characterized activators can be summarized as either phago-lysosomal 
disruptive (crystals) or as causing changes in ion homeostasis (ATP/ bacterial toxins) 
(Figure 3-3). There are some suggestions for common upstream activating events, 
but none is able to integrate all known activators. Mitochondrial damage and release 
of cardiolipin, mtDNA and ROS were discussed as common upstream events in the 
NLRP3 activation 88–90. However, it was shown that although these events co-occur, 
only potassium ion (K+) efflux activates NLRP3 91. 
The cytosolic concentration of K+ is much higher than in the extracellular space. An 
electrochemical gradient and active transport via the Na+/K+ pump keep the K+ 
gradient preserved in homeostatic cells 92. Several classical NLRP3 activators disrupt 
this gradient by allowing for net K+ efflux 93. The ATP receptor P2X7 works as a 
ligand-gated cation channel, which allows for the exchange of K+ against Na+ or H+ 
92. The bacterial toxin gramicidin acts as a channel ionophore as well, allowing for a 
flux of monovalent cations 94, whereas valinomycin and nigericin work as carrier 
ionophores, selectively binding and transporting K+ out of the cell 95. However, the 
exact NLRP3 activation mechanism downstream of K+ efflux remains elusive. Other 
ion fluxes have been associated with NLRP3 activation as well, but their role is not 
as clear. Some reports claim a significant role for Ca2+ mobilization, while the overall 
evidence rather suggests that an elevated intracellular Ca2+ concentration is not 
involved in NLRP3 activation 92.  
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Figure 3-3 NLRP3 inflammasome activation 
The NRP3 inflammasome is regulated on multiple layers. Most importantly, NLRP3 and pro-IL-1β 
expression need to be induced in most cells. This priming signal can be derived from PRR signaling or 
pro-inflammatory cytokines, which activate the NF-κB pathway. NLRP3 can be activated by a diverse 
set of stimuli, including lysosomal rupture by phagocytosed crystals or potassium efflux via pore-forming 
toxins or ion channels. NEK7 binding to NLRP3 is considered as a prerequisite for inflammasome 
formation. Upon activation, NLRP3 recruits ASC, which recruits pro-caspase-1. After proximity-induced 
self-activation, caspase-1 is capable of processing pro-IL-1β and GSDMD into their bioactive forms. The 
N-terminal GSDMD fragment forms pores in the cell membrane, resulting in pyroptotic cell death and 
IL-1β release. 
ASC: apoptosis- associated speck-like protein containing a caspase activation and recruitment domain; 
DAMP: Damage-associated molecular pattern; IκB: Inhibitor of κB; IL: Interleukin; NEK7: never in 
mitosis related kinase 7; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3: 
nucleotide-binding oligomerization domain, leucine-rich repeat, pyrin domain containing 3; P2X7: 
Purinergic Receptor P2X, Ligand Gated Ion Channel 7; PAMP: Pathogen-associated molecular pattern, 
PRR: Pattern recognition receptor. 
Modified from Grebe, Hoss and Latz, 2018 96 
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NIMA-related Kinase 7 (NEK7) was found in three independent screens to interact 
with NLRP3 as a prerequisite for NLRP3 inflammasome activation 97–99. It still needs 
to be determined how the interaction between NLRP3 and NEK7 is regulated. It was 
shown that the catalytic domain of NEK7, but not its kinase activity, is required for the 
interaction with the NLRP3 LRR domain 99. Additionally, the interaction is dependent 
on the phosphorylation of NEK7, although the kinase NEK9, known to phosphorylate 
NEK7, is dispensable 97,99. NEK7 has been linked previously to the formation of 
centrosomes and mitosis and the requirement for NEK7 results in the mutual 
exclusion of NLRP3 activation and mitosis 97. 
Beside the classical NLRP3 inflammasome activators, NLRP3 can be activated via a 
non-canonical pathway: Murine caspase-11 directly binds to cytosolic LPS and 
activates the NLRP3 inflammasome independent of TLR4 100,101 and human 
caspase-4 and -5 were found to be the functional homologues of murine caspase-11 
102,103. It is believed that caspase-11 initiates a K+ efflux, which in turn activates 
NLRP3. However, two different mechanisms are described: First, caspase-11 
cleaves pannexin-1, which forms a pore for ATP to be released from the cell, and 
ATP then activates the P2X7 receptor upstream of NLRP3 104. Second, caspase-11 
cleaves GSDMD, which induces pore formation leading to pyroptosis, but also K+ 
efflux activating NLRP3 27. Which of these mechanisms is of higher relevance or 
whether they might act in concert requires further investigation.  
In addition to the non-canonical inflammasome, the ‘alternative inflammasome’ was 
proposed. This pathway is suggested to be unique in human monocytes, does not 
induce ASC speck formation (although it is dependent on NLRP3, ASC and 
caspase-1) and pyroptosis, and is independent of K+ efflux. Here, the activation of 
NLRP3 is gradual and occurs via a TLR4-RIPK1-FADD-caspase-8 axis 105. Another 
inflammasome pathway exclusively described in human monocytes, explains the 
recognition of cytosolic DNA via cGAS/STING, which drives NLRP3 activation and 
renders NLRP3, instead of AIM2, the default inflammasome sensor for cytosolic DNA 
in this cell type 106. Similar to the alternative inflammasome, the activation of NLRP3 
via inhibition of hexokinase followed by its release from the mitochondria is reported 
to be independent of pyroptosis and K+ efflux. Bacterial N-acetylglucosamine, 
metabolic inhibitors or negative feedback loops can inhibit hexokinase and activate 
NLRP3 107. On the one side, this defines a metabolic enzyme as a PRR, on the other 
side, it promotes the idea that NLRP3 can act as general sensor for HAMPs and 
does not rely on a specific pathogen-derived ligand 10. However, some conflicting 
data on this topic is published. According to older publications, mTORC1- and PKM2-
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dependent induction of glycolysis via hexokinase-1 is required for NLRP3 activation 
108,109. 
Other studies provided evidence for an intense crosstalk between metabolic 
conditions and NLRP3 activation as well. β-hydroxybutyrate, a ketone metabolite, 
produced during starvation or low carbohydrate prevalence, acts as a potent inhibitor 
of NLRP3 110 and omega-3 fatty acids were also shown to act as negative regulators 
of the NLRP3 inflammasome 111. 
Other circulating molecules can also regulate the NLRP3 inflammasome. The 
neurotransmitter dopamine induces ubiquitination and degradation of NLRP3 upon 
binding to the dopamine D1 receptor 112. Type-1 interferons (IFNs) can dampen the 
inflammasome response via several mechanisms: Type-1 IFN-induced STAT-1 
signaling directly inhibits NLRP3 and NLRC4 activity and induces an autocrine IL-10 
STAT3 signaling loop restricting pro-IL-1β expression 113. Additionally, IFN-β induces 
IL-1RA secretion 114. However, IFNs are not exclusively negative regulators of the 
inflammasome. IFN-induced guanylate binding proteins and the immunity-related 
GTPase family member b10 are required to liberate ligands of cytosolic bacteria for 
sensing by the non-conical NLPR3 or the AIM2 inflammasome 115–117. 
Although the (NLRP3) inflammasome is widely recognized as a feature of the innate 
IS, future studies will be needed to shed light on the effects it might have on the 
adaptive IS. For example, an intracellular complement-driven pathway was described 
that induces ROS and NLRP3 activation in CD4 T-cells as an integral component of 
a normal adaptive T-cell response 118. 
Independent of its role as an inflammasome sensor, NLRP3 was shown to act as a 
transcription factor for TH2 differentiation of CD4 T-cells as well 119. While it binds as 
a transcription factor to the IL-4 promotor, IL-4 was shown to suppress NLRP3 
activation post-transcriptionally 120.  
 
3.1.8. NLRP3-associated diseases 
Diseases linked to or caused by the innate immune system are generally termed 
autoinflammatory. Both inherited or newly acquired specific mutations as well as 
misbalanced regulation of inflammatory processes can cause autoinflammatory 
diseases. They are not to be confused with autoimmune diseases, which are caused 
by auto-antibodies or other mis-regulated effectors of the adaptive IS 63. 
Mutations in NLRP3, NLRC4 and pyrin were reported to cause inflammasome-
dependent autoinflammatory diseases due to gain-of-function mutations. Mutations 
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within the NLRP3 gene (also known as CIAS1) cause a spectrum of different 
inflammasome-dependent diseases, which are summarized as cryopyrin-associated 
periodic syndromes (CAPS) and cause generalized painful rashes and fevers. Some 
subtypes are also associated with neurosensory hearing loss, bony overgrowth of the 
knees, central nervous system inflammation and amyloidosis 63. Mutations within 
MEFV, the gene coding for pyrin, cause familial Mediterranean fever (FMF) the most 
common autoinflammatory disease and NLRC4 mutations were described as a 
cause for autoinflammatory diseases as well 121,12263. 
Except for inflammasome-triggered autoinflammatory diseases, a multitude of 
diseases is not intrinsically caused by the NLRP3 inflammasome but closely linked 
and often aggravated by NLRP3, rendering NLRP3 activation a serious health issue. 
Whenever crystalline material enters the body, macrophages try to clear it by 
phagocytosis. However, if they fail to digest the crystals, this crystalline material may 
cause phago-lysosomal rupture, ROS production and NLRP3-dependent 
inflammasome activation. NLRP3 is triggered by asbestos, silica and other crystals, 
leading to progressive pulmonary fibrosis 123–125. Even everyday inhaled particulate 
matter airway pollution causes NLRP3 activation 126 and most likely contributes 
significantly to the high numbers of chronic inflammatory airways diseases. In gout, 
uric acid crystals are deposited within joints, where they are also phagocytosed by 
macrophages, leading to the same phago-lysosomal destabilization pathway and 
NLRP3-dependent inflammasome activation. The symptoms are pain and swelling of 
the joints 127. 
Gout is not the only metabolic disease linked to NLRP3 activation. Saturated fatty 
acids were shown to activate NLRP3 and to promote type 2 diabetes (T2B) 128. T2B 
in general is associated with increased inflammatory cytokine levels, including IL-1β 
129. It was also shown that pancreatic islet amyloid polypeptide, which is co-secreted 
with insulin, forms aggregates which induce NLRP3-dependent cell death of β-cells 
130,131. Atherosclerosis is another diet-induced NLRP3-dependent disease. 
Cholesterol crystals deposited within atherosclerotic plaques are strong 
inflammasome activators, leading to inflammation, swelling of the plaque and 
eventually rupture and thrombosis 96,132,133. 
Moreover, neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease and multiple sclerosis are strongly influenced by NLRP3. Amyloid-β plaques 
in Alzheimer’s disease or α-synuclein aggregates in Parkinson’s disease are NLRP3 
inflammasome activators promoting inflammation and cell death 26. Mice lacking 
NLRP3 showed a delayed development, less inflammation and weaker symptoms in 
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a murine model for multiple sclerosis (experimental autoimmune encephalomyelitis) 
26. 
Although NLRP3 seems to be rather detrimental to the host, an evolutionary 
beneficial role can be assumed. The above-mentioned diseases were most likely of 
no evolutionary impact, as they just started to exponentially gain significance when 
people became older and adopted a modern life style. Western-diet further 
aggravated the negative impact of NLRP3 since people started to suffer population-
wide from the above-mentioned metabolic disorders. 
Most likely, a key factor for the conservation of NLRP3 is its role in the immune 
response against influenza. Upon challenge with influenza viruses, NLRP3-, ASC- or 
caspase-1-deficient mice showed a diminished immune response and an increased 
mortality 134. However, another study showed that NLRP3 was obligatory for 
inflammasome formation in certain cell types, but only ASC and caspase-1 were 
required to mount an adaptive immune response 135. In conjunction with this, the 
necessity for the IL-1 signaling axis in establishing an anti-influenza CD8 T-cell 
response was shown 136. Proposed modes for the detection of viral RNA by NLRP3 
are via RNaseL 137 or DHX33 138. 
 
3.2. The leucine-rich repeat motif 
The leucine-rich repeat (LRR) motif is a widespread structural feature of many 
proteins, including the innate IS receptors TLRs and NLRs. As many as 500 human 
genes encode for LRR-containing proteins and hundreds of protein structures 
containing LRRs have been solved 76. The three-dimensional structure of LRRs was 
first determined by crystallization of the ribonuclease inhibitor 139. It is defined by the 
specific amino acid pattern LxxLxLxxNx(x/-)L (with L being  Leu, Ile, Val, or Phe and 
N being Asn, Thr, Ser, or Cys) followed by a variable sequence. Together, one 
repeat unit consists of 20 to 30 amino acids 140. The overall structure of LRRs is 
(depending on the number of repeats) horseshoe-like, with parallel β-strands forming 
the inner concave surface and α-helices building the outer convex surface. The 
xxLxL stretch defines the β-sheet, which is followed by a flexible loop as a 
connection to the α-helix. Another flexible loop links back to the next β-strand 76 
(Figure 3-4). 
The LRR is a versatile structural element, which enables interactions with a broad 
spectrum of ligands including proteins 141,142, lipids 143, nucleic acids 144 and bases 
145,146 and is therefore very suitable as a receptor domain. The LRR motif is not only 
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part of TLRs and NLRs, but it is also an integral components of plant resistance 
proteins 147 and in jawless vertebrates, a complete adaptive immune system is based 
on recombination of LRR fragments 148. The LRR gene conversion-derived variable 
lymphocyte receptors of jawless vertebrates functionally resemble T-cell and B-cell 
receptors of jawed vertebrates 148. 
 
 
 
Figure 3-4 The leucine-rich repeat fold is defined by a consensus sequence 
The leucine-rich repeat domain of NLRP3 (encoded by exons 5 to 10, bottom to top) was modeled 
based on the human ribonuclease inhibitor (RI) crystal structure by R. Brinkschulte. Different colors 
indicate different exons. One repeat is defined by a β-sheet and an α-helix connected via flexible linkers. 
This fold is defined by the LRR consensus sequence (bold letters). The N- to C-terminal direction of a 
single repeat is indicated on the right side by a surrounding arrow. 
 
3.3. Splicing 
In contrast to bacterial genes, which typically consist of a continuous protein-coding 
nucleotide sequence, eukaryotic genes are built up by coding and non-coding 
stretches, exons and introns, respectively. RNA splicing of freshly transcribed pre-
mRNA removes these intronic sequences. Only after splicing is completed and a 3’ 
poly-A tail and a 5’ cap is added, an mRNA molecule is considered mature and 
exported from the nucleus. It is assumed that early during evolution, self-splicing 
introns, as they still exist in chloroplasts, mitochondria and phages, developed. Later 
on, splicing became much more complex, but also more flexible. Today’s eukaryotic 
splicing machinery consists of 5 additional small nuclear RNAs (snRNAs) (U1, U2, 
U4, U5, U6) and as many as 200 proteins 149. Although protein splicing factors 
regulate and simplify the splicing reaction, the spliceosome depends on the RNA 
moieties and is a ribozyme. Since the biochemical reaction of group II self-splicing 
introns and the eukaryotic spliceosome is very similar, it is assumed that the snRNAs 
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took over the structural and catalytic roles of group II introns. Thereby, conservation 
pressure was relieved from the introns and the number of spliceable RNAs increased 
dramatically 150. 
 
3.3.1. The splice reaction 
The splice reaction itself takes place as two energy-neutral transestrerifications. 
However, the spliceosome complex, which catalyzes the reaction and positions the 
pre-mRNA accordingly, requires ATP as a source of energy. 
To remove one intron, the 2'-hydroxy group of a specific adenine at the 3’ end of that 
intron attacks the phosphate at the 5’ splice site. As a result of this reaction, the 
intron is cleaved from the 5’ exon and the 5’ end of the intron is covalently linked to 
the branch point adenine forming a lariat. Then, the 3’-hydroxy group of the detached 
exon attacks the phosphate at the 3’ end of the intron. Thereby, the two exons 
become joined and the intron, which remains a lariat, is released 151 (Figure 3-5). 
 
Figure 3-5 Splice reaction 
During the splice reaction, the 2'-hydroxy group of the branch point adenine in the intron attacks the 
phosphate at the 5’ splice site. The 5’ exon is released from the intron and the intron forms a lariat. 
Next, the 3’-hydroxy group of the 5’ exon attacks the phosphate at the 3’ end of the intron, the two 
exons join and the intron lariat is released. 
 
3.3.2. The spliceosome and splice regulation 
In order to catalyze and regulate the reaction, the spliceosome has to recognize 
three positions within the pre-mRNA for each splicing event: The 5’ splice junction, 
the branch point and the 3’ splice junction are mostly identified by base-pairing of 
pre-mRNA and snRNAs. During the splicing process, several complementary 
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interactions are necessary to break, shift or substitute, which allows for re-checking 
of the consensus sites as well as spatial rearrangement, facilitating the chemical 
reaction 150. Many of the spliceosomal proteins are DEAD/H-box RNA-dependent 
ATPases/helicases, most likely to facilitate all the necessary alterations in base-
pairing which occur during the splicing process 152. 
Typically, U1 and U2 bind first to the pre-mRNA, although their binding is only 
productive in rare cases at the first attempt. U1 binds to the 5’ exon-intron junction 
and U2 binds the intronic branch point. Next, a heterotrimer of U4/U5/U6 is recruited. 
U6 replaces U1, and U1 and U4 are released. U2 and U6 interact via base-pairing 
and form the catalytically active core of the spliceosome. The complex disassembles 
after the intronic lariat formation and joining of the exons 149. 
Beside the proteins making up the spliceosome itself, many additional proteins act as 
regulators (Table 3-1). Although many factors involved in the regulation have been 
discovered, the overall regulation is not yet well understood and needs further 
investigation 153. Three classes of regulators mainly influence the splicing: Serine-
arginine repeat (SR) factors, heterogeneous nuclear ribonucleoproteins (hnRNPs), 
and tissue-specific RNA-binding proteins 149. Dependent on the localization within the 
RNA and the local environment, including cooperative binding partners, they can 
either promote or inhibit splicing. However, the strongest effect is attributed to so-
called exonic or intronic splicing enhancer or silencer sites, defined regions within the 
pre-mRNA acting as binding sites for splice factors 149,153. 
 
 Exon inclusion Exon exclusion 
Conserved consensus splice 
site sequence 
++ - 
Exonic Splice Enhancer (ESE) ++ - 
Intronic Splice Enhancer (ISE) ++ - 
Exonic Splice Silencer (ESS) - ++ 
Intronic Splice Silencer (ISS) - ++ 
Serine-arginine repeat (SR)-
proteins 
++ + 
heterogeneous nuclear 
ribonucleoproteins (hnRNPs) 
+ ++ 
Cis-acting RNA-RNA base 
pairing 
Selection of a single alternative exon from a cluster 
Transcriptional speed ++/-- ++/-- 
Histone modifications Influences transcriptional speed, recruit pos. /neg. splicing 
factors 
Nucleosome occupancy +  
RNA pol II C-terminal domain 
(CTD) phosphorylation 
++ + 
Table 3-1 Multiple factors influence alternative splicing 
A diverse set of factors is described to regulate and influence alternative splicing. While a few features 
as the conservation of the consensus splice site and ESE motives can be associated relatively well with 
exon inclusion, most other factors are described to influence splicing either in one or the opposite 
direction dependent on the context of other factors and the gene specific environment.  
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Similar to other RNA maturation processes, splicing mostly takes place co-
transcriptionally and the C-terminal heptad repeat domain (CTD) of RNA polymerase 
II (Pol II) seems to be involved in the temporal-spatial coupling of transcription and 
splicing 154,155. The speed of transcription influences the exon inclusion, and 
nucleosome occupancy and histone modifications affect the speed of Pol II 155. 
 
3.3.3. Alternative splicing 
Alternative splicing (AS) occurs when not only an intron is removed from the 
pre-mRNA, but an intron-exon-intron stretch. Thereby, the functionality of gene 
products can be changed dramatically without the necessity of an increased number 
of genes. Indeed, the increased complexity of higher-order organisms is mostly 
achieved by a more diverse AS pattern, not by more coding genes. While C. elegans, 
mice and humans carry around 20,000 protein-coding genes, they express about 
50,000, 100,000 and 200,000 different isoforms, respectively 149. In humans, more 
than 95 % of multi-exonic genes are alternatively spliced 156,157. This is possibly due 
to a higher conservation of the consensus splice-sites in lower-order organisms and 
 
Figure 3-6 Principles of alternative splicing 
A Schematic drawing of the exon-intron structure of a gene. B Splicing removes introns. C to F Different 
kinds of alternative splicing: C Exon removal, D mutually exclusive exons, E intron retention, F usage of 
non-canonical splice sites within introns or exons. 
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a higher number of regulating splice factors in complex organisms 149. AS is 
especially prevalent in the nervous and immune systems 153,158 and increasing 
evidence suggests that AS contributes to the complexity of immune responses not 
only in humans 159. However, AS can also contribute to the development of various 
diseases 160. 
AS may not only delete functional domains, but it may also shift the reading frame of 
the mRNA, resulting in a new protein product or a premature stop codon. In general, 
one or several exons can be spliced out, exons can be mutually exclusive, introns 
can be retained, or non-canonical splice sites within exons or introns can be used 
151,153 (Figure 3-6). Although it is possible that AS leads to nonsense-mediated decay, 
most splicing events seem to retain the reading frame 156. Surprisingly, different 
isoforms of the same gene can behave like unrelated proteins and are characterized 
by significantly different interaction profiles 161. Moreover, AS seems to be regulated 
in an on/off fashion for most genes in a specific cell type 162. 
Over the last years, improvements in transcriptomics led to the discovery of an 
increasing number of new transcript variants. However, these data should be treated 
with caution since bioinformatic analysis of nucleic acid amplification assays can 
easily overestimate AS diversity 163 153. The regulation of AS is not perfect and just by 
chance, every exon-skipping event will take place at a very low incidence, inducing a 
stochastic noise 164. The average erroneous mis-splicing rate was determined to be 
0.7% per intron. Given that a median gene contains four exons, roughly 2% of every 
transcript will be mis-spliced 165. Taking into account the further increasing sensitivity 
of transcriptomics and that large-scale proteomic experiments support only a fraction 
of the transcript variants documented on RNA level 166, newly obtained data providing 
evidence of new AS products should be carefully evaluated for their biological 
relevance. The same is true for annotated isoforms, which were predicted from single 
expressed sequence tags (ESTs) in the beginning of the sequencing era and never 
systematically re-evaluated. Furthermore, over the last years it became evident that 
bioinformatics analysis of nucleic acid amplification assays can easily overestimate 
AS diversity 153,163. This is further supported, as large-scale proteomic experiments 
support only a fraction of the transcript variants documented on RNA level 166,167. 
Therefore it is of foremost importance to prove the existence of a splice isoform not 
only on nucleotide but as well on protein level. 
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3.3.4. Splicing in immunity 
Alternative splicing is a mechanism widely used to regulate immune responses. 
Upon activation of T- and B-cells AS can regulate gene sets that are not altered at 
transcriptional level 153. For example, different isoforms of CD45 homo-dimerize with 
different affinities to shape T-cell receptor signaling 168 and the expression of CD3ζ, 
which corresponds to the ability of a T-cell to be activated during antigen 
presentation, is significantly regulated by AS of CD3ζ exon 8 153. 
Not only the adaptive IS is regulated by AS, but also PRRs are known to be 
regulated by AS. Upon activation of TLRs, IL-6 or IFN signaling, a short isoform of 
MD-2 (MD-2s) lacking exon 2 is upregulated. MD-2s acts as a negative regulator of 
TLR4 activation by LPS 169. An alternative isoform of STING, named MRP, 
differentially suppresses the IFN signaling branch of STING, but keeps the NFκB 
signaling unaffected 170. Inflammasome activation can be regulated by AS of the 
adapter ASC, resulting in up to 4 different isoforms, of which two are LPS inducible 
and act as negative regulators. While ASC-c lacks most of the PYD and is a clear 
inhibitor of IL-1β secretion via a competitive mechanism, ASC-b only lacks the 
flexible linker between PYD and CARD and reduces the efficiency of inflammasome 
speck formation 72. Resistance proteins in plants are structural and functional 
homologous of vertebrate NLRs. Interestingly, AS has been reported as a key 
feature in plant defense against pathogens and in stress situations 171,172. Moreover, 
human NLRP3 mRNA can be alternatively polyadenylated in order to remove 
regulatory sites. This results in a shortened 3’UTR, which lacks the binding site for 
the negative regulators miRNA-223 and tristetraprolin 173. 
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3.4. Scope of this study 
NLRP3 is a key component of the inflammasome pathway, driving caspase-1-
dependent pyroptosis and IL-1β maturation in numerous metabolic and inflammatory 
diseases. Due to the high pro-inflammatory impact, NLRP3 activation is tightly 
regulated on multiple levels. Alternative splicing is known to drive functional diversity 
of proteins, and alternative splicing events have been described for some 
inflammasome components. However, alternative splicing of NLRP3 and related 
proteins has never been systematically investigated. Understanding the role of 
alternative splicing in inflammasome activation and the inherent mechanistic 
differences of alternative isoforms might help to expand the knowledge of basic 
NLRP3 activation and pave the way for novel treatments of inflammatory diseases.  
Therefore, the aim of this study was to evaluate whether the structural prerequisites 
for alternative splicing are present in NLR genes, and to determine whether 
alternative splicing is a conserved feature across related proteins. Furthermore, 
alternative NLRP3 variants were to be described with regard to their frequency and 
potential regulation of the frequency, as well as the isoform distribution on single-cell 
level. Finally, this study aimed to investigate the molecular mechanisms of how 
alternative splice variants of NLRP3 might influence inflammasome activation and 
regulation. 
The following objectives were formulated to meet these goals: 
 
(1) To assess the spliceability of NLRP3 and related proteins in silico. 
(2) To determine the prevalence of alternative splicing of NLR genes by deep 
RNAseq followed by hit validation and further qPCR analysis. 
(3) To clone and express NLRP3 splice variants in different cell types. 
(4) To analyze the different NLRP3 isoforms for their impact on inflammasome 
activation in primary human cells and in in vitro models. 
(5) To assess the NLRP3 isoform distribution on single-cell level by qPCR. 
(6) To decipher the molecular mechanisms of differential activity of different NLRP3 
isoforms using structure-guided mutagenesis. 
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4. Materials and Methods 
4.1. Materials 
4.1.1. Devices 
Product Supplier 
Blotting system Xcell II Blot Module Invitrogen 
Centrifuges Eppendorf 
Confocal microscope Leica SP5 AOBS with SMD Leica Microsystems 
Counting chamber Neubauer Brand 
DNA gel electrophoresis system PerfectBlue Peqlab 
Electronic E4 XLS+ multichannel pipets Mettler Toledo 
Epoch Microplate Spectrophotometer BioTek 
Flow cytometer Canto II BD 
Flow cytometer MACS Quant VYB/Analyzer 10 Miltenyi Biotechnology 
Flow cytometric cell sorter Aria III BD 
Freezing containers True North 
Gel electrophoresis chamber Novex mini cell Invitrogen 
Gel Imaging system VersaDoc Bio-rad 
Heatblock Thermomixer Eppendorf 
HiSeq2500 Illumina 
Incubator for tissue culture SANYO Biomedical 
MacBook Pro Apple 
MACS mix for rotation Miltenyi Biotechnology 
Magnet for Dynabead immunoprecipitation (IP) Invitrogen 
Molecular Immager VersaDoc BioRad 
Pipettes (0.1 µL – 1 ml) Mettler-Toledo 
Pipetting device Pipet boy acu  Integra Biosciences 
Plate reader SpetraMax i3 Molecular Devices 
Plate shaker DOS-10L neolab 
QuadroMACS separator Miltenyi Biotechnology 
QuantStudio 6 Flex Thermo Fischer 
Qubit 3.0 Thermo Fischer 
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Rotator for immunoblotting RM5 Ingenieurbüro CAT M. Zipperer 
Sterile tissue culture hood Fischer Scientific 
Tapestation Agilent 
Thermocycler T3000 Analytica Jena 
Thermocycler Tadvanced (96-well) Biometra 
Tissue culture microscope Leica DMIL LED Leica 
UV table for DNA imaging UVstar Biometra 
Western Blot reader Odyssey LICOR Biosciences 
Wide-field fluorescent microscope Zeiss 
Observer.Z1 
Carl Zeiss Jena  
 
4.1.2. Disposables 
Product Supplier 
0.45 µm filters, 0.22 µm filters  Millipore 
14 ml tubes for cultivating bacteria VWR 
15 ml, 50 ml tubes Greiner bio-one 
384-well clear plate (LDH) Thermo Fischer 
384-well qPCR plate Applied Biosystems 
384-well Small volume HTRF Plate Labomedic 
5 ml, 10 ml, 25 ml pipettes Greiner bio-one 
6-well plate Nunc delta surface (for hMDMs) Thermo Fischer 
96-well PCR plate  4titutde 
Cell scrapers Sarstedt 
Cell strainer 70 µm Greiner BioOne 
Enzyme linked immunosorbent assay  
(ELISA) plates maxisorp 
Nunc 
MACS MS columns Miltenyi Biotechnology 
Microcentrifuge tubes  Eppendorf 
Needles Braun Melsungen 
Opti-Seal Optical Disposable Adhesive Bioplastics 
PCR Stripes Sigma 
Pipet tips (0.1 µL – 1 ml, filtered and unfiltered) Mettler-Toledo 
Scalpel Feather 
Syringes BD Bioscience 
Tissue culture plasticware (flasks, plates) Greiner bio-one 
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4.1.3. Reagents and Kits 
Product Supplier 
10% NuPage Bis-Tris gels  Life Technologies 
10x PBS (2 g Potassium chloride, 2 g Potassium 
dihydrogen phosphate, 80 g Sodium chloride, 
11.5 g di-Sodium hydrogen phosphate anhydrous 
per 1 l) 
Pan Biotech 
10x reducing agent (500 mM dithiothreitol in 
stabilized form) 
Life Technologies 
10x Tris glycine (0.025 M Tris, 0.192 M glycine, 
pH 8.5 when diluted to 1x) 
Thermo Scientific 
16% formaldehyde, methanol-free Life Technologies 
20x MES buffer Life Technologies 
20x MOPS buffer  Life Technologies 
20x TBS (400 mM Tris, 3 M NaCl, pH 7.4) Santa Cruz Biotechnology 
37% formaldehyde, methanol stabilized Sigma 
4-12% NuPAGE Bis-Tris gels Life Technologies 
4x LDS sample buffer (8% LDS, 40% glycerol, 
2.04 mM EDTA, 0.88 mM SERVA Blue G, 0.7 
mM Phenol Red, 564 mM Tris, pH 8.5)  
Life Technologies 
AF488 mAb labeling kit Invitrogen 
Agarose Biozym 
Ampicilin Sigma 
AmpliTaq Gold™ DNA Polymerase Thermo Fischer 
Anthrax lethal factor List Biological Laboratories 
Anthrax protective antigen List Biological Laboratories 
ATP Sigma 
Bichoninic acid (BCA) assay Thermo Scientific 
Blasticidin Invivogen 
Bovine serum albumin (BSA) Roth 
CD14 MicroBeads UltraPure, human Miltenyi Biotechnology 
Chloroform Merck 
Cholera toxin B subunit (CTB) Sigma 
CloneJE PCR Cloning Kit Thermo Fischer 
cOmplete protease inhibitor Roche 
CRID3 Pfizer 
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Curdlan Invivogen 
D1000 ScreenTape, Sample buffer, Ladder Agilent 
Dexamethasone Sigma 
DMEM Life Technologies 
DMSO AppliChem 
DNase I Invitrogen 
dNTP mix (10 mM) Thermo Fischer 
DOTAP Roche 
Doxycyclin Sigma 
DRAQ5 eBioscience 
Dynabeads Protein A Life Technologies 
Dynabeads Protein G Life Technologies 
easysep human neutrophil enrichment kit StemCell 
EconoTaq PLUS GREEN 2 x Mastermix BioCat 
ELISA substrate solution BD Opteia BD Biosciences 
Endoporter Geen-tools 
Ethylenediaminetetraacetic acid (EDTA)  
solution 0.5 M, pH 8.0 
Life Technologies 
Ficoll-Paque PLUS GE Healthcare 
Genejuice Milipore 
Glycerol Roth 
Goat serum Life Technologies 
GoTaq Probe qPCR Master Mix Promega 
HEPES Gibco 
Hoechst34580 Life Technologies 
Human IL-1β ELISA R&D Systems 
Human IL-1β HTRF Cisbio 
Human TNFα HTRF Cisbio 
Hygromycin B PAA 
Isopropanol Roth 
L-Glutamine Life Technologies 
LB agar (Lennox L agar) (10 g Peptone 140, 5 g 
Yeast Extract, 5 g NaCl, 12 g Agar per 1 l) 
Life Technologies 
LB Medium (Luria/Miller) (10 g Tryptone, 10 g 
Yeast Extract, 10 g NaCl per 1 l) 
Roth 
LDH cytotoxicity assay Thermo Fischer 
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LeuLeuO-Me Chem -Impex 
Lfn-PrgI Geyer-Lab 
Lipofectamine 2000 Thermo Fischer  
LPS ultrapure EB Invivogen 
Methanol Roth 
Mouse IL-1β ELISA R&D Systems 
Mouse IL-1β HTRF Cisbio 
Mouse TNFα ELISA R&D Systems 
Mouse TNFα HTRF Cisbio 
NaCl Roth 
Nigericin Invitrogen 
Nonidet-P40 (NP-40) AppliChem 
OptiMEM Invitrogen 
Pam3CSK4 Invivogen 
pDC isolation kit II, human Miltenyi Biotechnology 
Penicillin/ Streptomycin Thermo Fischer 
PeqGreen PeqLab 
PFU Ultra II HS 2x Master Mix Agilent 
PGN from S. aureus Invivogen 
Phorbol-12-myristate 13-acetate (PMA) Sigma 
PhosSTOP Roche 
PMSF Applichem 
Poly (dA:dT) Invivogen 
Poly I:C Invivogen 
Poly-L-Lysine Sigma 
Polybrene Sigma 
Polymorphprep Progen 
PureLink Quick Gel Extraction Kit Life Technologies 
PureLink Quick Plasmid Maxiprep Kit  Life Technologies 
PureLink Quick Plasmid Miniprep Kit  Life Technologies 
PVDF membrane Immobilon-FL Millipore 
Qubit HS dsDNA assay kit Thermo Fischer 
Qubit HS RNA assay kit Thermo Fischer 
R837 Invivogen 
R848 Invitrogen 
Random Hexamers Thermo Fischer 
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Restriction enzymes Fermentas 
rhGM-CSF Immunotools 
rhIFN-α PeproTech 
rhIFN-β Immunotools 
rhIFN-γ Immunotools 
rhIL-10 PeproTech 
rhIL-18 Invivogen 
rhIL-1β R & D Systems 
rhIL-3 Immunotools 
rhIL-4 Immunotools 
rhM-CSF Immunotools 
rhTNFα R & D Systems 
RNA ScreenTape, Sample buffer, Ladder Agilent 
RNase Inhibitor Thermo Fischer 
RNeasy mini kit Quiagen 
RPMI-1640 Life Technologies 
Sense mRNA library Prep Kit Lexogen 
Silica US Silica 
Sodium hydroxide solution 5 M Merck 
Sodium Pyruvate Life Technologies 
Superscript III reverse transcriptase Thermo Fischer 
T4 DNA Ligase, HC Fermentas 
TAE buffer 50x (2 M Tris, 1 M acetic acid, 50 mM 
EDTA, pH 8.5 
Roth 
taqman gene expression assay human 18s RNA 
(Hs99999901_s1) 
Invitrogen 
TaqMan Gene Expression Assay human Hprt 
(Hs02800695_m1) 
Invitrogen 
Tris HCl pH 7.4 Roth 
Tris HCl pH 8.0 Roth 
Triton X-100 Roth 
Trypsin Invitrogen 
Tween 20 Roth 
Wheat germ agglutinin (WGA)-AF633 Invitrogen 
zVAD-FMK MBL 
β-Estradiol Tocris 
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4.1.4. Buffers and media 
Name Composition 
1x TBS 100 ml 10x TBS, water to 1 l 
1x TBST 100 ml 10x TBS, 1 ml Tween 20, water to 1 l 
2x freeze mix 60 % FCS, 20 % Medium, 20 % DMSO 
Blocking buffer 3% BSA in TBS  
Complete DMEM DMEM supplemented with 10% FBS, 100 U/ml penicillin, 
100 µg/ml streptomycin 
Complete RPMI RPMI supplemented with 10% FBS, 100 U/ml penicillin, 100 
µg/ml streptomycin, 1mM L-Glutamine, 0.5 mM sodium 
pyruvate 
IP-buffer 50 mM Tris (pH 7.8), 50 mM NaCl, 0.1% NP-40, 10 % 
Glycerol add fresh: cOmplete protease inhibitor, PhosSTOP 
inhibitor, PMSF 0.2 mM 
MACS buffer PBS, 0.5% BSA and 2 mM EDTA 
NP-40 buffer 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% 
Nonidet P-40, 10% glycerol, add fresh: cOmplete protease 
inhibitor, PhosSTOP inhibitor, PMSF 0.2 mM 
Permeabilization/ 
blocking buffer  
PBS, 10% FBS, 0.5% Triton-X100, Privigen 1:66 
WB buffer 3% BSA in TBST  
WB transfer buffer 100 ml 10x Tris-glycine, 150 ml methanol, water to 1 l 
 
4.1.5. Antbodies 
Immunoblot 
Primary antibodies (clone, species) Dilution Supplier 
ASC (polyclonal (AL-177), rabbit) 1:1000 Adipogen 
GFP (JL-8, mouse) 1:1000 Clonetech 
IL-1β (detection AB human ELISA kit, 
biotinylated) 
1:250-500 R&D Systems 
IL-1β (detection AB mouse ELISA kit, 
biotinylated) 
1:1000 R&D Systems 
Mouse caspase-1 (sc-514, rabbit) 1:200 Santa Cruz 
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NEK7 (EPR4900, rabbit) 1:500-1:2000 Abcam 
NLRP3 (Cyro2, mouse) 1:2000-1:5000 Adipogen 
tagRFP (polyclonal, rabbit) 1:5000 Evrogen 
β-Actin (rabbit/mouse) 1:1000 Licor 
 
Immunoprecipitation 
Primary antibodies (clone, species) Dilution Supplier 
GFP (96-well plate GFP-trap coated) --- Chromotek 
NLRP3 (D4D8T, rabbit) 1:100-200 Cell Signaling 
tagRFP (polyclonal, rabbit) 1:220 Evrogen 
 
Immunocytochemistry 
Primary antibodies (clone, species) Dilution Supplier 
ASC (TMS1, mouse), labeled with AF488 1:200 Biolegend 
 
Secondary antibodies 
Primary antibodies (clone, species) Dilution Supplier 
Anti-mouse IRDye 680 RD 1:25000 LICOR 
Anti-mouse IRDye 800 CW 1:25000 LICOR 
Anti-rabbit IRDye 680 RD 1:25000 LICOR 
Anti-rabbit IRDye 800 CW 1:25000 LICOR 
Streptavidin IRDye 680 RD 1:30000 LICOR 
 
4.1.6. Plasmids 
The complete annotated plasmid sequences can be retrieved from the Latz lab 
Geneious-database using the indicated IDs. Protein sequences for the artificially 
created NLRP3 variants can be found in the appendix (section 12.4). 
 
Plasmid ID Description Backbone 
56 CMV VSV-G pCMV 
57 CMV Gag-Pol pCMVR8.74 
486 CMV Flp recombinase pOG44 
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565 CMV 5' LTR hNLRP3 S5 (wt)-mCitrine, 3' LTR pR 
688 CMV 5' LTR hNLRP3 S5 (delta exon 5)-mCitrine, 3' 
LTR 
pR 
714 CMV 5' LTR hNLRP3 S5 (2x exon 6)-mCitrine, 3' 
LTR 
pR 
722 CMV 5' LTR hNLRP3 S5 (delta exon 5)-tagRFP, 3' 
LTR 
pR 
739 CMV 5' LTR hNLRP3 S5-tagRFP, 3' LTR pR 
785 CMV Tet. ind.-NLRP3-tagRFP, PGK-hASC-
mTurquoise, FRT, hygromycin resistance 
pcDNA5-FRT 
801 CMV Tet. ind.-NLRP3(delta exon 5)-tagRFP, PGK-
hASC-mTurquoise, FRT, hygromycin resistance 
pcDNA5-FRT 
978 CMV 5' LTR hNLRP3 S5 (double exon 6, rescue all 
surface)-mCitrine, 3' LTR 
pR 
1069 CMV 5' LTR hNLRP3 S5 (exon5 all surface to exon 
6)-mCitrine, 3' LTR 
pR 
 
4.1.7. Cell lines 
Unmodified/ received from collaborators 
Cell line Source 
A431 Received from Tomasz Próchnicki 
BLaER1 caspase-4-/- NLRP3-/- Gaidt et al. 2016 105 
E. coli DH5α Life Technologies 
ECV-304 Received from P. Langhof 
Flp-In 293 T-REx Life Technologies 
HEK 293T ATCC 
HEP-G2 Received from S. Schmidt 
Murine Balb/c immortalized 
macrophages (iMo) NLRP3-/- 
Latz Lab, UMASS Worcester, USA, 
produced as Hornung et al. 2008 124 
SW-620 Received from P. Langhof 
THP-1 ATCC 
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Generated cell lines 
Cell line Parent cell line Insert Technique 
BLaER1 NLRP3 ∆ exon 5 BLaER1 caspase-4-/- 
NLRP3-/- 
722 Retro-viral  
BLaER1 NLRP3 full-length BLaER1 caspase-4-/- 
NLRP3-/- 
739 Retro-viral  
Flp-In 293 NLRP3 ∆ exon 5 Flp-In 293 T-REx 801 Flp-In 
Flp-In 293 NLRP3 full-length Flp-In 293 T-REx 785 Flp-In 
iMo NLRP3 iMo NLRP3-/- 565 Retro-viral  
iMo NLRP3 ∆ exon 5 iMo NLRP3-/- 688 Retro-viral  
iMo NLRP3 2x exon 6 iMo NLRP3-/- 714 Retro-viral  
iMo NLRP3 2x exon 6 surface 
rescue 
iMo NLRP3-/- 978 Retro-viral  
iMo NLRP3 double expressing 
high 
iMo NLRP3 722 Retro-viral  
iMo NLRP3 double expressing 
high-intermediate 
iMo NLRP3 722 Retro-viral  
iMo NLRP3 double expressing 
low 
iMo NLRP3 722 Retro-viral  
iMo NLRP3 double expressing 
low-intermediate 
iMo NLRP3 722 Retro-viral  
iMo NLRP3 exon 5 surface to 
exon 6 
iMo NLRP3-/- 1069 Retro-viral  
 
4.1.8. Oligonucleotides 
Assay Target Sequence 
LRR PCR hNLRP3 exon 4 fwd GCTGCAGATCCAGCCCAGCCAG 
LRR PCR hNLRP3 exon 10 rev GTGGTCTTGGCCTGGATGGATCGC 
LRR PCR mNLRP3 Exon 4 for GCTGCAGTGGCAGCCCAGCCAAC 
LRR PCR mNLRP3 Exon 10 rev CCCTATACCAGAAGAGCCTCGGCTG 
LRR PCR pNLRP3 Exon 4 for GCTACAGATTGAGCCCAGCCAGC 
LRR PCR pNLRP3 Exon 10 rev ACATTGGCGTCTGACAGCCTTGG 
LRR PCR LRR PCR human exon 7/8 
rev 
CCAGAATTCACCAACCCCAGTTTCTG
CAGGTTACACTGTGGATTC 
qPCR  HPRT fwd TCAGGCAGTATAATCCAAAGATGGT 
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qPCR HPRT rev AGTCTGGCTTATATCCAACACTTCG 
qPCR hNLRP3 exon 4/5 fwd TGCCTGTTCTCATGGattggtg 
qPCR hNLRP3 exon 5/6 rev AGCGCCCCAACcacaatctc 
qPCR hNLRP3 exon 4/6 fwd CTGTTCTCATGGgttggggc 
qPCR hNLRP3 exon 6/7 rev GCAGCTGACCAACcagagc 
qPCR hNLRP3 exon 6/8 rev GCCAGAATTCACCAACcagagc 
qPCR hNLRP3 exon 6 rev GAGTGCTGCTTCGACATCTCC 
sc-pre-amp HPRT fwd ATTTATTTTGCATACCTAATCATT 
sc-pre-amp HPRT rev GTAATCCAGCAGGTCAGCAAAGAA 
sc-pre-amp hNLRP3 full-length fwd TTTTTGCCGGGGCCTCTTTTC 
sc-pre-amp hNLRP3 full-length rev AGGAGATGTCGAAGCAGCACTC 
sc-pre-amp hNLRP3 ∆ exon 5 fwd AGGCCGACACCTTGATA 
sc-pre-amp hNLRP3 ∆ exon 5 rev ACAGAAGTCTGATTCCGAAGTCAC 
sc-PCR hNLRP3 full-length fwd GACCCAGGGATGAGAGTGTTGT 
sc-PCR hNLRP3 full-length rev CCCAACCACAATCTCCGAAT 
sc-PCR hNLRP3 full-length probe AACGCTCCAGCATCCTGGCTGTAACA 
sc-PCR hNLRP3 ∆ exon 5 fwd CAAGCTCCTCTCATGCTGCC 
sc-PCR hNLRP3 ∆ exon 5 rev GAGATGTCGAAGCAGCACTCAT 
sc-PCR hNLRP3 ∆ exon 5 probe TTCTCATGGGTTGGGGC 
SSO hNLRP3 intron 4/ exon 5 
morpholino 
GCTGTTCACCAATCTAGGAATTAGA 
SSO Std. ctr. morpholino CCTCTTACCTCAGTTACAATTTATAT 
 
4.1.9. Software 
Software Supplier 
CellProfiler (version 2.1.1) Carpenter et al. 2006174 
FACS Diva BD 
Fiji (version 2.0.0) Schindelin et al. 2012175 
FlowJo V10 FlowJo 
Gel scan Quantity One (version 4.6.9) Bio-rad 
Geneious R11 Biomatters 
Illustrator CS6 Adobe 
ImageStudio (version 4.0) LI-COR Odyssey 
ImmunoSpot analysis CTL europe 
MacPyMol Schrödinger LLC 
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Mendeley Desktop Mendeley 
Office 2011 Microsoft 
Photoshop CS6 Adobe 
Prism 7 GraphPad 
QuantStudio 6 and 7 Software Life Technolgies 
SoftMax Pro (version 6.3) Molecular Devices 
ZEN (version 2.0) Carl Zeiss Jena 
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4.2. Methods 
4.2.1. Molecular Biology 
Generation of plasmids 
New plasmids were either created by restriction digest/ ligation of existing plasmids 
or by overlap extension PCR and synthetic fragments. Non-project specific plasmids 
were not newly generated but taken from the Latz laboratory plasmid repository. R. 
Stahl helped with generation of plasmids. 
 
Restriction digest 
3 µg of insert or 6 µg of vector were digested with 2 µL of each enzyme in a volume 
of 50 µL for 60 min at 37 °C. Enzymes with STAR activity where only incubated for 
30 min and inactivated for 5 min at 80 °C. Reaction products were separated on a 1-
2 % agarose gel with PeqGreen (1:20000) in TAE buffer. Respective bands were 
visualized and sliced out on a UV-table. DNA was isolated from gel fragments using 
PureLink Quick Gel extraction kit according to the manufacturer’s instructions. 
 
Overlap extension PCR 
Synthetic fragments were ordered via GeneArt (Thermo Fisher). Overlapping primers 
were used to create fragments, which could be fused by splice PCR and ligated into 
the respective vector. 
 
Ligation 
Purified vector and insert were combined in a molar ration of 1:3 (200 ng vector) with 
4 µL 5x ligation buffer and 1 µL ligase. The reaction was carried out in a volume of 
20 µL for 30 min at 22°C.  
 
Transformation  
20 µL of competent bacteria (DH5α) were thawed on ice, 3 µL ligation mix were 
added and cells were incubated for 30 min on ice before heat shock at 42°C for 45 s. 
Then bacteria were incubated for another 2 min on ice and allowed to grow for 1 h at 
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37 °C in 150 µL LB medium at 750 rpm. Pre-culture was streaked out on an LB agar 
plate with selection antibiotic and incubated at 37 °C over night. 
 
Plasmid preparation 
For plasmid preparation, a single clone was picked from an LB plate or a culture was 
inoculated from a clonal glycerol stock. Miniprep cultures were grown in 4 mL LB 
medium, maxiprep cultures in 100 mL LB medium with 100 µg/ mL ampicillin 
overnight shaking at 37 °C. Plasmid preparations were performed with the PureLink 
Quick Miniprep/ Maxiprep kit according to the manufacturer’s recommendations. 
 
Plasmid verification 
Each newly created plasmid was controlled by test digestion to verify successful 
ligation. Positive clones were Sanger-sequenced (GATC Biotech, Konstanz) over the 
insertion/ mutation sites. Received DNA sequences were aligned against the in silico 
created vector in Geneious software using pairwise alignment. 
 
RNA extraction 
A confluent 12- or 6-well was used for RNA extraction. Cells were primed as 
indicated in the figures. Afterwards, cell culture supernatants were discarded and 
cells were washed once with PBS. RNA isolation was performed using the RNeasy 
mini kit according to the manufacturer’s recommendations. Cells were lysed in 350 
µL RLT lysis buffer supplemented with 1% β-mercaptoethanol. Lysates were stored 
at -80 °C. A DNase I digest on columns was performed for 15 min at RT. Eluted RNA 
was spectroscopically quantified (260 nm) and analyzed for contaminations (260:280 
<2 for proteins, 260:230 for organic solvents). RNA was stored at -80 °C. 
 
cDNA transcription 
The amount of RNA used for cDNA transcription was adjusted between samples of 
one experiment (between 250 ng to 1 µg of RNA). The volume of RNA was adjusted 
with RNase-free water to 12.9 µL. 1 µL of oligo-dT(18) primer was added and 
samples were heated up to 65 °C for 5 min. Then, the samples were transferred to 
ice and 4 µL 5x reaction buffer, 1 µL 10 mM dNTPs, 1 µL 0.1 M DTT and 0.1 µL 
SuperScript III were added to each sample. A pooled control without reverse 
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transcriptase (noRT) reaction was performed as well. Reverse transcription was 
conducted at 50 °C for 50 min and terminated by heating to 85 °C for 5 min. cDNA 
samples were diluted 1:10 to 1:20 for use in qPCR and stored at -20°C. 
 
LRR PCR 
PCRs of the whole NLRP3 LRR were performed to detect all possible isoforms. 2 µL 
of cDNA were mixed with 12.5 µL EconoTaq Plus 2x mix, 0.4 µL of an exon 4 binding 
fwd primer and an exon 10 binding rev primer. The reaction volume was adjusted to 
25 µL with water.  
The following PCR program was used: 
1. 94°C 1 min 
2. 94°C 30 s 
3. 58°C/65°C 30 s 
4. 72°C 3 min  ->34x back to 2. 
5. 72°C 10 min 
Human- and mouse-specific primers were annealed at 65 °C, pig-specific primers at 
58 °C. 
Afterwards, the PCR products were separated on a 1 % agarose gel stained with 
PeqGreen and bands were visualized using VersaDoc Molecular Imager. 
 
Sanger sequencing of LRR PCR Products 
NLRP3 LRR PCR products were generated as described above, with the only 
modification that a Pfu proofreading polymerase was used. All fragments lacking one 
or more exons were isolated from the gel, purified and blunt-ligated into pJet vectors, 
using CloneJET PCR Cloning Kit. Bacteria were transformed, single clones were 
picked and plasmids were isolated. Afterwards, the inserted PCR fragment was sent 
for Sanger sequencing (GATC Biotech, Konstanz). Sequencing results were 
pairwise-aligned against NLRP3 (NM_004895) using Geneious software to 
determine which exon was spliced out. 
 
Sybr Green qPCR for NLRP3 isoform abundance 
Quantitative realtime PCRs were performed in 384 well plates on a Quant Studio 6. 2 
µL of cDNA were mixed with 5 µL Sybr Green mastermix, 2 µL of 2 µM 
forward/reverse primer mix and 1 µL water. 
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40 PCR cycles were performed, starting with an initial denaturation at 95 °C for 10 
min followed by cycles of denaturation at 95 °C for 15 s annealing/elongation phase 
at 60 °C for 1 min (1.6 °C/s). After the last cycle, a meltcurve analysis was 
performed, ranging from 60 °C to 95 °C with 0.05 °C/s. 
The primer efficiency was determined for each primer pair. Therefore. highly 
concentrated cDNA from different samples was pooled and used for all primer pairs. 
cDNA was diluted 1:3 over 8 steps in triplicates. The efficiency was calculated from 
the slope of the standard curve (e=10(-1/slope)). Primer specificity within the highly 
repetitive sequence of the NLRP3 LRR was controlled by Sanger sequencing of the 
PCR fragments. 
 
NLRP3 isoform abundance calculation 
To calculate the relative abundance of each splice variant, the following equation 
was developed: 
Starting with the basic equation of PCR kinetics 
 
(#1) Nc = N0 * Ec 
Nc -> amount of amplicon after c cycles 
N0 -> amount of target at reaction start 
E -> efficiency 
 
Within the log-linear phase of the PCR reaction this can be reformulated to calculate 
the starting concentration 
 
(#2) N0 = Nt / Ec(t)  
Nt -> amount of amplicon at threshold 
C(t) -> fractional cycle to reach threshold 
 
The abundance of one isoform (independent of transcriptional regulation of the gene) 
can be calculated as a fraction of the sum of all isoforms 
 
(#3) RA =N0A / !!"!!!!  
N0A -> Starting concentration of isoform A 
N0B -> Starting concentration of isoform B 
…. 
N0x -> Starting concentration of Isoform X 
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RA -> relative abundance of isoform A 
 
Taking (#2) the equation can be transformed into  
 
(#4) RA = (NtA / EAC(t)A) / (!!"/!!!! !!! ! !)  
 
For a given fixed threshold for all isoforms (NtA= NtB = … = NtX) applies 
 
(#5) RA = (1 / EAc(t)A) / (1/!!!! !!! ! !) 
(#6) RA = EA-c(t)A / (!!!! !!! ! !) 
 
It was further taken into account that two primer pairs had to be designed in a way 
that they could also detect a minor additional splice variant. The primer pair exon 4/5 
to 5/6 designed for the full-length variant would also detect a exon 7 missing variant 
and the primer pair 6 to 6/8 would not only detect exon 7 missing but also exon 5 and 
7 missing. To correct for this, the respective E-c(t) of the respective minor variant was 
subtracted. 
 
Single-cell semiquantitative PCR 
The single-cell semiquantitative PCR protocol was developed with the help of G. 
Seifert. 
Human GM-CSF derived macrophages were LPS-primed for 3 h with 2 ng/ mL LPS. 
Cells were washed with PBS to remove LPS and non-adherent cells (not properly 
differentiated/activated). Cells were trypsin-harvested, washed in media and 
Propidium iodide (PI)-stained 1:500 for 5 min (to discriminate dead cells). Cells were 
washed in medium once more, resuspended at a density of around 2*106 cells/ mL 
and passed through a 70 µm cell strainer. Single PI-negative cells were sorted into 
96-well PCR plates containing 5 µL of PBS using the BD FACS Aria III cell sorter in 
the flow cytometry core facility. Before every sort, the droplet deposition in the middle 
of wells was controlled to prevent cells from being positioned outside of the PBS and 
subsequent desiccation. Plates were sealed, immediately frozen on dry ice and 
stored at -80°C until further use. 
Cells were lysed by thermal shift from -80 °C to 65 °C (2 min). Afterwards, plates 
were placed on ice and reverse transcription mastermix was added. 
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2 µL 5x buffer (Superscript) 
0.5 µL dNTPs (10 mM) 
1 µL DTT (100 mM) 
0.25 µL random hexamers (50 µM) 
0.01 µL RNase inhibitor 
0.25 µL Superscript III (200 U/ µL) 
1 µL water 
 
After a short centrifugation step, the plate was incubated at 37 °C for 60 min, 
followed by an enzyme inactivation phase for 3 min at 95 °C. Targeted pre-
amplification was performed with the whole input cDNA in the same well by 
expanding the volume. The pre-amplification mix contained primers for NLRP3 full-
length, NLRP3 ∆ exon 5 and HPRT. 
 
5.625 µL 10x Ampli taq gold mix 
5.625 µL MgCl2 (25 mM) 
1.125 µL dNTPs (10 mM) 
6x 1.125 µL primer (10 µM) 
0.5 µL Ampli taq gold 
25.375 µL water 
 
The content was mixed on a PCR plate shaker and spun down. The following pre-
amplification PCR protocol was used 
 
1 95 °C 10 min  
2 94 °C 25 s  
3 45 °C 2 min  
4 72 °C 25 s 5x to 2 
5 94 °C 25 s  
6 47 °C 45 s  
7 72 °C 25 s 15x to 5 
8 72 °C 7 min  
9 10 °C --  
 
Detection of pre-amplified cDNA species was performed using taqMan assays for 
NLRP3 full-length, NLRP3 ∆ exon 5, HPRT and 18S RNA on a QuantStudio 6 Flex 
system in 384-well setup. Every reaction was performed in duplicates. 
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NLRP3 variants HPRT/ 18S  
1.8 µL water 
5 µL universal GoTaq Pro Mastermix 
1 µL fwd primer (10 µM) 
1 µL rev primer (10 µM) 
0.2 µL probe (5 µM) 
1 µL pre-amplified cDNA 
3.75 µL water 
5 µL GoTaq qPCR MM 
0. 25 µL HPRT TaqMan assay 
1 µL pre-amplified cDNA 
 
NLRP3 primers were annealed at 55 °C, HPRT and 18S primer at 60 °C. 
 
1 95 °C 2 min  
2 95 °C 15 s  
3 60 °C/55 °C 60 s 40x to 1 
 
Positive control cDNA from bulk cells was created using respective higher 
concentrations of PCR components suitable to reverse-transcribe more RNA. 
 
0.5 µg RNA 
4 µL 5x buffer (Superscript) 
2 µL dNTP (10 mM) 
2 µL random hexamers (50 µM) 
1 µL Superscript III 
2 µL DTT (100 mM) 
fill up to 20 µL with water 
 
Library Prep RNA Seq 
Human GM-CSF-derived macrophages were primed for 3 h with 2 ng/ mL LPS. RNA 
was isolated and stored at -80 °C. RNA integrity was checked for every sample 
before library preparation using an RNA ScreenTape on a Tapestation. RNA content 
and DNA contamination of samples were quantified using a Qubit device. 
2 µg of total RNA were used as input material. RNA Seq library was generated using 
‘SENSE mRNA-Seq Library Prep Kit V2’ according to the manufacturer’s 
recommendation with the following details: For reverse transcription and ligation, the 
RTL buffer was used to generate rather bigger fragments. To further adjust the size 
of the library fragments during the purification after second strand synthesis 14 µL 
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PB and 2 µL PS were used. Before library amplification and adapter attachment, a 
test amplification was performed to prevent over- or under-amplification of the library. 
The library was amplified over 12 cycles using the i7 index primers 7001, 7002, 
7004, 7005 and 7007 to maintain the best possible color-balance during the first 
cycles of RNA Seq. 
The fragment size of the generated library was controlled using a Tapestation D1000 
Screen Tape. 
 
RNASeq 
RNA sequencing was performed on an Illumina HiSeq high output flow cell using V4 
chemistry in the Next Generation Sequencing (NGS) Core Facility of the Medical 
Faculty of the University of Bonn. Sequencing was aimed at 200 M paired-end reads 
per sample (2*125 bp). RNA libraries from 5 donors were pooled and distributed on 4 
lanes. 
 
RNASeq analysis 
Analysis was performed by F. R. Ringeling and S. Canzar (Gene Center, Ludwig-
Maximilians-Universität München). 
Sequencing reads were aligned to the human genome (build GRCh38/hg38) using 
STAR aligner 176 with default settings and transcript annotations from Ensembl 
GRCh38.90: 
> STAR --runThreadN 3 --genomeDir /genome/human/staridx_primary/ --sjdbGTFfile 
/annotation/Homo_sapiens.GRCh38.90.chr.gtf --readFilesIn Donor*_1.fastq 
Donor*_2.fq --outSAMtype BAM SortedByCoordinate 
Transcript abundances for all samples were quantified using Kallisto 177 with default 
settings 
> kallisto quant -i Homo_sapiens.GRCh38.cdna.all.gene.kidx -o $outdir -t 3 
Donor*_1.fastq Donor*_2.fq 
and then summarized to gene level abundances using the tximport Bioconductor 
Package 178. 
Sashimi plots were generated using the sashimi_plot utility from the MISO software 
179, and exon-skipping events were quantified using MISO “exon-centric” percentage-
spliced-in analysis. Soft-clipped adapter sequence was removed from all STAR 
aligned samples and reads were subsequently trimmed to a uniform length of 91 
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bases per read, using in-house developed scripts. MISO was run with the following 
command: 
> miso --run ./index_dir/ ./bams/Donor*.sorted.bam --output-dir miso_out --read-len 
91 
 
4.2.2. Cell culture 
Isolation and differentiation of human primary cells 
Human blood and cells freshly isolated from human blood were always handled with 
special care and were treated as potentially infectious until all tests by the blood 
donation service were passed. 
Human and pig peripheral blood mononuclear cells (PBMCs) were isolated from 
blood cell concentrates from the blood donation service of the University Hospital 
Bonn or heparin anti-coagulated full blood from pigs (received from the UKB animal 
facility, taken from surgery-training animals pre-euthanasia). Blood was diluted 1:1 
with PBS before being layered over Ficoll. Samples were centrifugated for 20 min at 
700 x g without brake. The PBMC layer was collected, re-diluted in PBS to wash 
away remaining contaminations of Ficoll and platelets, and pelleted at 340 x g for 10 
min. The wash step was repeated once and if necessary, red blood cells were lysed. 
The lysis was not performed if PBMCs were further used for a CD14 monocyte 
selection. 
Human monocytes were positively selected using CD14 MACS beads and 
magnetically sorted according to the manufacturers recommendations.  
In order to generate human monocytes derived macrophages (hMDMs), 107 cells 
were seeded per 6 well delta surface plates in 5 mL complete RPMI with 55 ng/ mL 
rhGM-CSF or rhM-CSF (100 ng/ mL) and incubated at 37 °C in a humidified 
incubator with 5% CO2. Cells were used at day 3 and 4 as M0 macrophages or 
further differentiated into M1 or M2 macrophages. Cells were scrape-harvested, 
counted and re-seeded as before and incubated for another 3 days with GM-CSF + 
IFNγ (200 U/ mL) for M1 or GM-CSF + IL-4 (1000 U/ mL) for M2 macrophages. 
Neutrophils were obtained by enrichment of polymorphonuclear cells from fresh 
drawn blood using polymorhprep followed by negative selection for neutrophils 
(easysep human neutrophil enrichment kit. pDCs were isolated from PBMCs using 
the pDC isolation kit from Miltenyi. 
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Generation of BMDMs 
6 - 8 week old WT C57BL/6 mice (Charles River) were sacrificed, femurs and tibias 
were isolated and muscle and tissue was removed. Bones were cut off adjacent to 
the joints and bone marrow was flushed out with PBS. The cell suspension was 
pipetted up and down to prepare a single-cell suspension and passed through a 
nylon filter (70 µm) to a new falcon tube. Cells were pelleted (300 x g 5 min) once 
and resuspended in DMEM supplemented with 20% L929-conditioned supernatant. 
BMDMs were differentiated over 6 days in 5x 10 cm dishes in 10 mL of media at 37 
°C, 5% CO2 in a humidified incubator. Adherent BMDMs were harvested by removing 
media, washing cells in PBS and then incubating cells at 4°C for 10 min in cold PBS 
supplemented with 2 % FCS and 2 mM EDTA. Plates were tapped and still adherent 
cells were gently scraped. Cells were collected, pelleted (5 min at 340 x g) and 
resuspended in DMEM. 
 
Culturing of immortalized murine macrophages 
Immortalized murine macrophages (iMos) were cultured in complete DMEM at 37 °C 
and 5% CO2 in a humidified incubator. Cells were passaged every second day at a 
ratio of 1:10 to 1:20. Therefore, medium was aspirated, cells were washed with PBS 
and harvested with trypsin. Cell suspension was diluted in complete DMEM and cells 
were pelleted at 340 x g for 5 min and reseeded in fresh medium. 
 
Culturing of HEK293T cells 
HEK 293T cells and Flp-In 293 TREx cells were cultured in complete DMEM at 37°C, 
5% CO2 in a humidified incubator. Cells were passaged every second to third day at 
a ratio of 1:5 to 1:15. Therefore, medium was aspirated, cells were washed with PBS 
and harvested with trypsin. Cell suspension was diluted in complete DMEM and cells 
were pelleted at 340 x g for 5 min and reseeded in fresh medium. 
 
Culturing of THP-1 cells 
THP-1 monocytes were cultured in suspension flasks in complete RPMI at 37 °C, 5% 
CO2 in a humidified incubator. Cells were passaged to maintain a density of 3x105-
8x105 cells/ mL. Before experiments, cells were differentiated in complete RPMI with 
500 nM PMA overnight. The next day, cells were washed and left to rest for another 
24 h in fresh complete RPMI before experiments were performed. 
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Culturing of BLaER1 cells 
BLaER1 cells were cultured in complete RPM in suspension flasks at 37 °C, 5% CO2, 
in a humidified incubator. For experiments, cells were trans-differentiated into 
monocytes. 7*105 cells were seeded in 100 µL RPMI supplemented with 10 ng/ mL 
of hrIL-3, 10 ng/ mL hrM-CSF and 100 nM β-Estradiol per 96-well for 6-7 days at 37 
°C, 5% CO2, in a humidified incubator. 
 
Culturing of further cell lines 
A-431, HepG2 and SW-620 cells were cultured in complete DMEM, ECV-304 were 
cultured in 199-Medium supplemented with 10% FCS. 
 
Freezing and thawing of cells 
Cells were harvested and resuspended in fresh medium at a density of 1 x106 to 
10x106 cells. 500 µL of cell suspension were mixed with 500 µL of 2x freeze mix in 
cryo-tubes. Vials were frozen down in isopropanol freezing containers at -80 °C to 
ensure a slow and continuous temperature drop. After one day, cells were 
transferred to -150 °C for permanent storage. Cells were thawed in a water bath at 
37°C. As soon as nearly all ice was melted, cell suspension was mixed with 10 mL 
pre-warmed medium to dilute the DMSO. Cells were pelleted, resuspended in fresh 
medium and plated. 
 
Transient transfection of cells 
Cells were seeded and allowed to settle down. DNA was diluted in serum-free Opti-
MEM medium. Transfection reagent (Genejuice or Lipofectamin 2000) was also 
diluted in serum-free Opti-MEM medium according to the manufacturers 
recommendations. After 5 min, DNA and transfection reagent were mixed and 
incubated for another 15 min before addition to cells. 
 
Splice-switching oligos 
Day 3 differentiated hMDMs were seeded with rhGM-CSF (55 ng/ mL) in complete 
medium and were allowed to settle before transfection. Morpholinos were heated up 
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to 65 °C before use to recover full activity. Morpholinos and Endoporter were 
premixed and carefully added to the cells to a final concentration of 6 µM each, or 
respective concentrations during the titration experiment. Cells were LPS-primed 39 
h after transfection. 
 
Viral transduction and fluorescent cell sorting 
Virus-related work was exclusively performed in S2 areas and only after extensive 
training. 
Viral vectors for retroviral transduction of target cells were produced in HEK 293T 
cells. To prevent further reproduction of the virus, the viral vector was created by 
transfecting 3 separate plasmids into HEK 293T cells: The gene of interest in a 
retroviral vector plasmid, a gag-pol packaging plasmid and vesicular stomatitis virus 
(VSV)-G plasmid for virus entry into cells. 
0.6*106 HEK 293T cells were seeded per 6 well in DMEM in the evening before 
transfection and incubated at 37 °C, 5% CO2 in a humidified incubator. The next day, 
2 µg of retroviral vector construct, 1 µg of gag-pol plasmid and 100 ng of VSV-G 
plasmid were transfected using GeneJuice. Medium was replaced with 30 % FCS 
containing DMEM (for iMos) or RPMI (for BLaER1, THP-1) 24 h after transfection. 
For transduction of iMOs, arround 0.1*106 immortalized macrophages were seeded 
as target cells. Another 24 h later, the viral vector-containing supernatant was 
harvested and filtered through a 0.45 µm filter to exclude cellular contamination of 
the target cells. Media was removed from the target cells and replaced with filtered 
supernatant. 
Suspension cells were spin-transduced. 105 cells were resuspended in filtered 
supernatants with 8 µg/ mL (THP-1) or 2 µg/ mL (BLaER1) polybrene. Cells were 
pelleted at 800 x g for 50 min at 32 °C. Cells were carefully resuspended and further 
incubated at 37 °C, 5% CO2 in a humidified incubator. 
The viral vector-containing media was removed 24 h after infection. Cells were kept 
for 3 further passages before being moved to the normal cell culture or FACS sorting 
facility. 
Most transduced genes of interested were fused to fluorescent reporter tags which 
were used to select for positively transduced cells and to sort cell lines of one 
experiment to a comparable expression level. FACS sorts were performed with 
assistance of the staff of the flow cytometry core facility of the University Clinics 
Bonn. 
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Flp-In 
Flp-In 293 TREx cells were used to generate NLRP3-expressing ASC reporter cells. 
The Flp-In system was chosen to ensure that every cell contains exactly one copy of 
the genes of interest. By combining NLRP3 and ASC into one Flp-In vector, it was 
ensured that all cells were double positive. NLRP3 expression was strongly 
suppressed by the Tet-repressor to prevent overexpression-induced activation of the 
NLRP3 inflammasome. Cells were selected over 3 passages with 15 µg/ mL 
blasticidin before transfection to select for the expression of TetR. 
7.5*104 cells were seeded in 0.6 mL complete DMEM and co-transfected with a 
vector encoding Flp recombinase and an FRT-site containing vector encoding 
tetracycline-inducible NLRP3-tagRFP, ASC-mTurquoise and a hygromycin 
resistance using GeneJuice transfection reagent. Medium was changed after 12 
hours, and one day post transfection, hygromycin B (150 µg/ mL) selection was 
started. The following 3 days, medium was changed every day, afterwards as 
necessary. Hygromycin selection was performed for two to three weeks. 
 
Activation of cells 
0.7*105 to105 cells were seeded for activation assays per 96 well or 2*106 per 6 well 
in the evening before. Medium was changed before stimulations. Cells were 
activated in 100 µL per 96 well or 1 mL per 6-well. If not indicated differentially, the 
following concentrations and time points were used: Human cells were primed with 2 
ng/ mL LPS, mouse cells with 200 ng/ mL LPS for 3 h, R848 1 µg/ mL for 3 h, 
Pam3CSK4 1 µg/ mL for 3 h. 50 µL of supernatant were taken worth after priming to 
determine TNF levels. Inflammasome activators were afterwards added as 50 µL 2x 
concentrate per 96-well. The NLRP3 inflammasome was activated with 10 µM 
nigericin for 60 to 90 min, 5 mM ATP for 60 min, 1 mM LeuLeuO-Me for 4 h, Silica 
1000 µg/ mL for 6 h, R837 20 µg/ mL for 1.5 h, PGN 25 µg/ mL for 20 h, the non-
canonical NLRP3 inflammasome was activated with cytosolic LPS, delivered with 
Cholera toxin subunit B (20 µg/ mL + 2 µg/ mL LPS) or with DOTAP (3.75 µg/ mL + 
750 ng/ mL LPS); the NLRP1B inflammasome with 1 µg/ mL Anthrax lethal factor + 1 
µg/ mL protective antigen (PA) for 4 h; the NLRC4 inflammasome in mouse cells with 
LFn-PrgI (4 µg/ mL)+ PA (1 µg/ mL) for 4 h and in human cells with LFn-PrgI 3 ng/ 
mL and PA 1 µg/ mL for 2.5 h; the AIM2 inflammasome with poly (dA:dT) (200 ng 
transfected with 0.5 µL Lipofectamine 2000 per 96-well). 
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4.2.3. Microscopy and Flowcytometry assays 
Expression analysis (flow cytometry) 
To verify equal expression of recombinant proteins with fluorescent color tags in 
stable cell lines, cells were harvested, resuspended in PBS and passed through a 70 
µm cell strainer to ensure a single-cell suspension before analysis at a MACSquant 
(VYB/ Analyzer10) or Canto II flow cytometer. Debris was excluded by gating in the 
FSC/SSC. Next, doublets were excluded by plotting SSC-A vs. FSC-W. All remaining 
events were considered cells and analyzed for their intensity in the respective 
fluorescent channel. 
 
ASC speck assay (microscopy) 
To ensure a good attachment of cells to the bottom of the well, plates were 
pretreated with poly-L-lysine for 5-10 min at 37 °C and washed afterwards with PBS 
before cells were seeded.  
Flp-In 293 TREx cells expressing NLRP3 variants were either activated using 
nigericin or doxycycline-induced overexpression of NLRP3 variants was used to 
induce ASC speck formation. Cells were seeded the evening before and were 
stimulated with 10 µM and lower doses of nigericin for 2.5 h. For doxycycline-induced 
overexpression activation, cells were treated for a minimum of 8 h with doxycycline 
doses between 100 and 0.05 ng/ mL. 
After the activation was completed, all cell types were fixed with 2% formaldehyde 
and nuclei were stained using DRAQ5 for 30 min at RT. Cells were washed once in 
PBS before imaging. hMDMs were stained in permeabilization/ blocking-buffer at 4 
°C overnight with anti-ASC-AF488 antibody. 
Cells were imaged using a Zeiss Observer.Z1 epifluorescence microscope. Five to 
nine images were taken per well. Images were quantified using Fiji software (using 
find maxima function) 175 or Cell Profiler 174 software, based on a pipeline created by 
G. Horvath. 
 
ASC speck assay (flow cytometry) 
Cells were harvested and 5*104 cells were resuspended in 500 µL HEPES-buffered 
DMEM containing 20 µM zVAD-FMK. Cells were activated in suspension for 3 h with 
nigericin in a shaking heat block at 37 °C. Cells were fixed with 4 % formaldhyde and 
analyzed on a CANTO II flow cytometer. Data was analyzed using FlowJo software. 
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Confocal microscopy 
iMos were primed with LPS. Caspase inhibitor VX-765 (30 µM) was added 20 min 
before the addition of nigericin to prevent pyroptosis. Cells were pulsed with nigericin 
(20 µM) in the presence of the membrane dye WGA-Alexa Fluor 633 (25 ng/ mL) and 
the nuclear dye Hoechst 34580 (1:1000). Cells were washed twice in PBS after 20 
min and cells were covered in medium before imaging at a Leica SP5 AOBS with a 
63x objective. 
 
4.2.4. Biochemical Assays: 
Cytokine detection 
Cytokine release after stimulation of cells was quantified using either enzyme-linked 
imunnosorbent assay (ELISA) or homogenous time-resolved fluorescence assay 
(HTRF).  
Supernatant was either used immediately after the experiment or stored at -20 °C. If 
necessary, supernatants were diluted in the respective medium.  
ELISAs were performed according to the manufacturer’s recommendation, except for 
the fact that all volumes were reduced by 50 %. TMB substrate color change was 
measured at 450 nm and 570 nm at the SpectraMax i3 plate reader. 
HTRFs for mouse cytokines were performed using 12 µL of supernatant and 1.5 µL 
each of the donor and acceptor antibody. HTRFs for human cytokines were 
performed using 5 µL of supernatant and 2.5 µL of each antibody. Assays were 
either incubated for 3 h at RT or over night at 4 °C. Fluorescence of donor and 
acceptor were measured at 620 and 668 nm, respectively, at the SpectraMax i3 plate 
reader with a measurement delay of 50 ms. 
ELISpot assays were performed according to the manufacturer’s recommendations. 
To assure enough distance between single-cells and to allow for single spot 
discrimination, 300 hMDMs were seeded per 96 well. ELISpots were measured at 
CTL Europe (Bonn). 
 
Cell viability assays 
Cell viability after inflammasome activation was either assessed via CellTiterBlue 
(CTB) or lactate dehydrogenase (LDH) release assay. The CTB assay measures 
cellular viability via the metabolic activity of the cell, whereas the LDH assay 
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indicates loss of cellular membrane integrity, causing the release of strictly cytosolic 
LDH into cell supernatants. 
After supernatants for cytokine detection had been harvested, 50 µL medium 
containing 10% CTB reagent were added per 96-well and incubated for 30 min to 2 
h. Fluorescence was measured using a SpectraMax i3 fluorescence plate reader 
using an excitation wavelength of 530-570 nm and detecting emission at a 
wavelength of 580-620 nm.  
If LDH assays were performed, inflammasome activation was performed under 
serum-free conditions to minimize background. Supernatants were used fresh or 
after one freeze/thaw cycle. 12 µL of cell supernatants were mixed with 12 µL of 
assay reagent in a 384 well plate. The colorimetric assay was measured using 
SpectraMax i3 plate reader at 490 nm und 680 nm. 
 
Generation of lysates/ precipitates from supernatants 
2*106 iMos were seeded per 6-well in complete DMEM. Cells were stimulated after 
overnight incubation in serum-free medium. Supernatants were harvested and 
proteins were precipitated by addition of an equal volume of methanol and 0.25 
volumes of chloroform. The upper phase was discarded after centrifugation for 3 min 
at 20 000 x g, the same volume methanol was added and the centrifugation was 
repeated. The pellet was air-dried and resuspended in LDS-buffer. Cells were 
washed with PBS and lysed in NP-40 buffer supplemented with cOmplete protease 
inhibitor and PMSF (0.2 mM). Cells were incubated on ice for 10 min, scrape-
harvested, transferred into microreaction tubes and incubated for another 10 min on 
ice before nuclei were pelleted at 1000 x g for 10 min at 4 °C. A BCA assay was 
performed according to the manufacturer’s recommendations and samples were 
adjusted to same protein content. Lysates and precipitates were denatured by 
addition of LDS and reducing reagent and subsequent heating to 85 °C for 10 min. 
Samples were either stored at -20 °C or used immediately. 
 
(Co-)Immunprecipitation (IP) 
1 to 3 confluent 6-wells were lysed in IP-buffer supplemented with cOmplete, PMSF 
(0.2 mM) and phosStop. Samples were kept on ice for a total of 20 min and carefully 
vortexed every 5 min. Nuclei were removed as above and protein content was 
adjusted after BCA. mCitrine IPs were performed in GFP-trap plates, all other IPs 
using protein G Dynabeads coupled to the respective antibodies. IPs were performed 
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with agitation at 4 °C for 2 to 4 h. Samples were eluted using LDS buffer and 
reducing agent. 
 
Isolation of ASC specks 
2*106 cells were seeded per condition, primed as usual and activated with 5 mM ATP 
for 3 h. Supernatants of pyroptotic cells were harvested and passed through a 5 µm 
strainer to exclude cells and specks were pelleted at 20,000 x g for 10 min. The 
pellet was resuspended in LDS buffer and separated by SDS-PAGE. 
 
SDS-PAGE and Westernblotting 
Samples were heated up to 85 °C for 10 min with agitation before loading on a 4-
12% or 10% NuPage Bis-Tris gel. Samples and 3 µL PAGE Ruler Plus protein 
marker were separated by gel electrophoresis with MES or MOPS buffer until 
sufficient separation was achieved. Proteins were transferred at 30-32V for 60 to 90 
min in an XCell II blotting system on an Immobilon-FL PVDF membrane. Membranes 
were blocked with 3% BSA in TBS. Primary antibody staining was performed at 4 °C 
ON in 3% BSA/TBS-T. Blots were washed 3 times, secondary antibody was 
incubated for 1 h at RT, Blots were washed another 3 times and imaged with a 
LICOR near-infrared detection system. 
 
4.2.5. In silico analysis 
Sequence motive dependent alternative splice prediction 
Spliceport (http://spliceport.cbcb.umd.edu/) was used to analyze the strength of the 
splice donor and acceptor sites of human NLRP3 180. The number of exonic splice 
enhancer sites within the LRR exons of human NLRP3 was assessed with 
RescueESE (http://genes.mit.edu/burgelab/rescue-ese/) 181. 
Physico-chemical protein characteristics for the (artificial) splice variants were 
calculated using the ProtParam online tool (http://web.expasy.org/protparam/). 
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Structural analysis of LRRs 
Structural models of the NLRP3 LRR were generated by R. Brinkschulte and M. 
Geyer using SwissModel. The crystal structure of human ribonuclease inhibitor (PDB 
accession: 2q4g) was used as a template. 
Most structural alignments of LRRs were based on previous work by M. Geyer. RI- 
and T-Type consensus sequences were published before182. 
NLRP3 LRR sequence logo was generated using Geneious software. 
 
LRR exon structure analysis 
LRR exon database extractions were performed by F. R. Ringeling (Gene Center, 
Ludwig-Maximilians-Universität München), based on my ideas. Data was provided in 
form of text files listing all LRR exons and the respective genomic locations. 
Phylogenetic analysis of the identified ‘peak-genes’ was performed by F. R. 
Ringeling. 
LRR annotations for human proteins were performed using the ensmbldb 
Bioconductor Package 183. All known canonical transcripts as defined by UCSC 
(GRCh38) were queried for LRR domains annotated by the SMART database, 
namely: SM00369, SM00370, SM00364, SM00367, SM00368 and SM00365.  
All exons spanning LRR domains were extracted for further analysis: exons were 
divided into frame-preserving (dividible by 3) or frame-shifting, and plotted for their 
length distribution. Genes contributing to the major peaks within the exon length 
distribution plot (69-75, 81-87, 141-147, 168-174 bp) were identified and used to 
create a phylogenetic tree. Amino-acid sequences were aligned using MUSCLE 184 
and the dist.ml function from the phangorn Bioconductor package 185 was used with 
default settings to create a distance matrix that was then used to estimate an un-
rooted phylogenetic tree using the Neighbor Joining clustering method. 
 
4.2.6. Statistics 
Data are typically represented as mean ± standard error of the mean (SEM) for 
pooled data of a minimum of 3 independent experiments or pooled date from a 
minimum of 3 individuals. Otherwise, data were represented as mean ± standard 
deviation (SD). Statistical analysis was performed using Microsoft Excel and 
GraphPad Prism. Statistical differences were calculated using two-way ANOVA with 
Tukey post-test for multiple comparisons. 
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4.2.7. Ethics 
Human primary cells were extracted from blood concentrates provided by the blood 
donation service of the University Clinics Bonn (ERC Ethikantrag Lfd. Nr. 184/16 
“Activation and regulation of Inflammasomes (InflammAct)” 
Mouse bone marrow was isolated in accordance with local regulations. 
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5. Results 
5.1. The LRR domain of NLRs exhibits a highly 
conserved exon organization 
LRRs are widely used structural elements and the innate immune receptor families of 
NLRs and TLRs rely on them. While in TLRs most of the LRR is encoded by a single 
long exon, the NLR LRR is encoded by multiple short exons (Figure 5-1 A). 
The repetitive architecture of LRR exons suggests a potential gain of receptor 
diversity through AS, which might be conserved across further LRR-encoding genes. 
A database analysis of exons from all human proteins within annotated LRR regions 
was performed in cooperation with F. R. Ringeling (Figure 5-1 B). The majority of all 
detected exons contains less than 200 bp (Figure 5-1 C), similar to the exons in NLR 
LRRs. 
 
 
Figure 5-1 LRR domains often consist of multiple short exons 
A Schematic of domain and exon distribution in TLR4 and NLRP3. B Workflow of the database 
extraction of LRR exons from the human proteome. Database extraction was performed by F. R. 
Ringeling according to my design. C Length distribution of exons extracted in B. E: Exon, TM: trans 
membrane domain, TIR: Toll/IL-1 receptor homology domain. 
 
Depending on their exact length, exons can be frame-shifting, which results in the 
disruption of an open-reading frame in case of AS. To further characterize the 
aforementioned in silico extracted exons, they were divided into frame-shifting and 
frame-preserving exons and plotted for their length distribution (Figure 5-2 A). 
Although in a random distribution of splice sites, two thirds of exons should be frame-
shifting, the huge majority of the LRR exons is frame-preserving, indicating an 
evolutionary pressure to preserve protein translation after AS. Moreover, the exons 
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cluster in 4 distinct peaks corresponding to the typical size of one or two LRRs (69-
87 bp or 23 to 29 aa per LRR), indicated by grey boxes. Next, the genes contributing 
to the different peaks were identified and plotted in size according to their 
contribution to each peak (Figure 5-2 B). To analyze the relationship of the identified 
genes, a phylogenetic tree was created by F. R. Ringeling (Figure 5-2 C). An 
enrichment of several gene families, which cluster for the number of encoded LRRs 
per exon and the LRR type, can be observed. While all LRRs share the characteristic 
secondary protein structure and a core consensus sequence, several subtypes can 
be defined 182. The here extracted LRRs belong either to the ribonuclease inhibitor 
(RI) or bacterial/typical (S/T) type of LRRs. 
 
 
Figure 5-2 LRR domains have a conserved multi-exon organization 
A All LRR exons extracted in Figure 1 of up to 200 bp in length were plotted for their frequency 
distribution. Exons were divided in frame-shifting or frame-preserving. The typical length of LRRs (23 to 
29 aa) is indicated by grey boxes in the upper panel. Colored boxes in the lower panel are included to 
allow for the assignment of groups in the following subfigures. B Genes in word clouds represent genes 
whose exons contribute to the respective peaks in A. Word size corresponds to the number of 
contributing exons. C Phylogenetic analysis of all genes contributing to the 4 major peaks in A. 
Phylogenetic tree was created by F. R. Ringeling. D LRR consensus sequences 182 and structural 
alignments for the 4 groups identified in A to C. Each line represents on repeat, colors mark different 
exons. In the consensus sequence, ‘x’ is any residue, ‘o’ is a non-polar residue, ‘z’ is a frequent 
deletion. Structural RI-type LRR alignments are based on previous analysis by M. Geyer. aa: amino acid 
RI: ribonuclease inhibitor, S/T bacterial/ typical. 
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Figure 5-3 NLR LRRs are highly conserved and qualify for alternative splicing 
Structural alignments of NLR LRRs were created based on previous work by M. Geyer (for all 
alignments, see appendix Figure 12-1). A Most NLRs can be grouped according to their exon LRR 
structure: ones encoding two LRRs per exon and ones encoding a single LRR per exon. Structural 
alignments of NLRP3 and NOD1 LRR are given as examples. Secondary structure elements are 
indicated on top. Blue and red indicate repetitive LRR exons. Conserved residues defining the LRR fold 
are highlighted in bold. B Sequence logo of the NLRP3 LRR (exon 5 to 9), indicating the high degree of 
conservation of leucine residues. Size of letters indicates conservation and aminoacids with a minimum 
of 65 % conservation are shown in the consensus sequence. Mean hydrophobicity and identity of each 
position of the LRR are plotted as well. C Model of the NLRP3 LRR based on the human ribonuclease 
inhibitor LRR crystal structure. The different exons are indicated in different colors. R. Brinkschulte 
created the model. D Quantification of frame-shifting vs frame-preserving exons of all LLR exons vs. 
non-LRR exons of all NLRs. 
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A structural alignment for the RI-type and T-type LRRs encoding one or two LRRs 
per exon was generated according to the respective consensus sequences 182 
(Figure 5-2 D). Each line indicates one LRR encoding for a β-sheet and a α-helix and 
colors indicate exons. Intriguingly, in all four LRR subtypes, the exon-exon boundary 
is conserved within the same position of the repeat, suggesting a conservation of the 
exon-LRR organization to maintain the compatibility for AS in multiple gene families. 
The further analysis was focused on LRRs in genes associated with the IS. Structural 
alignments for all NLR LRRs were generated based on previous work by M. Geyer 
(for all alignments, see appendix Figure 12-1). Interestingly, most NLRs cluster into 
two groups based on their exon size. NLRP exons encode two alternating repeats of 
28 and 29 aa, while NOD/NLRC exons encode a single LRR of 28 aa. Yet, the exon-
exon boundary is conserved in the same position at the end of the β-sheet (Figure 
5-3 A). NLRC5 constitutes an exception, as the first part of the unusually long LRR 
domain (> 40 repeats) does not show a conserved exon-LRR relationship, while the 
second part correlates with the other NLRCs/NODs. This repetitive exon architecture 
is a necessary precondition for the generation of functional isoforms by AS. The 
removal of one or several exons will produce a shorter LRR domain, likely without 
interfering with the overall protein fold, as the hydrophobic residues forming the core 
of the LRR scaffold are conserved (Figure 5-3 B). The overall shortening of the LRR 
without interfering with the secondary structure, is also supported by a model of the 
NLRP3 LRR structure, based on the RI crystal structure (Figure 5-3 C). Moreover, 
close to two thirds of the non-LRR exons of all NLRs are frame-shifting as 
stochastically expected, but nearly all LRR-exons are frame-preserving (Figure 5-3 
D), allowing for AS without introducing nonsense mutations. 
In conclusion, the small LRR exons of NLRs and some other protein families show a 
conserved exon organization allowing for AS without frame-shifts and without 
destroying the secondary structure and support a modular-splicable structure of the 
LRR. 
 
5.2. The splicing landscape of human NLRP3  
In order to analyze AS of NLRs, deep RNASeq was performed from LPS-primed GM-
CSF-derived human monocyte derived macrophages (hMDMs) of 5 healthy donors, 
and bioinformatics analysis was done in cooperation with S. Canzar and F. R. 
Ringeling (for mapping summary, see appendix Table 12-1). From all previously 
identified RI-type LRR-expressing genes (Figure 5-2 C), only 8 were expressed  
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(Figure 5-4 A): RNH1, the prototype LRR ribonuclease inhibitor, as well as NLRP3, 
NLRP1, NOD2, CIITA, NLRP2, NOD1 and NLRP12. For all of these genes, MISO 
was used to analyze AS and to generate sashimi plots (Figure 5-4 B and appendix 
Figure 12-2). Sashimi plots show the mapping of reads to a genomic location and 
highlight exon-spanning reads as arcs connecting exonic locations. Of all analyzed 
NLRs, NLRP3 shows the most prominent AS events. In order to quantify the AS 
events, exon inclusion levels (ψ) and confidence intervals were calculated for exon 5 
and 7 (Figure 5-4 C, D). The narrow confidence intervals of the ψ histograms indicate 
a high level of certainty for the inclusion frequency of the respective exon according 
to the read distribution. It is obvious that exon 5 is consistently the most skipped 
exon (33 %) followed by exon 7 (2.6 %). Although this pattern was consistent, minor 
splicing differences were observed between donors.  
 
 
Figure 5-4 The splicing landscape of human NLRP3 
Deep RNASeq was performed on LPS-primed human monocyte-derived macrophages (hMDMs) from 5 
healthy donors. A Gene expression as transcripts per million (tpm) of all previously identified RI-type 
LRR encoding genes (Figure 5-2 D to F). B Sashimi plot of NLRP3 created with MISO. Read frequency 
within exons is plotted as reads per kilobase million (RPKM) and exon-spanning reads are labeled with 
the number of mapped reads. The NLRP3 gene structure is plotted above. Boxes indicate exonic 
regions and arrows within intronic stretches indicate the reading directions. Short repetitive LRR exons 
are highlighted with a grey box. The genomic location is depicted below. C and D Sashimi plots as in B, 
focused on exons 4-5-6 and 6-7-8, respectively. MISO ψ values (red bars in histogram) indicate the 
calculated frequency of exon inclusion. Confidence intervals (CI) are indicated as grey bars in the 
histogram. Ψ and CI values are also listed numerically. 
Results 
65 
 
 
Figure 5-5 The LRR domain of human NLRP3 is subject to alternative splicing 
A Illustration of the NLRP3 exons (E) and domains. Arrows indicate primers used in B, C and Figure 
5-6) B PCR of the NLRP3 LRR on cDNA isolated from LPS-primed mouse BMDMs, pig and human 
PBMCs, respectively. Data are representative of at least 3 (mouse, human) or 2 (pig) individuals. C 
Human PBMCs primed with TLR agonists or left untreated were analyzed as in B noRT: no reverse 
transcription. D The lower band of PCR reactions (as in B) after LPS priming was isolated and 28 clones 
from different donors were sequenced to determine which exon is mostly alternatively spliced. E 
Immunoblot of human NLRP3 from primary human monocyte-derived macrophages (hMDM) or THP-1 
cells. Whole cell lysates (WCL) or NLRP3 immunoprecipitation (IP) with a monoclonal antibody (mAb) 
targeted against the NACHT domain of NLRP3, were detected with an mAb targeted against the PYD to 
ensure NLRP3 specificity. Immunoblots are representative of two experiments. 
 
To validate the bioinformatics analysis, PCRs across the whole canonical LRR region 
of NLRP3 were performed using primers binding in exon 4 and 10 (Figure 5-5 A). 
BMDMs or PBMCs from mouse, pig and human were tested for AS. Slightly different 
primer binding sites in different species cause a different size of the major band 
representing the full-length versions. Surprisingly, an additional shorter band, 
corresponding to the exclusion of one exon, could only be detected in human 
samples (Figure 5-5 B). Next, human PBMCs primed with different TLR agonists 
were tested to determine whether the alternative splice variant expression would be 
changed by stimulation (Figure 5-5 C). While overall NLRP3 expression was 
increased by TLR agonists, the smaller splice variant was neither drastically up- or 
down-regulated relative to the full-length variant. Since the LRR PCR could not 
reveal which of the 5 exons of the exact same length was alternatively spliced, the 
lower band PCR product was isolated, cloned and sequenced. In the large majority 
of sequenced clones, exon 5 was missing and only in one clone, another exon was 
missing (Figure 5-5 D). Since transcription does not necessarily correlate with 
productive translation and a stable protein product, the presence of an alternative 
NLRP3 splice form was confirmed by immunoblot in primary hMDM and in the 
human myeloid cell line THP-1 (Figure 5-5 E). To ensure high specificity of both 
detected bands, the immunoblot was combined with an immunoprecipitation (IP). 
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Different monoclonal antibodies (mAbs) targeted against the NACHT domain and the 
PYD were used. 
AS is reported to be much more prevalent in human than in mice 149. Still, an LPS 
stimulation time-course was performed on mouse BMDMs to exclude a potential up-
regulation of AS at later timepoints after prolonged priming. However, AS of the 
mouse NLRP3 LRR could neither be detected on transcript level by PCR (Figure 5-6 
A) nor by a combined IP-immunoblot approach (Figure 5-6 B).  
 
 
Figure 5-6 Alternative splicing of the NLRP3 LRR cannot be detected in BMDMs 
A PCR of NLRP3 LRR on cDNA from mouse bone marrow derived macrophages (BMDMs) after 
different timepoints of LPS priming. Image is representative of 3 mice. B Immunoblot of mouse NLRP3 
from BMDMs after different timepoints of LPS priming. Whole cell lysates (WCL) or NLRP3 
immunoprecipitation (IP) using mAb against the NLRP3 NACHT domain were detected with an mAb 
against the PYD to ensure NLRP3 specificity. Immunoblots are representative of 3 mice. 
 
PCRs across the whole LRR are a valuable approach as long as it is not known 
which exons can be alternatively spliced. However, bioinformatics analysis of the 
RNASeq data revealed only exon 5 and 7 to be significantly alternatively spliced. A 
qPCR splice panel was developed to specifically detect the prevalence for 4 NLRP3 
isoforms: full-length, ∆ exon 5, ∆ exon 7, ∆ exon 5/7 (Figure 5-7 A). Normalization 
against a housekeeping gene such as hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) (Figure 5-7 B) is suitable to detect the differences 
in expression levels between individuals or after treatments. However, extremely 
different expression levels make it difficult to visualize changes in splice form 
abundance that way. Therefore, the relative abundance of NLRP3 splice forms was 
calculated as a fraction of the overall NLRP3 per sample. As seen before, the most 
strongly expressed alternative splice form is by far ∆ exon 5. Both other targeted 
isoforms can be detected as well, but at expression levels several orders of 
magnitude lower (Figure 5-7 C). Since the regulation of the most prominent and likely 
most biologically important AS events was of highest interest, all results were plotted 
in a linear scale to focus on the most highly expressed variants (Figure 5-7 D to M). 
Multiple different primary myeloid cell types and cell lines treated with various pro- 
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and anti-inflammatory stimuli were tested. Although minor differences could be 
observed between different donors, the splice ratio was always kept stable within one 
donor and no major changes could be detected in the ratio of isoforms across all 
tested samples. Even in a clonal cell line (Figure 5-7 M, BLaER1), the isoform ratio 
was maintained, suggesting no inherited splicing pattern of subpopulations, but 
rather a spontaneous de novo adjustment.  
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Figure 5-7 NLRP3 isoforms show a non-variable expression ratio 
A Illustartion of NLRP3 isoform-specific exon-spanning qPCR primers used to detect NLRP3 full-length, 
∆ exon 5, ∆ exon 7 and ∆ exon 5/7. B Expression of NLRP3 isoforms relative to the housekeeping gene 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). C Exemplary depiction of one data set with a 
logarithmic scale to demonstrate the much lower expression of NLRP3 ∆ exon 7 and ∆ exon 5/7. C to M 
Relative expression of NLRP3 isoforms depicted in A. Expression is calculated as fraction of the sum of 
all NLRP3 isoforms from different human primary cell types and cell lines after different treatments. If 
not differently indicated, LPS treatment was performed for 3 h with 2 ng/ mL. H, I, J and L were 
stimulated for 15 h as indicated. Figure B, C and D are different presentations of the same dataset. B, 
C, D, E, F, L Mean and SD of 2 donors, G, J Mean and SEM of 4 donors, H, I, K Mean and SEM of 3 
donors, M Mean and SD of 2 independent experiments. cDNAs for J and K were provided by L. Labzin. 
 
The structural features of the NLRP3 LRR described above would allow every LRR 
exon to be spliced out equally well. However, our RNAseq and PCR analysis 
revealed a strong tendency for AS of exon 5. Little is known about the complex 
integration of positive and negative splice factors on each splice site to regulate 
splicing. Yet, certain sequence elements can be associated with the strength of a 
splice acceptor or donor side. SplicePort is a tool to analyze pre-mRNA sequences 
and reports scores for splice acceptor or donor sites respectively 180. SplicePort was 
used to analyze the strength of splice donor and acceptor sites in human NLRP3 pre-
mRNA and identified the exon 5 acceptor, followed by the exon 7 acceptor, to be the 
least likely of all NLRP3 LRR splice acceptors to be used (Figure 5-8 A). Exonic 
splice enhancer (ESE) sites assist in exon recognition and are crucial to direct the 
spliceosome towards exon integration. In line with the other findings, the fewest ESE 
sites of the LRR stretch were detected in exon 5 of human NLRP3 using ESEfinder 
186 (Figure 5-8 B).  
Taken together, these findings reveal that alternative splicing of NLR LRR-exons 
takes place, that especially NLRP3 exon 5 is alternatively spliced and that the ratios 
of NLRP3 AS variants are kept stable in all tested conditions and cell types. 
 
 
Figure 5-8 NLRP3 exon 5 shows the highest predisposition for alternative splicing 
A Scores for the probability to function as splice acceptor and donor sites were calculated for all human 
NLRP3 LRR exon boundaries using SplicePort. High scores indicate a high probability to be recognized 
by the spliceosome B Number of exonic splice enhancer (ESE) sites within the exons of the LRR as 
predicted by RESCUE-ESE. 
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5.3. NLRP3 ∆ exon 5 is inactive 
The relatively high expression level of NLRP3 ∆ exon 5 suggests a deliberate isoform 
rather than splicing noise. To elucidate a potential function of this splice variant, 
different model systems and NLRP3 inflammasome activation assays were used, 
which require some considerations: Assays should be performed in cells not 
expressing endogenous NLRP3 to not superimpose the observed effects of a given 
isoform. However, the cells need to express all other inflammasome components or 
a reporter for inflammasome activation. Moreover, transient transfections of NLRP3 
isoforms in cells expressing a functional AIM2 inflammasome result in ASC speck 
formation, caspase-1 maturation and IL-1β secretion via detection of the plasmid 
DNA by AIM2, making the NLRP3 isoform analysis impossible. Finally, NLRP3 over-
expression can cause NLRP3 activation without any further trigger. 
 
5.3.1. NLRP3 ∆ exon 5 is not able to induce ASC speck 
formation in Flp-In 293 reporter cells 
To circumvent the above-mentioned obstacles, 293 T-REx reporter cell lines were 
created using the Flp-In technology. 293 T-REx cells do not endogenously express 
inflammasome components and the Flp-In technology enables exactly one 
integration at a pre-determined site within the genome, reducing the risk of different 
basal expression levels. The Flp-In constructs used here encode inducible NLRP3-
tagRFP behind a tet-repressor, ASC-mTurquoise (mTurq) and a hygromycin 
selection cassette. NLRP3 integration and transcription was assessed by PCR 
across the exon 5 area (Figure 5-9 A), and NLRP3 and ASC protein expression were 
verified by immunoblot (Figure 5-9 B). In order to test the inducible upregulation of 
NLRP3 expression, cells were treated with increasing amounts of doxycycline to 
switch off the tet-repressor. TagRFP fluorescence was monitored by flow cytometry 
as a measure for NLRP3 expression in the different cell lines (Figure 5-9 C and D). 
Of note, a low background expression of both NLRP3 isoforms was observed even 
without doxycycline induction. 
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Figure 5-9 Generation of isoform-specific inducible NLRP3 reporter cells 
Characterization of Flp-In T-REx 293 cells expressing either tetracycline-inducible NLRP3 full-length or 
∆ exon 5, both fused C-terminally to tagRFP. Both Flp-In vectors also encode ASC-mTurquoise. A PCR 
on cDNA created from the stable Flp-In cell lines. Primers targeted against exon 4 and the exon 7/8 
boundary were used to amplify the LRR exon 5 area to verify isoform specificity of the cell lines. B 
Immunoblot expression control of NLRP3-tagRFP and ASC-mTurquoise from Flp-In T-REx 293 cells. 
Control: non-transfected Flp-In T-REx 293 cells. C NLRP3-tagRFP expression was induced in Flp-In T-
REx 293 cells with the respective concentrations of doxycycline. Expression levels were measured by 
flow cytometry. D Quantification of C. Shown are the tag-RFP fluorescence levels as geometric means. 
 
Upon inflammasome activation, all molecules of the adapter ASC are recruited into a 
single multi-protein complex termed ASC speck or pyroptosome. By using 
fluorescently labeled versions of ASC, ASC speck assembly can be used as readout 
for inflammasome activation (Figure 5-10 A). The activity of NLRP3 full-length and 
NLRP3 ∆ exon 5 were assessed by fluorescence microscopy after doxycycline-
induced overexpression (Figure 5-10 B, C) and in the absence of doxycycline after 
activation with the NLRP3 activator nigericin (Figure 5-10 D). Nuclei were 
counterstained and the proportion of cells with an ASC speck was calculated. While 
NLRP3 full-length induced a dose-dependent ASC speck formation for both triggers, 
NLRP3 ∆ exon 5 remained completely inactive. 
To further confirm that NLRP3 ∆ exon 5 expressing cells do not assemble 
inflammasomes with ASC, the interaction between NLRP3 and ASC was 
investigated by co-IP. NLRP3 was immunoprecipitated with an mAb against its 
fluorescent label tagRFP. While both cell lines expressed similar amounts of NLRP3 
and ASC, an interaction between ASC and NLRP3 could only be detected for NLRP3  
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Figure 5-10 10 NLRP3 ∆ exon 5 is not able to induce ASC speck formation in Flp-In 293 
cells 
A Schematic of an inflammasome ASC speck assay. The inflammasome adapter ASC is equally 
distributed across the cytosol in non-activated cells. Upon inflammasome activation all ASC molecules 
oligomerize into one speck. B Flp-In T-REx 293 cells expressing inducible NLRP3-tagRFP and ASC-
mTurquoise (green) were analyzed for ASC speck formation by fluorescence microscopy. Cell nuclei 
were counterstained with DRAQ5 (blue). C Quantification of ASC speck formation after doxycycline-
induced NLRP3 overexpression (0 – 10 ng/ mL doxycyclin). Mean and SD of 9 frames per condition 
N=1. D Quantification of ASC speck formation after 2.5 h stimulation with nigericin (0 - 10 µM). Mean 
and SD of technical duplicates, 9 frames per well, representative of 3 independent experiments. E Co-
immunoprecipitation (IP) of ASC with NLRP3-tagRFP from Flp-In T-REx 293 cells. NLRP3 was 
immunoprecipitated using anti-tagRFP mAb. Asterisk indicates heavy chain of mAb used for IP. Blots 
are representative of 2 independent experiments. 
 
full-length, but not for NLRP3 ∆ exon 5 (Figure 5-10 E). While the presence of the 
heavy chain of the IP mAb (indicated with a red asterisks) at a similar apparent 
molecular weight complicated the analysis, the differential ASC interaction was 
nevertheless obvious. 
To further investigate NLRP3 activation, an assay to detect inflammasome formation 
by flow cytometry based on ASC specks was developed during this study. While 
most flow cytometric assays concentrate on the overall fluorescence (area of the 
signal pulse) or the maximum peak fluorescence (height of the signal pulse), the 
width of the signal pulse provides information about the size of the fluorescent object. 
While the width of a signal, generated by fluorescently marked, randomly distributed 
proteins correlates with the cell size, a dramatic decrease in the width of the signal 
can be observed when all fluorescent molecules cluster in one defined aggregate per 
cell (Figure 5-11 A). Since ASC gets recruited into one spot per cell upon 
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inflammasome activation, the width of the fluorescent signal can be used to 
discriminate cells containing an ASC speck from non-activated cells. 
As seen before by microscopy, NLRP3 full-length expressing cells form ASC specks 
upon nigericin stimulation, while NLRP3 ∆ exon 5 expressing cells stay inactive. A 
respective second population/ peak in the ASC-mTurq width channel can be 
observed for specking cells, confirming the microscopy results (Figure 5-11 B and C). 
The validity and usefulness of this flow cytometry-based approach was confirmed by 
Sester et al., who published similar findings187. 
 
 
Figure 5-11 ASC speck formation can be detected by flow cytometry 
A Principle of the detection of ASC speck formation by flow cytometry. The clustering of all fluorescent 
ASC molecules results in a reduced width of the signal. Scale bar in micrograph 2.5 µm. Modified from 
Hoss et al. 2018 188. B Quantification of nigericin (0 - 7.5 µM) -induced ASC speck formation in Flp-In T-
REx 293 cells cells, analyzed by flow cytometry. C Flow cytometry graphs of B (7.5 µM nigericin). Top 
panel shows ASC speck formation as a dotplot of ASC-mTurquoise area signal versus width signal A – 
area, W – width. Bottom panel shows ASC speck formation as an additional smaller peak in the 
histogram of the ASC-mTurquoise width signal. 
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In summary, it was shown, that NLRP3 ∆ exon 5 is not capable to interact with ASC 
and to induce ASC speck formation. 
 
5.3.2. NLRP3 ∆ exon 5 does not induce caspase-1 maturation 
and IL-1β  secretion in macrophages 
Although Flp-In 293 T-REx cells represent a valuable tool, it is critical to analyze the 
activity of the NLRP3 isoforms also in the context of naturally inflammasome-
competent cells. Therefore, NLRP3-deficient immortalized mouse macrophages 
(iMos) were retroviral reconstituted with the different NLRP3 isoforms fused to a C-
terminal mCitrine fluorescence tag. After generation of stable cell lines, they were 
FACS-sorted to a comparable and low expression level to reduce the risk of 
overexpression-induced activation (Figure 5-12 A). Of note, constantly expressed 
functional NLRP3 results in reduced fitness of the cell and down-regulation after a 
few passages. This might explain the minimally lower expression of NLRP3 full-
length. 
NLRP3 deficient and reconstituted cells were primed with LPS to induce the up-
regulation of pro-IL-1β, and subsequently activated with nigericin or ATP for NLRP3 
inflammasome activation or with B. anthracis lethal toxin (LT) for NLRP1B 
inflammasome activation (Figure 5-12 B). While NLRP3 activation of the full-length 
cell line resulted in mature caspase-1 and IL-1β in lysates and supernatants, NLRP3 
knock-out and ∆ exon 5 expressing cells generated no detectable levels of mature 
caspase-1 and IL-1β. However, both cell lines were fully active after NLRP1B 
stimulation, providing evidence for the functionality of all inflammasome components 
besides NLRP3 in these cells. The apparently reduced expression of β-actin and  
 
Figure 5-12 NLRP3 ∆ exon 5 does not induce caspase-1 maturation and IL-1β  secretion 
in macrophages 
NLRP3-deficient immortalized macrophages (iMos) were retrovirally reconstituted with either NLRP3 
full-length or NLRP3 ∆ exon 5, both with a C-terminal mCitrine tag. Stable cell lines were FACS-sorted 
on a low equivalent NLRP3 expression level. A Flow cytometry analysis of NLRP3-mCitrine showing the 
expression levels of NLRP3 isoforms in the respective cell lines. B Immunoblots of iMos after activation 
of the NLRP3 inflammasome (ATP, nigericin) or the NLRP1B inflammasome (lethal toxin, LT). Blots are 
representative of two independent experiments. C IL-1β secretion after activation of the NLRP3, 
NLRP1B or AIM2 inflammasomes. D TNF secretion after LPS treatment. C and D Mean and SD of 
technical triplicates, representative of 3 independent experiments. E IL-1β secretion after Pam3CSK4 
priming and non-canonical inflammasome activation. Mean and SD of technical duplicates 
representative of 2 independent experiments. F and G IL-1β secretion after potassium-independent 
NLRP3 inflammasome activation via R837 and PGN. F Mean and SD of 2 independent experiments G 
Mean and SD of technical triplicates. N=1. H Confocal micrograph of LPS-primed and nigericin-pulsed 
iMos. Nuclei and Membranes were stained with Hoechst 34580 and wheat germ agglutinin (WGA) AF-
633, respectively. Arrowheads indicate NLRP3 specks. Representative of 2 independent experiments. 
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NLRP3 after inflammasome activation is caused by a pyroptotic burst of 
inflammasome-activated cells and loss of protein content. 
Further inflammasome activators were tested and released IL-1β levels were 
analyzed by ELISA. The NLRP3 activators nigericin, ATP, and silica induced IL-1β 
secretion exclusively in NLRP3 full-length expressing cells, while all cell lines 
secreted IL-1β upon activation of the AIM2 (poly dA:dT) or the NLRP1B (LT) 
inflammasome. LPS-induced TNF secretion (as a control for priming and therefore 
the expression of pro-IL-1β) was also comparable between the cell lines (Figure 5-12 
D). 
After ruling out a role for NLRP3 ∆ exon 5 in canonical inflammasome activation, the 
activation of the non-canonical inflammasome was tested. The non-canonical 
inflammasome is activated upon detection of cytosolic LPS 101. As LPS already 
serves as the activation signal, cells were primed with the TLR2 agonist Pam3CSK4. 
LPS was delivered to the cytosol either using cholera toxin B (CTB) induced 
endocytosis or via transfection with DOTAP. Again, only the NLRP3 full-length cell 
line secreted IL-1β in response to cytosolic LPS (Figure 5-12 E). The same was 
observed when NLRP3 was activated via the non-potassium dependent activators 
R837 and PGN (Figure 5-12 F, G). 
Since inflammasome activation downstream of NLRP3 (recruitment of ASC, 
polymerization of ASC, maturation of caspase-1, and secretion of IL-1β) was not 
triggered, the question was addressed whether NLRP3 ∆ exon 5 is still capable to 
form a seed for ASC recruitment. While some NLRP3 aggregates could be observed 
by confocal microscopy after inflammasome activation in the full-length expressing 
cells, this was not as obvious for NLRP3 ∆ exon 5 (Figure 5-12 H).  
In summary, NLRP3 ∆ exon 5 was shown to be not activatable in reconstituted iMos, 
while NLRP3 full-length acted as expected. 
 
5.3.3. Morpholinos can be used to alter splice patterns in 
primary human monocyte-derived macrophages 
While the inactive phenotype of NLRP3 ∆ exon 5 was highly reproducible in model 
systems, confirmation of these findings in primary cells was missing. However, it 
remained a challenge to analyze this splice form in primary cells because they 
always expressed both major splice variants and none of the tested stimuli was 
shown to regulate NLRP3 splicing. 
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Figure 5-13 Morpholinos can be used to alter splice patterns in primary human 
monocyte-derived macrophages 
A Left panel: Chemical structure of morpholino oligomers. Right panel: schematic of the principle of 
splice-switching oligonucleotide (SSOs). B Endoporter titration to assess cytotoxicity. DMSO only 
corresponds to the highest used DMSO concentration (10 µM Endoporter, 1% DMSO). Cells were 
incubated for 48 h after Endoporter treatment. LPS was added for the last 24 h. C Titration of a 
fluorescein-tagged morpholino transfected with 6 µM Endoporter. D Cross-titration of Endoporter 
concentration and the concentration of a SSO morpholoino targeted against the NLRP3 exon 5. Graph 
shows qPCR analysis of the relative abundance of the NLRP3 ∆ exon 5 after splice induction N=1. E 
Changes in the NLPR3 alternative splicing pattern of hMDMs were induced with an exon 5 SSO. NLRP3 
isoform expression analysis by qPCR. Mean and SEM of 3 (or 2, untreated ctr.) donors. F IL-1β 
secretion of morpholino-treated cells after nigericin-induced activation of the NLRP3 inflammasome (IL-
1β). G TNF secretion after LPS treatment. F and G mean and SEM of 3 donors (2 donors, LPS-only 
ctr.). 
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Morpholinos are a class of DNA analogues with a non-charged backbone, which are 
highly protected against degradation. I made use of morpholinos as so-called splice-
switching oligonucleotides (SSOs), which can direct alternative splicing towards the 
exclusion of an exon by complementary binding and blocking the spliceosomal 
access to the intron-exon boundary (Figure 5-13 A). The intracellular delivery of 
these uncharged oligonucleotides can be achieved by Endoporter, which induces 
phagocytosis and release into the cytosol. First, it was confirmed that Endoporter 
treatment of primary hMDMs had no cytotoxic effects (Figure 5-13 B). Next, the 
cytosolic delivery of morpholinos was controlled using a fluorescein-tagged 
oligonucleotide (Figure 5-13 C). An increased background fluorescent was detected 
with increasing oligonucleotide concentration, probably due to binding to the plastic 
dish. Yet, an intracellular enrichment can be observed with increasing 
concentrations. To analyze the splice-switching effect, different concentrations of a 
NLRP3 intron 4/ exon 5 targeted SSO were applied to hMDMs of one donor (Figure 
5-13 D). The relative abundance of NLRP3 ∆ exon 5 was analyzed by qPCR, 
demonstrating 6 µM Endoporter to be the most effective concentration. Since no 
dramatic difference could be observed between the tested concentrations of SSO, 
the lowest concentration (6 µM) was chosen for all following experiments. 
While Endoporter treatment alone or a control Morpholino did not induce any 
changes in the NLRP3 splice pattern, the specific NLRP3 exon 5 SSO strongly 
induced alternative splicing of NLRP3 ∆ exon 5 across hMDMs of multiple donors 
(Figure 5-13 E). SSO treatment before NLRP3 activation resulted in a nearly 
complete inhibition of the IL-1β secretion, while TNF levels remained unaffected 
(Figure 5-13 F). Of note, some degree of inter-donor differences can be observed, as 
well as a slight background activation for TNF in the non-primed cells, possibly due 
to Endoporter-induced increased phagocytosis. 
Taken together, these results provide evidence for the inactivity of NLRP3 ∆ exon 5 
in primary human cells. 
 
5.3.4. NLRP3 ∆ exon 5 has no inhibitory function on the 
NLRP3 full-length variant 
After establishing evidence for the inactivity of NLRP3 ∆ exon 5, the role of this 
transcript variant remained elusive. A possible role for NLRP3 ∆ exon 5 might be the 
inhibition of full-length NLRP3 when co-expressed. To investigate whether this was 
the case, the NLRP3 full-length expressing iMo cell line was retrovirally transduced  
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Figure 5-14 Generation of iMos co-expressing NLRP3 full-length and ∆ exon 5 in 
different ratios 
A iMos expressing NLRP3 full-length with a fluorescent mCitrine tag were retrovirally transduced with 
NLRP3 ∆ exon 5 with a fluorescent tagRFP tag. The resulting stable cell line was FACS-sorted into 4 
different NLRP3 ∆ exon 5 expression bins (low, low-intermediate, high-intermediate, high), while 
keeping the NLRP3 full-length expression stable. B Flow cytometry analysis of mCitrine (NLRP3 full-
length) and tagRFP (NLRP3 ∆ exon 5) expression levels shown as geometric means of the respective 
fluorescence. C qPCR analysis of the expression of both transduced NLRP3 isoforms. Shown are the 
expression levels as relative abundance of the overall NLRP3. 
 
with NLRP3 ∆ exon 5-tagRFP. The cells were FACS-sorted for 4 different NLRP3 ∆ 
exon 5 expression levels, while keeping NLRP3 full-length expression constant 
(Figure 5-14 A). The desired expression levels of NLRP3 full-length-mCitrine and 
NLRP3 ∆ exon 5-tagRFP expression in the stable cell lines were confirmed by flow 
cytometry (Figure 5-14 B). While a linear increase in tagRFP was detectable across 
the four cell lines, mCitrine levels remained comparable. Since fluorescence 
intensities acquired in different channels are not comparable, NLRP3 transcription 
was analyzed by qPCR (Figure 5-14 C). As intended, the NLRP3 isoform ratio 
ranged from mostly full-length to mostly ∆ exon 5 expression across the 4 cell lines. 
The co-expressing cell lines were primed with LPS and activated for NLRP3 or the 
NLRP1B inflammasome as above. No significant difference in IL-1β secretion could 
be observed with increasing levels of NLRP3 ∆ exon 5 expression (Figure 5-15 A). 
The non-significant increase in IL-1β from low NLRP3 ∆ exon 5 to high-intermediate 
NLRP3 ∆ exon 5 correlates with minimally higher NLRP3 full-length expression 
(Figure 5-14 B) and with a minor, non-significant increase in priming as testified by 
increased TNF levels (Figure 5-15 B). LDH release as a measure for pyroptosis 
could be detected after inflammasome activation, however without any significant 
differences between different expression levels of NLRP3 ∆ exon 5 (Figure 5-15 C). 
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Figure 5-15 NLRP3 ∆ exon 5 has no inhibitory function on the NLRP3 full-length 
variant. 
A IL-1β secretion after activation of the NLRP3 or NLRP1B inflammasome. B TNF priming control after 
LPS treatment. A and B mean and SEM of 3 independent experiments. C Cell death was measured by 
LDH release as surrogate marker for loss of membrane integrity of cells after inflammasome activation. 
Mean and SEM of 3 independent experiments. D Cells expressing low or high levels of NLRP3 ∆ exon 5 
were primed with LPS and stimulated for 2.5 h with ATP in order to induce pyroptosis and speck 
formation. ASC specks were purified from the supernatant and immunoblotted for the presence of 
NLRP3 full-length and NLRP3 ∆ exon 5. Representative of 3 independent experiments. LeuLeu: l-Leucyl 
l-leucine methyl ester, ns: non-significant, two-way ANOVA with Tukey multiple comparison correction. 
 
The same dual expressing cells were used to check whether NLRP3 ∆ exon 5 is 
actively excluded from the inflammasome complex. After prolonged NLRP3 
inflammasome activation with ATP to induce strong ASC speck formation and 
pyroptosis, ASC specks were isolated from the supernatant of NLRP3 ∆ exon 5 low 
and high expressing cells. Purified ASC specks were analyzed by immunoblot to 
detect whether both NLRP3 variants could be detected within NLRP3 specks. 
Although NLRP3 full-length seemed to be predominantly incorporated, NLRP3 ∆ 
exon 5 could be detected as well (Figure 5-15 D).  
In conclusion, NLRP3 ∆ exon 5 seems not to act as dominant negative form to inhibit 
NLRP3 full-length activation. Instead, if highly expressed, it can be incorporated into 
ASC specks. 
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5.4. NLRP3 splicing is regulated on a single-cell level 
After demonstrating that NLRP3 ∆ exon 5 does not act as a regulator of full-length 
NLRP3 when co-expressed, the question of its function remained open. A 
conceivable hypothesis would be that NLRP3 alternative splicing is regulated on a 
single-cell level. This would result in different ‘populations’ with different NLRP3 
activities. 
To analyze NLRP3 isoform expression on single-cell level, LPS-primed, viable 
hMDMs were FACS-sorted into separate wells of 96-well PCR plates. Nearly 200 
cells of each of 3 donors were lysed, cDNA was reverse-transcribed and NLRP3 
isoforms and the housekeeping gene HPRT were pre-amplified in a nested PCR set-
up. Then, expression of NLRP3 isoforms, HPRT and 18S rRNA was analyzed by 
TaqMan PCR (Figure 5-16 A and B). In each of the 3 donors, 4 different NLRP3 
expressing populations were observed: Cells expressing both isoforms, cells 
expressing only one or the other, and cells with no detectable NLRP3 expression. In 
some cells, it was not even possible to detect HPRT expression. This is because the 
transcription process is subject to a burst kinetic. Once a gene locus is activated and 
transcribed, the mRNA level increases in a transcriptional burst and slowly declines 
after the gene locus is inactivated. While the protein product is as well affected by 
theses fluctuations, it is more stable (Figure 5-16 C) 189,190. When analyzing gene 
expression on a pool of cells, the mRNA level of a gene of interest is expressed at a 
stable mean over all cells, as they are not synchronized in their transcriptional burst 
of a given gene. Moreover, the expression of different genes is not necessarily 
synchronized on single-cell level, making it unreasonable to normalize RNA 
 
 
Figure 5-16 NLRP3 splicing is regulated on a single-cell level.  
A Dead cells were discriminated by PI stain. Single, PI-negative hMDMs were FACS-sorted into 
individual wells and lysed. RNA was reverse-transcribed and NLRP3 full-length, NLRP3 ∆ exon 5 and 
HPRT encoding mRNAs were pre-amplified. Transcripts were detected with nested TaqMan assays. 
187 to 192 individual cells per donor were analyzed, each line represents the CT-values of a single-cell. 
B Quantification of the single-cell NLRP3 splice pattern. Shown as the mean of 3 donors from A. C 
Schematic of the burst-kinetic of gene-expressions on single-cell level, resulting in oscillations of 
produced mRNA levels per gene over time.  
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expression. 18S rRNA is an exception and can be used to control for technical 
dropouts. It is expressed several orders of magnitude higher than most other RNAs 
and even more importantly, the RNA itself and not a protein product is the active 
moiety which needs to be stably present in a cell. 
 
After providing evidence for the stochastic expression of NLRP3 isoforms, the next 
question to be addressed was whether this expression pattern correlates with NLRP3 
activity of single human primary cells. To investigate NLRP3 activity on a single-cell 
level, NLRP3 was activated with increasing amounts of nigericin or NLRC4 with PrgI 
in primary hMDMs and the percentage of cells with ASC specks was determined. 
Surprisingly, only a small fraction of cells responded to NLRP3 stimulation, while 
100% of the cells formed ASC specks upon NLRC4 activation (Figure 5-17 A, B). To 
control for a typical NLRP3 activation, the secreted IL-1β was measured by HTRF. 
For better visualization, cells were treated with the caspase inhibitor VX-765 to  
 
 
Figure 5-17 Only a fraction of primary hMDMs can activate the NLRP3 inflammasome 
A and B ASC speck analysis of hMDMs after NLRP3 activation with nigericin and NLRC4 activation with 
bacterial product PrgI. 5 images per well were captured, plotted are means and SD of two replicate 
wells, representative of 4 individual experiments. C Secretion of IL-1β measured in parallel to A/B with 
and without caspase inhibitor VX-765 treatment (ASC speck analysis samples were treated with VX-765 
to prevent pyroptosis) D and E IL-1β ELISpot assay of hMDMs after NLRP3 or NLRC4 inflammasome 
activation. Shown are results from two donors. Assays were performed in technical duplicates. Mean 
and SD of technical duplicates. 
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prevent pyroptosis during ASC speck assays. Since VX-765 would inhibit the release 
of IL-1β, cells for IL-1β detection were treated with and without VX-765 in parallel to 
the ASC speck assay. An IL-1β response in the expected range could be observed 
(Figure 5-17 C). Of note, NLRC4 activation resulted also in a higher IL-1β response 
compared to NLRP3 activation, which was not completely inhibited at the used VX-
765 concentration. While hMDMs were capable of secreting IL-1β, only a minor 
fraction of the cells formed ASC specks. The question remained how many cells 
contribute to the secreted IL-1β. To address this, ELISPOT assays were performed. 
ELISPOT assays capture and visualize a cytokine at the site of secretion, resulting in 
discriminate spots for each activated cell. While again, all cells secreted IL-1β upon 
NLRC4 activation, the number of responsive cells was much lower for NLRP3 
activation, even at later time points and with increased nigericin concentrations 
(Figure 5-17 D, E). Together these findings suggest that NLRP3 as a danger sensor 
is highly regulated in primary human cells, correlating to the observed single-cell AS 
pattern, while NLRC4 as a sensor for microbial infections induces an unbridled 
response. 
 
5.5. NLRP3 ∆ exon 5 does not interact with NEK7 
While the stochastic single-cell NLPR3 isoform expression and NLRP3 activity 
provide a physiological relevance for NLRP3 splicing, the molecular mechanistic 
reason for the NLRP3 ∆ exon 5 inactivity remained to be determined. NEK7 binding 
was demonstrated as a pre-requisite for NLRP3 activation 97–99. To test whether 
NLRP3 ∆ exon 5 was inactive due to the loss of the NEK7 interaction, NLRP3-NEK7 
Co-IPs were performed from iMos using the mCitrine tag to pull down either NLRP3 
full-length or NLRP3 ∆ exon 5. While NLRP3 full-length co-precipitated NEK7, NEK7 
could not be detected in the Co-IP of NLRP3 ∆ exon 5 (Figure 5-18 A). In the 
literature, NEK7 is postulated to bind NLRP3 progressively upon activation 99. 
However, here the interaction could be observed independent of NLRP3 activation. 
Yet the same assay was also performed after NLRP3 activation with nigericin. As a 
further control, treatment with the NLRP3 inhibitor CRID3 was included (Figure 5-18 
B). Regardless of the activation status NLRP3-NEK7 interaction could be 
demonstrated, but only for the NLRP3 full-length variant.  
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Figure 5-18 NLRP3 full-length, but not NLRP3 ∆ exon 5 interacts with NEK7 
A Co-immunoprecipitation (IP) from iMos stably expressing the respective NLRP3-mCitrine variants. IP 
was performed in GFP-trap plates. B as A, but from LPS-primed and nigericin-activated iMos with and 
without treatment with the NLRP3 inhibitor CRID3. WCL – whole cell lysate. 
 
Two hypotheses why NLRP3 ∆ exon 5 is inactive and why it does not interact with 
NEK7 are conceivable: Either, due to the overall shortened LRR, or because exon 5 
is critical for the NEK7 interaction. To distinguish between these two hypotheses, a 
NLRP3 variant containing no exon 5 but a doubled exon 6 was created (Figure 5-19 
A). This was possible due to the high degree of conservation of the LRR exons. As 
before, stable iMo cell lines were created and IL-1β secretion was analyzed after 
NLRP3, AIM2 and NLRC4 activation (Figure 5-19 B). While all cell lines secreted IL-
1β upon AIM2 or NLRC4 activation, NLRP3 ∆ exon 5 and 2x exon 6 could both not 
be activated with NLRP3 stimuli. All cell lines responded to priming with LPS as 
assessed by TNF secretion (Figure 5-19 C). These results suggest that not the 
shortened overall length of NLRP3 ∆ exon 5 LRR but rather the specific absence of 
exon 5 caused the NLRP3 inactivity. 
Assuming that exon 5 acts as the interaction surface for NEK7 binding, is can be 
assumed that the surface exposed amino acids are especially important. Therefore, 
a NLRP3 hybrid variant of NLRP3 full-length and 2x exon 6 was generated. All amino 
acids defining the NLRP3 exon 5 surface according to the structural model were 
mutated to their respective analogues from exon 6 (Figure 5-20 A). IL-1β secretion 
after inflammasome activation was measured, demonstrating the inactivity of NLRP3 
lacking the exon 5 surface, while all cells were capable of IL-1β secretion after AIM2 
or NLRC4 activation (Figure 5-20 B). The TNF response as a surrogate for priming 
was similar for all cell lines under all conditions (Figure 5-20 C). 
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Figure 5-19 NLRP3 ∆ exon 5 is not inactive due to its shortened LRR 
A Models of the NLRP3 LRRs based on the crystal structure of human ribonuclease inhibitor. Shown 
are the LRR model structures and schematics of NLRP3 full-length and NLRP3 ∆ exon 5, as well as an 
artificially created LRR: NLRP3 LRR lacking exon 5 but carrying a duplicate exon 6. R. Brinkschulte 
generated the ribbon models. B Stable iMo cell lines expressing the respective NLRP3 variants were 
created as described above. IL-1β secretion was analyzed after activation of the NLRP3, AIM2 or 
NLRC4 inflammasome. C TNF secretion after LPS treatment. B and C mean and SD of technical 
triplicates N=1. 
 
Introducing as many mutations, even in a highly conserved repeat unit, may cause 
an unspecific loss of functionality, caused by mis-folding of the protein. Therefore, a 
rescue mutation strategy was chosen: Based on the inactive 2x exon 6 NLRP3 
variant, a surface rescue for the residues of exon 5 was generated (Figure 5-21 A). 
Due to the high level of conservation of the LRR exons, the overall physico-chemical 
characteristics of the hybrid isoforms are similar to the wildtype (wt) isoforms (see 
appendix, Table 12-2). Stable iMo cell lines were primed and activated as before. As 
expected, all cell lines secreted IL-1β after AIM2 and NLRC4 activation, but only the 
NLRP3 full-length and NLRP3 2x exon 6 surface rescue variant were responsive to  
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Figure 5-20 The NLRP3 exon 5 surface is relevant for the activity 
An exon 5 hybrid variant, in which all surface amino acids of the structural model were mutated to their 
analogue from exon 6, was created and a stable cell line expressing this NLRP3 variant was generated. 
A IL-1β secretion was analyzed after activation of the NLRP3, AIM2 or NLRC4 inflammasome. B TNF 
secretion after LPS treatment. A and B mean and SEM of 5 independent experiments. 
 
NLRP3 activators (Figure 5-21 B), while all of them were equally primed (Figure 5-21 
C). 
Taken together, these experiments provide evidence that the surface of exon 5 is 
needed for the activation of NLRP3. 
Given that NLRP3 ∆ exon 5 was not capable of interacting with NEK7 and that the 
specific surface of NLRP3 exon 5 is needed for activation, the exon 5 replacement 
mutants from above were used to investigate the NEK7 interaction. NLRP3 Co-IPs 
for the interaction with NEK7 were performed from iMo lysates using the mCitrine tag 
to pull down NLRP3 (Figure 5-21 D). Although the interaction between NLRP3 2x 
exon 6 surface rescue and NEK7 was weaker than between NLRP3 full-length and 
NEK7, a clear increase in interaction was detectable compared to the ∆ exon 5 and 
2x exon 6 NLRP3 variants. It has to be taken into account that in these cell lines 
human NLRP3 interacts with mouse NEK7, which may be sufficient to allow for 
NLRP3 activation, but may be more sensitive to minor structural differences at the 
interaction side than a human-human interaction pair. Therefore, the experiments 
were repeated in 293T cells, which were transiently transfected to express the 
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different NLRP3 isoforms before mCitrine pull-downs were performed. Under these 
conditions, a solid interaction between NLRP3 2x exon 6 surface rescue and NEK7 
could be detected, while ∆ exon 5 and 2x exon 6 NLRP3 variants did not interact with 
NEK7 (Figure 5-21 E).  
Taken together, these experiments map the interaction site of NEK7 to exon 5 of 
NLRP3 and thereby explain why NLRP3 ∆ exon 5 is inactive. 
 
 
Figure 5-21 The NLRP3 exon 5 surface is essential for the interaction with NEK7 
A Schematic and ribbon model of an artificial NLRP3 hybrid LRR based on the crystal structure of 
human ribonuclease inhibitor. Surface residues of exon 5 are shown in red. The model was generated 
by R. Brinkschulte. The LRR lacks exon 5 but carries a duplicate exon 6 in which all surface amino 
acids of exon 5 were rescued. NLRP3-deficient iMos were reconstituted with full-length or the hybrid 
NLRP3-mCitrine variants as before. B IL-1β secretion was analyzed after activation of the NLRP3, AIM2 
or NLRC4 inflammasome. C TNF secretion after LPS treatment. B and C mean and SEM of 5 
independent experiments. D Co-immunoprecipitation (IP) from iMos stably expressing the respective 
NLRP3-mCitrine variants. IP was performed in GFP-trap plates. Representative of 2 independent 
experiments. E As D, but from HEK 293T cells transiently transfected to express the respective NLRP3-
mCitrine variants. Representative of 3 independent experiments. 
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5.6. NLRP3 ∆ exon 5 regains activity after prolonged 
priming 
BLaER1 cells are derived from a human B cell line, and can be transdifferentiated 
into macrophage-like cells 191. In these cells, an LPS-dependent NLRP3 
inflammasome activation was demonstrated independently of the non-canonical 
inflammasome, the so-called alternative inflammasome 105. To rule out non-canonical 
inflammasome activation, these cells were generated in a caspase-4 (the human 
homologue of mouse caspase-11) deficient background. Similar to the NLRP3 ∆ 
exon 5 variant, the alternative inflammasome was described to only exist in human, 
but not in mouse cells 105. To control for an involvement of NLRP3 ∆ exon 5 in the 
alternative inflammasome, NLRP3/caspase-4 double deficient cells were retrovirally 
reconstituted with NLRP3 full-length or NLRP3 ∆ exon 5, both with a C-terminal 
tagRFP (Figure 5-22 A). An isoform-specific qPCR was performed to ensure that 
both cell lines only express the indicated NLRP3 splice variant (Figure 5-22 B). Next, 
the cells were primed for 3 h or for 14 h with LPS before nigericin activation. As 
expected, only NLRP3 full-length cells secreted IL-1β after short priming and 
nigericin activation. The alternative inflammasome activation following 14 h of LPS as 
a sole stimulus was also NLRP3 full-length dependent. Unexpectedly, after 
prolonged priming for 14 h followed by nigericin activation, NLRP3 ∆ exon 5 became 
fully active (Figure 5-22 C). The overall higher levels of IL-1β after 14 h of LPS 
treatment can be explained by prolonged priming as evinced by the higher TNF 
levels after 14 h LPS treatment (Figure 5-22 D). As observed before, LPS treatment 
induced increased metabolic activity, resulting in ‘viability’ values above 100% 
compared to an untreated control (especially after 14 h of LPS). However, after 
inflammasome stimulation and IL-1β secretion, a reduction in viability relative to the 
respective control was observed in the activated cells (Figure 5-22 E). To ensure that 
the secreted IL-1β by NLRP3 ∆ exon 5 cells is not only non-specifically released pro-
IL-1β, but bioactive, cleaved IL-1b, immunoblots were performed (Figure 5-22 F). 
Although pro-IL-1β was detected as well, NLRP3 ∆ exon 5 induced similar levels of 
mature IL-1β secretion after 14 h LPS and nigericin as NLRP3 full-length. Finally, it 
could be shown that the long priming effect is not LPS-specific but could also be 
achieved with the TLR agonist R848 (Figure 5-22 G). Taken together, these findings 
suggest an unexpected role for NLRP3 ∆ exon 5 as an inflammasome sensor 
allowing a delayed response. How the NLRP3 ∆ exon 5 splice variant overcomes the 
NEK7 dependency remains to be addressed by further studies. 
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Figure 5-22 NLRP3 ∆ exon 5 regains activity after prolonged priming 
Human BLaER1 caspase-4/ NLRP3 double-deficient cells (a kind gift from M. Gaidt, V. Hornung) were 
virally transduced to express either NLRP3 full-length or NLRP3 ∆ exon 5, both with a C-terminal 
tagRFP. Stable cell lines were FACS-sorted for equal NLRP3 expression. A Immunoblot of NLRP3 to 
verify comparable expression levels of both isoforms. B Isoform-specific qPCR to verify the exclusive 
expression of only the respective NLRP3 isoform in both cell lines. C to E BlaER1 cells were 
transdifferentiated into macrophages and primed either for 3 or 14 h with LPS before stimulation with 
nigericin. C IL-1β secretion after nigericin stimulation. Mean and SEM of 7 independent experiments D 
TNF secretion after LPS priming. Mean and SEM of 6 independent experiments. E CTB assay to 
determine the viability after inflammasome activation. Mean and SEM of 5 independent experiments. F 
Immunoblot of mature and pro-IL-1β from lysates and supernatants after indicated activations. 
Representative of 2 independent experiments. G IL-1β secretion after short and long priming with R848 
followed by nigericin activation. Mean and SEM of 3 independent experiments (3 h: 1 experiment). 
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6. Discussion 
Alternative splicing is a key mechanism driving diversity of the proteome, especially 
but not exclusively in higher eukaryotes. Since proteins are key molecules that 
contribute to the cell structure, act as molecular machines to generate lipids, nucleic 
acids and metabolites and coordinate nearly all cellular functions, AS can 
dramatically influence cell identity and cell specific functions. Alternatively spliced 
proteins can vary in their domain composition and sub-cellular localization. Different 
isoforms of the same gene can even act like unrelated proteins and are frequently 
characterized by significantly different interaction profiles 161. These transcriptional 
alterations provide additional functional diversity from a limited genome allowing for a 
much faster diversification, specialization and adaptation than classical mutagenesis 
driven evolution.  
The work described here shows the conservation of a spliceable LRR motif across 
multiple gene families and how AS influences the innate IS. Surprisingly, alternative 
splicing of NLRP3 could only be detected in human, but not in mouse or pig cells. 
The most prevalent alternative splice variant of NLRP3 lacks exon 5 and is not 
activatable by commonly used NLRP3 activation protocols. It is only after a 
prolonged priming phase of more than 10 h that NLRP3 ∆ exon 5 suddenly gains full 
activity. Furthermore, it was shown that NLRP3 exon 5 is an integral component of 
the NLRP3-NEK7 interaction interface and loss of NEK7 binding was accompanied 
by loss of NLRP3 activity. NLRP3 isoform expression was shown to be stochastic at 
single-cell level, most likely contributing to the low number of NLRP3 responsive 
human primary cells. Together with the gain of activity after prolonged priming, this 
suggests that NLRP3 ∆ exon 5 expressing cells act as a backup population, which 
does not immediately succumbs pyroptosis, but rather allows for a sustained 
inflammatory response. 
Although many new insights have been gained over the last decade in the field of 
inflammasome research, most work is performed in mouse models. We have only 
started to decipher the functional and regulatory differences between the mouse and 
human inflammasome 105,106,192. The species differences between mouse and human 
NLRP3 reported here indicate the importance of NLRP3 studies performed in 
(primary) human cells to discover all regulatory levels of human NLRP3 activation. 
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6.1. LRR domains of the NLR family have a conserved 
multi-exon organization suitable for AS 
Although TLRs and NLRs both contain LRRs, they belong to different subfamilies 
and are more closely related to other non-immune genes than to each other 76. While 
the other functional domains of NLRs are usually encoded by single exons, most of 
the LRR domain is encoded by a repetitive exon pattern 193. The LRR region of 
NLRPs is characterized by alternating 28 and 29 amino acid stretching LRRs with 
one exon encoding two repeats, while in NODs one exon encodes one repeat of 28 
residues. This repetitive exon structure is not present in TLRs, in which the LRR is 
encoded by a single exon 76. This is in line with the exon-LRR relationship, which 
was observed in the structural alignments presented here (Figure 5-2, Figure 5-3, 
appendix Figure 12-1). The LRR pattern in NLRP3 is very suitable as a target for AS, 
since the exon length of 171 nucleotides prevents AS-induced frame shifts. 
Moreover, the exon-exon boundary is always located within the same position of the 
β-strand of the LRR, making it unlikely to destroy the three-dimensional structure. 
The here detected exons, which mostly encode for either 24 or 28/29 aa LRRs, 
represent LRR modules which were identified as ideal self-compatible building blocks 
to create well-folded protein structures when repeatedly stacked 194. Together, these 
two findings suggest that spliceability of NLR LRR-exons comprises an evolutionary 
benefit and that AS of LRR modules could create diverse protein functions or could 
regulate the activity of human NLR family members. Furthermore, the exon-LRR 
structure relationship, resembles the jawless vertebrate VLR system, which is based 
on the recombination of LRRs 148. The parallels between the jawless vertebrate 
adaptive immune system and the exonic organization of the NLR LRRs may suggest 
a convergent evolution of different classes of immune receptors. 
The in silico approach employed here to detect multiple spliceable LRR encoding 
gene-families is a database approach, and therefore dependent on available 
annotation data (Figure 5-2). LRR motifs are not always automatically detected and 
annotated, especially if the consensus sequence is interrupted or degenerated. 
Therefore, many LRRs are only partially or not at all annotated and consequently not 
picked up in this analysis. For example, the NLRP6 and NLRC5 LRRs are at least 
partially encoded by repetitive canonical exons (see structural alignments, appendix 
Figure 12-1), yet they were not identified as LRR-exons in the databases approach. 
However, the primary aim of this analysis was not to discover all LRR exons, but to 
assess whether spliceable, short, repetitive exons represent a conserved feature.  
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Domain boundaries and exon junctions show a consistently strong correlation, which 
further increases from invertebrates to higher vertebrates 195. On the one hand, this 
correlation allows for genomic exon re-shuffling 196, and on the other hand, it 
facilitates the recombination or deletion of functional units by AS. 
Interestingly, some of the non-NLR LRR-proteins, which were discovered in silico as 
containing small modular LRR exonic structures are indeed reported to encode 
multiple isoforms. As an example, LRRC37 was restricted to the testis in earlier 
evolution, but its expression pattern rapidly evolved in the hominid lineage with an 
increasing diversity of alternative splice forms and higher levels of expression in the 
cerebellum and thymus 197. Similarly, LRR-containing Slit proteins act as synaptic 
adhesion molecules and are involved in axon guidance. A large heterogeneity of Slit 
mRNA could be identified, and multiple Slit protein isoforms are suggested to exist 
with a varying number of LRR units that may regulate their binding properties 198,199. 
Even some NLRs were reported to be alternatively spliced, although to my 
knowledge, AS of the LRR region was never systematically analyzed. Similar to my 
findings for NLRP3, multiple isoforms of NOD2, mostly differing in their LRR, were 
described. The alternative isoforms are inactive for MDP stimulation, but do not 
antagonize the full-length MDP response 200. Similarly, 4 different AS variants of the 
NLRP12 LRR are reported, although the respective data is not shown in the original 
publication 201. Even the original study describing the role of NLRP3 in CAPS 
mentions multiple AS variants within the LRR region, but again, without showing any 
data 202. The importance of AS in context of inflammasomes is further emphasized by 
the existence of up to 4 different ASC isoforms, of which two are LPS inducible and 
act as negative inflammasome regulators72. Moreover, AS has been reported in the 
context of plant R-proteins as a key feature in defense against pathogens and in 
stress situations. R-proteins in plants are structural and functional homologous of 
vertebrate NLRs 171,172. Analogous to the AS mediated removal of the NKE7 binding 
site described in this study, human NLRP3 mRNA can be alternatively 
polyadenylated in order to remove regulatory sites. Consequently, the resulting 
shortened 3’UTR lacks the binding site for the negative regulators miRNA-223 and 
tristetraprolin 173. 
 
From the data presented in this thesis and related publications, AS of the LRR region 
appears to be a conserved feature to create functional diversity not only in the 
immune system. However, it is surprising that multiple spliceable LRR exons per 
gene exist, although only a fraction can be detected as alternatively spliced. One 
potential explanation is that AS of other LRR exons happens in a tissue- or 
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environment-specific manner correlating with different functionality, as it is described 
for many genes 203,204. Consequently, potential isoforms and AS of other exons might 
be missed in the approach used here. Likewise, the exon structure, as seen in 
human NLRP3, is conserved in mouse and pig NLRP3, yet AS of the LRR could not 
be detected in mouse BMDMs and pig PBMCs. 
SplicePort and RESCUE-ESE analysis of the NLRP3 LRR support a static, 
sequence-dependent preference for AS of the NLRP3 exon 5 (Figure 5-8). It might 
be possible that the conserved LRR exons are derived from genomic duplication 
events or are conserved to allow for exon shuffling during evolution 195,196 and the 
respective highly repetitive exons were only harnessed later in evolution by AS 
processes. Existing exons can gain AS patterns due to a lower conservation of the 
consensus splice-sites and increased numbers of regulatory splice factors in higher-
order organisms 149. Overall, the species differences in AS underline the importance 
of studies performed in human in vitro systems instead of relying solely on mouse 
model systems. To decipher the evolutionary conservation of AS in NLRs, it would be 
of further interest to also analyze RNA samples of species closer related to humans, 
like monkeys or apes.  
 
6.2. Detection of AS by NGS 
Although databases as Ensemble or NCBIgene list a large number of isoforms for 
many genes, it can not be assumed that all of them are expressed in every tissue or 
cell type at a certain time. For some annotated isoforms, it is even questionable 
whether they play any physiological role.  
As the focus of this thesis is not the detection of alternative splicing events using 
bioinformatics approaches, I decided, together with our bioinformatics collaboration 
partners, to stick to a conservative approach, which rather focuses on exon skipping 
than transcript calling. The sashimi plots205 presented in Figure 5-4 (and appendix, 
Figure 12-2) show the read distribution across a gene of interest and highlight exon-
spanning reads as arcs. Arcs joining non-adjacent exons give a good intuitive 
impression on AS events. Quantification of AS events is possible, but should be 
treated with caution because it relies on an equal read distribution within a library. As 
it can be seen in Figure 5-4, read distribution within one long stretching exon, which 
cannot be affected by AS, can still vary even more than between AS exons. Since 
these coverage biases are mostly derived during library preparation and depend on 
the local sequence environment 206,207, the bias between the highly conserved LRR 
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exons should be smaller than within non-conserved regions. Still, exon-spanning 
reads of adjacent LRR exons show a variability in counts, which cannot be explained 
by AS. Although many approaches have been developed to bioinformatically reduce 
these biases in follow-up quantifications, employing and evaluating these 
approaches would be beyond the scope of this thesis and outside the field of my 
research. Therefore, I decided to rather use the RNAseq-derived results as 
qualitative indicators for AS events than for transcript quantification. 
A promising approach for further analysis of AS would be the use of third generation 
long-read sequencing technologies as PacBio or Oxford Nanopore. Although they 
overcome transcript assembly issues by covering a whole transcript in one read, they 
are much more limited in the number of generated reads and suffer from comparably 
high sequencing error rates 208. 
 
6.3. NLRP3 splice ratios are non-variable 
To my knowledge, the regulation of exon skipping in NLRs has not yet been 
addressed. The coordination of AS is very complex and in addition to the core 
spliceosome, many additional factors are involved.  
When analyzing the relative expression of NLRP3 full-length, ∆ exon 5, ∆ exon 7 and 
∆ exon 5/7 by qPCR across multiple cell types in a variety of conditions, no 
considerable change in the AS ratios could be observed despite diverse pro- or anti-
inflammatory treatments (Figure 5-7). However, this was not a technical problem 
because the experimental design correctly detected induced splice changes, such as 
the upregulation of ∆ exon 5 NLRP3 after SSO treatment (Figure 5-13 E) and the 
reconstitution of BLaER1 cells with ∆ exon 5 NLRP3 (Figure 5-22 B). 
Although minor changes of a few percent in the AS ratio can be observed between 
different cell types, these are rather derived from individual differences between the 
blood donors than from cell-type or treatment differences. Moreover, minor changes 
in measured splice ratios, even if statistically significant, are considered biologically 
non-significant in the splicing field and only a change of at least 10-20% in AS ratios 
is considered relevant 153. 
The binding of the initial spliceosomal factors, defining the splice site, is a 
probabilistic process determined by the binding energy of a given site. Therefore, the 
splice site recognition represents a stochastic minimization process aiming for a 
global (or local) minimum in binding energy 209. Based on this assumption, a 
mathematical model for the relative abundance of alternative splice variants was 
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developed and validated on simulated and measured RNAseq data. The model 
predicts always one predominant splice variant and mean frequency distributions for 
all variants209. The here measured ratios of the four NLRP3 isoforms fit to the 
calculated mean frequency distributions. Furthermore, the detected differences in 
ESE-binding sites and conservation of the scpliceosomal recognition motifs of the 
splice-donors and acceptors of the NLRP3 LRR exons are most likely shaping the 
observed AS pattern. Since the model does not include the effect of all splice factors 
and provides mean frequency distributions, it does not exclude a differential 
regulation of AS, but explains the surprisingly stable relative expression levels 
between the major and minor isoforms. Of note, further dynamic regulatory 
mechanisms in a specific environmental context cannot be excluded, neither by the 
here analyzed isoform expression levels and sequence-based splice site analysis, 
nor by the transcriptome wide mathematical model. 
 
6.4. NLRP3 ∆ exon 5 remains inactive after standard 
activation 
I could demonstrate the inactivity of NLRP3 ∆ exon 5 after standard priming followed 
by standard activation, non-canonical activation and potassium independent 
activation with multiple readouts covering all levels of inflammasome assembly and 
IL-1β secretion (Figure 5-10 to Figure 5-13). Although this is the first analysis on the 
effect of AS on the NLRP3 inflammasome, two alternative NLRP3 isoforms were 
used before in functional assays. Shortly after the discovery of the NLRP3 gene 
(CIAS1) and the mention of AS in the NLRP3 LRR 202, the NLRP3 variants ∆ exon 5 
and ∆ exon 5/7 (annotated with a different exon nomenclature as exon 4 and 6) were 
tested, without any effect, for their NF-κB-inhibitory activity 210, which was the 
proposed effect of NLRP3 before the inflammasome concept was developed. 
Many key experiments in this thesis were performed with NLRP3-deficient mouse 
iMos, which were heterologously reconstituted to stably express the human NLRP3 
splice variants. The same system was used before 78,85 and findings achieved with 
human NLRP3 in iMos could be recapitulated with mouse NLRP3 reconstitution in 
iMos. Since the investigated NLRP3 splice variant could not be detected in murine 
samples, I decided to only work with human NLRP3 instead of generating artificial 
mouse NLRP3 isoforms. The mouse iMos were used as a model system, but the 
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obtained findings were corroborated by experiments with HEK cells, BLaER1 cells 
and primary hMDMs. 
MRP is an AS variant of the innate signaling adaptor STING and suppresses STING-
mediated interferon signaling. A mouse model of HBV suggests that both STING and 
MRP coordinate the innate and adaptive immune response in concert 170. Similarly, 
splice variants of ASC can suppress Inflammasome formation 72. As NLRP3 ∆ exon 5 
remained inactive for all tested stimuli, an inhibitory function similar to MRP or ASC-c 
was conceivable. However, the mixed reconstituted cell lines expressing both NLRP3 
splice variants in different ratios did not provide any indication for a suppressive 
function of the NLRP3 ∆ exon 5 variant (Figure 5-15). Although non-significant 
differences in IL-1β secretion could be detected between the four NLRP3 co-
expressing cell lines, they correlate perfectly with slightly different expression levels 
of full-length NLRP3 (Figure 5-14 B) and with minimal differences in priming 
efficiency (Figure 5-15 B). Therefore, it is very unlikely that the observed differences 
in IL-1β levels refer to a modulating capacity of NLRP3 ∆ exon 5. 
While NLRP3 ∆ exon 5 was neither activatable after normal priming nor acted as an 
NLRP3 full-length inhibitor, it could be detected in ASC-specks of activated cells 
expressing both splice variants (Figure 5-15 D). Whether this is by PYD-PYD 
interaction after activated full-length NLRP3 molecules form a seed for homo-
interactions, or whether NLRP3 ∆ exon 5 just binds non-specifically to the ASC 
protein aggregate needs further investigation. 
Together, the findings show that NLRP3 ∆ exon 5 has no inhibitory capabilities over 
full-length NLRP3. 
 
6.5. NLRP3 exon 5 is critical for the interaction with 
NEK7 
Three independent studies identified NEK7 as an interaction partner of NLRP3, 
which is necessary for NLRP3 inflammasome activation 97–99 The interaction surface 
could be localized to the NLRP3 LRR and the catalytic domain of NEK7, although its 
catalytic activity is dispensable 99. 
In the experiments presented here, I could show that NEK7 binding to NLRP3 
specifically requires the surface of NLRP3 exon 5, and that the NEK7-NLRP3 
interaction correlated with NLRP3 activatability (Figure 5-18 to Figure 5-21). I could 
detect a stable interaction between NLRP3 and NEK7 already in non-activated cells. 
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In my hands, the NLRP3-NEK7 interaction was not highly strengthened in activated 
cells and pretreatment with the NLRP3 inhibitor CRID3 did not affect the NLRP3-
NEK7 interaction. This places the NLRP3-NEK7 interaction upstream of NLRP3 
activation and inflammasome formation and indicates that the mechanism of NLRP3 
inhibition by CRID3 is independent of NEK7. 
According to the literature a weak NLRP3-NEK7 interaction can be observed under 
steady-state conditions and an enhanced interaction after NLRP3 activation in 
mouse macrophages 99. The authors claim that K+ efflux in primed cells initiates the 
interaction between NLRP3 and NEK7, nominating NEK7 as the missing integrator of 
the highly diverse NLRP3 activators 99. This is partially in contrast to the here 
observed NLRP3-NEK7 interactions independent of NLRP3 activation. However, 
several reported findings also support the NLRP3-NEK7 interaction upstream of 
NLRP3 activation. First, the increase in interaction was only observed when NLRP3 
was immunoprecipitated, and not when NEK7 was immunoprecipitated 99. Second, 
experiments with mouse NLRP3 R258W (corresponding to the human CAPS 
mutation R260W) demonstrated a NEK7 requirement for activation, but no K+ efflux 
99. Third, overexpressed NLRP3 mutants bound NEK7 solely dependent on their 
intrinsic activity 97. Forth, all cell lysates and IPs were generated under K+-free 
condition in the publication suggesting NEK7 as the activator downstream of K+ efflux 
99. However, if the interaction between NLRP3 and NEK7 were solely dependent on 
the drop in K+ levels, one could also expect an interaction in the non-activated 
conditions. Together, the above-mentioned and my results suggest that NEK7 
binding is a necessary prerequisite for NLRP3 activation which occurs upstream of 
the activation process. 
One limitation of this study is that some results are based on human NLRP3 
expressed in mouse iMos. Human NLRP3 and endogenous murine NEK7 might not 
be ideal interaction partners. Yet, all active NLRP3 variants demonstrated interaction 
with NEK7, while all inactive variants did not. Although NLRP3-NEK7 interaction 
strength was reduced in the NLRP3 2x exon 6 surface rescue variant in iMos, a 
comparable level of interaction could be shown between NLRP3 full-length and 2x 
exon 6 surface rescue in HEKs (Figure 5-21 D and E). A possible explanation is that 
the interaction surface between human NLRP3 and human NEK7 is evolutionarily 
better fitted than between human NLRP3 and mouse NEK7 and therefore tolerates 
minimal structural changes, which might occur in the artificial NLRP3 2x exon 6 
surface rescue variant. 
I cannot prove that the generated artificial NLRP3 variants (Figure 5-19 to Figure 
5-21) fold perfectly into the natural NLRP3 secondary structure. However, based on 
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the perfect building block architecture of the human NLRP3 exons 194, the high 
degree of exon conservation (Figure 5-3), the stable expression in generated cell 
lines (Figure 5-21 D), the similar physico-chemical properties (appendix, Table 12-2), 
the fit to the LRR model (Figure 5-19 A and Figure 5-21 A) and the activity rescue of 
the 2x exon 6 surface rescue variant (Figure 5-21), it is very likely that the NLRP3 
secondary structure is not affected by the introduced mutations.  
In summary, the structure-guided surface mapping approach for the NLRP3-NEK7 
interaction provides a molecular mechanism explaining why NLRP3 ∆ exon 5 is not 
responsive to standard NLRP3 activation. 
 
6.6. Single-cell gene expression of NLRP3 splice 
variants 
Single-cell gene expression analysis of NLRP3 full-length and ∆ exon 5 revealed a 
stochastic expression of both splice variants. Of note, it was shown before that 30-
100 single cells provide a reliable and robust measure for the transcriptome of bulk 
cells 211. In this study, I analyzed nearly 200 cells per donor of three donors, 
suggesting that the observed expression pattern reflects the overall expression of 
that donor (Figure 5-16). Four different populations in terms of NLRP3 isoform 
expression were identified in all 3 donors: Only NLFP3 full-length, only NLRP3 ∆ 
exon 5, both NLRP3 isoforms, or neither NLRP3 isoform expressing cells. Yet, the 
number of NLRP3 expressing cells varied between donors. Individual levels of LPS 
response between different donors can explain inter-donor differences in the 
percentage of NLRP3 expressing cells. This is a common phenomenon of primary 
cells from different donors which was observed before in our lab (e.g. Figure 5-7 B), 
but also by others 212. It is not clear how the stochastic expression is regulated. Since 
gene expression on a single-cell level is subject to a burst kinetic 213, one might 
argue that such bursts also cause the observed differences in NLRP3 isoform 
expression. However, both transcript variants are expressed as the same pre-mRNA 
from the same gene locus and are therefore not independent. Thus, a stochastic 
regulation of AS is more likely than an experimental bias caused by the single-cell 
burst kinetics. A monoallelic expression was shown for several genes including many 
cytokines 214,215, but an allele-specific expression is not known to correlate with 
specific isoforms. If NLRP3 splice variants were allele-specifically expressed, a 
single-cell expression analysis could be affected by the burst kinetics. However, the 
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allele-specific expression would already imply a stochastic allele regulation as a pre-
requisite. Therefore, in either case one can assume a stochastic element in the 
expression of NLRP3 splice variants at single-cell level. 
In general, little is known about splice regulation on single-cell level. Expression and 
splicing differences on single-cell level are reported 211 and a few years ago, a large 
study on single-cell transcriptomics in BMDCs showed a bimodal expression and 
splicing pattern in immune cells after LPS challenge 216. However, it was later shown 
that the studied cell population of GM-CSF-derived BMDCs actually consisted of DCs 
and macrophages and that the bimodal response rather reflected the different cell 
types 217,218. Theoretically, the hMDMs used in this study could represent as well a 
mixed population. hMDMs were not generated from a heterogenic population such as 
bone marrow, but from CD14+ selected monocytes, which are much more limited in 
their differentiation capabilities than stem cells. Yet, in vitro generated hMDMs were 
also shown to be phenotypically heterogeneous 219. Nevertheless, it is unlikely that 
different subpopulations contribute to the different splicing patterns on single-cell 
level in this study, as I observed the expression of NLRP3 isoforms in the same fixed 
ratios on multiple cell-lines and other primary cell types (Figure 5-7). Together, a 
stochastic ‘de novo’ AS decision in each cell is more likely than a lineage-dependent 
isoform expression. 
 
6.7. Stochastic distribution of NLRP3 activity in human 
macrophages 
The single-cell gene expression analysis demonstrated that NLRP3 splicing is not 
deterministic, because both NLRP3 full-length and NLRP3 ∆ exon 5 expressing cells 
were detected at the same time. Stochasticity in gene transcription influences the 
variability of cell responses because single cells can behave differently depending on 
the expression of any given gene. To assess whether the stochastic expression of 
NLRP3 might contribute to an adjustable response of cells to danger signals, I 
evaluated whether AS of NLRP3 correlates to the number of cells responsive to 
NLRP3 triggers. I made use of two independent assays to analyze the activation 
status of single cells after inflammasome activation in primary human macrophages. 
While nearly all human macrophages responded to an NLRC4 trigger, surprisingly, 
only a minor fraction of human macrophages responded to NLRP3 stimuli (Figure 
5-17). It is tempting to speculate that AS of NLRP3 contributes to the stochastic 
Discussion 
99 
nature of NLRP3 responses. The stochastic distribution of NLRP3 inflammasome 
activation causes stimulated cells to exhibit large variability in their response to 
danger signals. Since the NLRP3 inflammasome is highly regulated by many feed-
forward as well as negative feed-back loops, stochastic distribution in the 
inflammasome response would allow for fine-tuning of a graded, adjusted response. 
At the same time, different activation thresholds of NLRP3 could be important to 
prevent a coordinated pyroptotic cell death of macrophages in the presence of 
danger signals, which could subject the host to increased susceptibility for infections. 
In contrast, detection of cytosolic bacterial components (e.g. PrgI by NLRC4) most 
likely reflects an infection of the macrophage itself. In this scenario, limiting bacterial 
proliferation within the macrophage by pyroptotic self-removal is favorable and an 
immediate full response is necessary to prevent further spreading of an infection. 
Of course, many factors as NLRP3 expression 78, PTMs 85, NEK7 regulation via the 
cell cycle 97 and others were shown to influence NLRP3 activity, but AS of NLRP3 
defines a new level of NLRP3 regulation. 
 
6.8. Delayed inflammasome assembly by NLRP3 ∆ exon 
5  
Unexpectedly, it was found that NLRP3 ∆ exon 5 could gain full activity after 
prolonged priming. This is independent of the alternative inflammasome, because 
LPS treatment for 14 h alone did not induce IL-1β secretion, but only the combination 
of 14 h of priming followed by canonical inflammasome activation (Figure 5-22). 
Moreover, this effect was not LPS-specific, but could also be achieved with another 
TLR agonist (R848). Although immature pro-IL-1β was also secreted from all cell 
lines after activation, cleaved IL-1β could be detected from NLRP3 full-length and to 
the same degree from NLRP3 ∆ exon 5 expressing cells. To exclude a potential 
cross-contamination of NLRP3 full-length causing the increased activity after 
prolonged priming, I checked the cell lines for their ‘purity’ by NLRP3 isoform-specific 
qPCR. A marginal level of NLRP3 full-length can be detected by qPCR in the 
BLaER1 NLRP3 ∆ exon 5 cell line (Figure 5-22 B). Since the NLRP3 deficiency of 
the parental cell line was achieved by CRISPR/Cas9-mediated genomic modification, 
a functional endogenous NLRP3 expression is prevented by introducing a nonsense 
mutation. This mutation does not prevent the production of endogenous NLRP3 
encoding mRNA. The detected minimal level of NLRP3 full-length mRNA 
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corresponds to the level of NLRP3 full-length mRNA in the parental NLRP3-deficient 
cell line (data not shown) and does not contribute to functional NLRP3 protein, as 
shown by the lack of response to nigericin. 
How NLRP3 ∆ exon 5 gains activity after prolonged priming, and the physiological 
consequences of this activity need further investigation. If the NLRP3 LRR acts as a 
self-inhibiting domain, as shown for NLRC440, NEK7 might stabilize an activatable 
state instead of directly causing inflammasome activation. Indeed, a nonsense 
mutation in NLRP3 exon 4 (R554X) results in the complete loss of the LRR and the 
patient presents an inflammatory FMF/FCAS-like phenotype 220, suggesting that self-
inhibition of NLRP3 is lost. It would be conceivable that beside NEK7 other factors 
might get activated or up-regulated after prolonged priming and are capable of taking 
over the role of NEK7, but act independently of exon 5. One possibility to address 
this question would be a differential mass spectrometry interaction screen.  
The physiological role of the delayed inflammasome assembly of NLRP3 ∆ exon 5 
remains to be determined.  
Possibly, cells which are not immediately responsive for NLRP3 activators act as a 
backup population, which is spared of pyroptosis in the first round of NLRP3 
inflammasome activation. Thereby, NLRP3 ∆ exon 5 contributes to a long-lasting IL-
1β response. In response to danger signals, cells expressing full-length NLRP3 
quickly activate inflammasome signaling and produce a first wave of IL-1β, to recruit 
and activate other immune cells. In contrast, cells expressing NLRP3 ∆ exon 5 can 
respond at a later time point if the danger signals are still present and a second wave 
of IL-1β is required. Through these two waves of response to danger signals, the 
innate immune response can be maintained over a longer period of time and non-
pyroptotic macrophages are still capable of recruiting an adaptive immune response. 
 
6.9. Further implications of NLRP3 splicing 
Beside gene expression and AS, post-translational modifications comprise another 
important layer to modulate the function of proteins. Although the integration of all 
three regulatory layers is not far to seek, little is known about their interplay on a 
global level. Interestingly, for some GPCRs it was shown that AS can influence 
GPCR activity or localization by removing exons which bear crucial PTM sites 221. 
Similarly, AS-mediated removal of PTM sites within NFAT transcription factors was 
shown 221.  
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Of note, mass spectrometry of NLRP3 identified three phosphorylation sites, one of 
which is located in exon 5. However, when mutating the exon 5 phosphorylation site 
to a phospho-mimetic residue (S to D) or to a non-phosphorylatable residue (S to A), 
no changes in NLRP3 activity could be observed 85. Another group reported a 
NLRP3 phosphorylation in exon 7 as a negative regulator of NLRP3 86. It is tempting 
to speculate about a functional connection between these two alternatively spliced 
exons and the detected phosphorylated residues. However, a role for the 
phosphorylation in exon 5 could not be established and due to the low expression 
levels of NLRP3 ∆ exon 7, I did not functionally characterize this isoform. When 
examining a potential relationship between annotated PTM sites 
(https://www.phosphosite.org 222, accessed may 2018) with spliceable NLR-LRR 
exons, no enrichment could be found (data not shown). The overall interplay 
between AS and PTMs is still to be defined and requires further investigation. 
In this thesis, the use of SSOs to induce an inactive NLRP3 variant was 
demonstrated (Figure 5-13). SSOs cannot only be used as research tools, but also 
as therapeutics. For example, they can be used to correct the reading frame by 
inducing AS of certain genes after exon duplications or deletions. Tow SSO drugs 
have been recently approved to treat Duchenne muscular dystrophy and spinal 
muscular atrophy 223,224. Using SSOs to induce the skipping of NLRP3 exon 5 in 
NLRP3-driven diseases might also hold therapeutic potential as an NLRP3-specific 
anti-inflammatory approach. 
 
6.10. Conclusion 
AS is known to significantly contribute to protein diversity and flexibility of the 
transcriptome. In this thesis, I could show that NLRs, but also other LRR domain-
containing protein families, are characterized by an evolutionarily conserved 
modularity of exons encoding for short LRR segments. The exonic organization of 
LRR modules allows for multiple AS events, while keeping the overall domain 
architecture unaffected. Indeed, RNAseq revealed AS of the LRR domain in several 
NLR proteins in human macrophages, most prominently in NLRP3. I focused the 
further analysis on NLRP3 and identified exon 5 as the most prominent alternatively 
spliced exon. Of note, alternative splicing of the NLRP3 LRR seems to be a unique 
feature of humans, which could not be detected in mouse or pig cells, stressing the 
value of studies using human primary cells. 
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I characterized the ∆ exon 5 isoform as a loss of function version of NLRP3 and 
surface mapping analysis determined exon 5 to be critical for NEK7 binding and thus 
for NLRP3 activity. NLRP3 isoform expression was shown to be stochastic at a 
single-cell level and contributes to an adjustable NLRP3 inflammasome response. 
Moreover, NLRP3 ∆ exon 5 was found to gain activity after prolonged priming, 
allowing for the activation of those cells, which were kept in standby in an immediate 
first wave responds. 
 
The findings presented in this study describe a novel, human specific mechanism 
involved in the regulation of innate immunity by shaping the NLRP3 inflammasome 
response. 
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7. List of abbreviations 
aa amino acid 
AIM2 absent in melanoma 2 
AS alternative splicing 
ASC apoptosis associated speck-like protein 
containing a CARD 
ATP Adenosine triphosphate 
BMDM bone marrow derived macrophage 
bp basepair 
CAPS cryopyrin-associated periodic syndrome 
CARD caspase activation and recruitment domain 
cGAMP cyclic GMP-AMP 
cGAS cGAMP synthase 
CI confidence interval 
CIITA class II MHC transactivator 
CLR C-type lectin receptors 
COP CARD-only proteins 
CTD C-terminal heptad repeat domain 
DAMP damage associated molecular pattern 
DNA Deoxyribonucleic acid 
dsRNA double strand RNA 
ELISA enzyme-linked immunosorbent assay 
ERK1 extracellular signal-regulated kinase 1 
ESE Exonic splice enhancer 
FMF familial Mediterranean fever 
GSDMD gasdermin D 
HAMP homeostasis altering molecular processe 
hMDM human monocyte derived macrophage 
hnRNP heterogeneous nuclear ribonucleoproteins 
HPRT hypoxanthine-guanine 
phosphoribosyltransferase 
HTRF homogenous time-resolved fluorescent assay 
IFI-16 interferon gamma inducible protein 16 
IFN interferon 
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IL interleukin 
IL-1R interleukin-1 receptor 
IL-1Ra IL-1 receptor antagonist 
iMo immortalized mouse macrophage 
IP Immunoprecipitation 
IRAK4 IL-1R-associated kinase 4 
IS immune system 
LPS lipopolysaccharide 
LRR leucine-rich repeat 
LT anthrax lethal toxin 
mAb monoclonal antibody 
MAPK mitogen-activated protein kinase 
MHC major histocompatibility complex 
mtDNA mitochondrial DNA 
mTurq mTurquoise 
MyD88 myeloid differentiation primary-response 
protein 88 
NACHT NAIP, CIITA, HET-E and TP1 
NAIP NLR family apoptosis inhibitor protein 
NEK7 never in mitosis gene a related Kinase 7 
NF-kB nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NLR NOD-like receptor 
NLRC NLR family CARD containing 
NLRP NLR family PYD containing 
NOD nucleotide oligomerization domain 
noRT no reverse transcription 
PAMP pathogen associated molecular pattern 
pol II (RNA) polymerase II 
POP pyrin-only proteins 
PRR pattern recognition receptors 
PTM post-translational modification 
PYD pyridine domain 
PYHIN N-terminal PYD and C-terminal DNA binding 
HIN domain containing 
RI ribonuclease inhibitor 
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RIG-I retinoic acid inducible gene 1 
RLR RIG-I-like receptor 
RNA ribonucleic acid  
RNA pol II RNA polymerase II 
ROS reactive oxygen species 
RPKM reads per kilobase million 
SD standard deviation 
SEM standard error of the mean 
snRNA small nuclear RNA 
SR serine-arginine repeat factor 
SSO splice switching oligonucleotide 
STAT signal transducer and activator of 
transcription 
STING stimulator of interferon genes 
T2B type 2 diabetes 
TLR Toll-like receptor 
TNF tumor necrosis factor 
tpm transcripts per million  
TRAF TNF receptor associated factor 
TRIF Toll-/ IL-1R homologous domain containing 
adapter inducing interferon-β 
WCL whole cell lysate 
wt wildtype 
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12.  Appendix 
12.1. NLR LRR alignments 
>NLRP1 
     PTMVVLFRWVPVTDAYWQILFSVLKVTR 
     NLKELDLSGNSLSHSAVKSLCKTLRRPRC 
     LLETLRLAGCGLTAEDCKDLAFGLRANQ 
     TLTELDLSFNVLTDAGAKHLCQRLRQPSC 
     KLQRLQLVSCGLTSDCCQDLASVLSASP 
     SLKELDLQQNNLDDVGVRLLCEGLRHPAC 
     KLIRLGLDQTTLSDEMRQELRALEQEKPQLLIFSR 
 
>NLRP2 
     NLQKMSLQVIKENLPENVTASESDAEVER 
           SQDDQHMLPFWTDLCSIFGSNK 
     DLMGLAINDSFLSASLVRILCEQIASDTC 
     HLQRVVFKNISPA DAHRNLCLALRGHK 
     TVTYLTLQGNDQD DMFPALCEVLRHPEC 
     NLRYLGLVSCSATTQQWADLSLALEVNQ 
     SLTCVNLSDNELLDEGAKLLYTTLRHPKC 
     FLQRLSLENCHLTEANCKDLAAVLVVSR 
     ELTHLCLAKNPIGNTGVKFLCEGLRYPEC 
     KLQTLVLWNCDITSDGCCDLTKLLQEKS 
     SLLCLDLGLNHIGVKGMKFLCEALRKPLC 
     NLRCLWLWGCSIPPFSCEDLCSALSCNQ 
     SLVTLDLGQNPLGSSGVKMLFETLTCSSG 
     TLRTLRLKIDDFNDELNK LLEEIEEKNPQLIIDTEKHHPWAERPSSHDFMI* 
 
>NLRP3 
    SQQIRLELLKWIEVKAKAKKLQIQ 
      PSQLELFYCLYEMQEEDFVQRAMDYF 
     PKIEINLSTRMDHMVSSFCIENCH 
     RVESLSLGFLHNMPKEEEEEEKEGRHLDMVQCVLPSSSH 
     AACSHGLVNSHLTSSFCRGLFSVLSTSQ 
     SLTELDLSDNSLGDPGMRVLCETLQHPGC 
     NIRRLWLGRCGLSHECCFDISLVLSSNQ 
     KLVELDLSDNALGDFGIRLLCVGLKHLLC 
     NLKKLWLVSCCLTSACCQDLASVLSTSH 
     SLTRLYVGENALGDSGVAILCEKAKNPQC 
     NLQKLGLVNSGLTSVCCSALSSVLSTNQ 
     NLTHLYLRGNTLGDKGIKLLCEGLLHPDC 
     KLQVLELDNCNLTSHCCWDLSTLLTSSQ 
     SLRKLSLGNNDLGDLGVMMFCEVLKQQSC 
     LLQNLGLSEMYFNYETKSALETLQEEKP 
     ELTVVFEPSW* 
 
>NLRP4 
     SLRKLCFSVQNVFKKEDE 
          HSSTSDYSLICWHHICSVLTTSG 
     HLRELQVQDSTLSESTFVTWCNQLRHPSC 
     RLQKLGINNVSFS GQSVLLFEVLFYQP 
     DLKYLSFTLTKLSRDDIRSLCDALNYPAG 
     NVKELALVNCHLSPIDCEVLAGLLTNNK 
     KLTYLNVSCNQLDT GVPLLCEALCSPDT 
     VLVYLMLAFCHLSEQCCEYISEMLLRNK 
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     SVRYLDLSANVLKDEGLKTLCEALKHPDC 
     CLDSLCLVKCFITAAGCEDLASALISNQ 
     NLKILQIGCNEIGDVGVQLLCRALTHTDC 
     RLEILGLEECGLTSTCCKDLASVLTCSK 
     TLQQLNLTLNTLDHTGVVVLCEALRHPEC 
     ALQVLGLRKTDFDEETQALLTAEEERNP 
     NLTITDDCDTITRVEI* 
 
>NLRP5 
     IASSFCLQHCPYLRKIRVDVKGIFPRDESAEAC 
     PVVPLWMRDKTLIEEQWEDFCSMLGTHP 
     HLRQLDLGSSILTERAMKTLCAKLRHPTC 
     KIQTLMFRNAQITP GVQHLWRIVMANR 
     NLRSLNLGGTHLKEEDVRMACEALKHPKC 
     LLESLRLDCCGLTHACYLKISQILTTSP 
     SLKSLSLAGNKVTDQGVMPLSDALRVSQC 
     ALQKLILEDCGITATGCQSLASALVSNR 
     SLTHLCLSNNSLGNEGVNLLCRSMRLPHC 
     SLQRLMLNQCHLDTAGCGFLALALMGNS 
     WLTHLSLSMNPVEDNGVKLLCEVMREPSC 
     HLQDLELVKCHLTAACCESLSCVISRSR 
     HLKSLDLTDNALGDGGVAALCEGLKQKNS 
     VLARLGLKACGLTSDCCEALSLALSCNR 
     HLTSLNLVQNNFSPKGMMKLCSAFACPTS 
     NLQIIGLWKWQYPVQIRKLLEEVQLLKPRVVIDGSWHSFDEDDRYWWKN* 
 
>NLRP6 
VKQEALRWVQGQGQGCPGVAPEVTEGAKGLEDTEEPEEEEEGEEPNY 
        PLELLYCLYETQEDAFVRQALC 
     RFPELALQRVRFCRMDVAVLSYCVRCCP 
     AGQALRLISCRLVAAQEKKKKSLGKRLQASLGGG 
       SSSQGTTKQLPASLLHPLFQAMTDPLC 
     HLSSLTLSHCKLPDAVCRDLSEALRAAP 
     ALTELGLLHNRLSEAGLRMLSEGLAWPQC 
     RVQTVRVQLP DPQRGLQYLVGMLRQSP 
     ALTTLDLSGCQLPAPMVTYLCAVLQHQGC 
     GLQTLSLASVELSEQSLQELQAVKRAKPDLVITHPALDGHPQPPKELISTF* 
 
>NLRP7 
     DLQKLSLQVAKGVFLENY 
    MDF ELDIEFERCTYLTIPNWARQDLRSLRLWTDFCSLFSSNS 
     NLKFLEVKQSFLSDSSVRILCDHVTRSTC 
     HLQKVEIKNVTP DTAYRDFCLAFIGKK 
     TLTHLTLAGHIEWERTMMLMLCDLLRNHKC 
     NLQYLRLGGHCATPEQWAEFFYVLKANQ 
     SLKHLRLSANVLLDEGAMLLYKTMTRPKH 
     FLQMLSLENCRLTEASCKDLAAVLVVSK 
     KLTHLCLAKNPIGDTGVKFLCEGLSYPDC 
     KLQTLVLQQCSITKLGCRYLSEALQEAC 
     SLTNLDLSINQIAR GLWILCQALENPNC 
     NLKHLRLWSCSLMPFYCQHLGSALLSNQ 
     KLETLDLGQNHLWKSGIIKLFGVLRQRTG 
     SLKILRLKTYETNLEIKKLLEEVKEKNP 
     KLTIDCNASGATAPPCCDFFC* 
 
>NLRP8 
     TLNFMNVWKLSSSSHPGSE 
           APESNGLHRWWQDLCSVFATND 
     KLEVLTMTNSVLGPPFLKALAAALRHPQC 
     KLQKLLLRRVNSTMLNQDLIGVLTGNQ 
     HLRYLEIQHVEVESKAVKLLCRVLRSPRC 
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     RLQCLRLEDCLATPRIWTDLGNNLQGNG 
     HLKTLILRKNSLENCGAYYLSVA 
     QLERLSIENCNLTQLTCESLASCLRQSK 
     MLTHLSLAENALKDEGAKHIWNALPHLRC 
     PLQRLVLRKCDLTFNCCQDMISALCKNK 
     TLKSLDLSFNSLKDDGVILLCEALKNPDC 
     TLQILELENCLFTSICCQAMASMLRKNQ 
     HLRHLDLSKNAIGVYGILTLCEAFSSQKK 
     REEVIFCIPAWTRITSFSPTPHPPDFTGKSDCLSQINP* 
 
>NLRP9 
     HLTTLRMCVENIFPDDSGCIS 
             DYNEKLVYWRELCSMFITNK 
     NFQILDMENTSLDDPSLAILCKALAQPVC 
     KLRKLIFTSVYFGH DSELFKAVLHNP 
     HLKLLSLYGTSLSQSDIRHLCETLKHPMC 
     KIEELILGKCDISSEVCEDIASVLACNS 
     KLKHLSLVENPLRDEGMTLLCEALKHSHC 
     ALERLMLMYCCLTSVSCDSISEVLLCSK 
     SLSLLDLGSNALEDNGVASLCAALKHPGC 
     SIRELWLMGCFLTSDSCKDIAAVLICNG 
     KLKTLKLGHNEIGDTGVRQLCAALQHPHC 
     KLECLGLQTCPITRACCDDIAAALIACK 
     TLRSLNLDWIALDADAVVVLCEALSHPDC 
     ALQMLGLHKSGFDEE TQKILMSVEE 
     KIPHLTISHGPWIDE EYKIRGVLL* 
 
>NLRP10 
no LRR domain 
 
>NLRP11 
HHMPLFYCLYENREEEFVKTIVDALMEVTVYLQSDKDMMVSLYCLDYCC 
     HLRTLKLSVQRIFQNKEPLIRPTA 
             SQMKSLVYWREICSLFYTME 
     SLRELHIFDNDLNGISERILSKALEHSSC 
     KLRTLKLSYVSTAS GFEDLLKALARNR 
     SLTYLSINCTSISLNMFSLLHDILHEPTC 
     QISHLSLMKCDLRASECEEIASLLISGG 
     SLRKLTLSSNPLRSDGMNILCDALLHPNC 
     TLISLVLVFCCLTENCCSALGRVLLFSP 
     TLRQLDLCVNRLKNYGVLHVTFPLLFPTC 
     QLEELHLSGCFFSSDICQYIAIVIATNE 
     KLRSLEIGSNKIEDAGMQLLCGGLRHPNC 
     MLVNIGLEECMLTSACCRSLASVLTTNK 
     TLERLNLLQNHLGNDGVAKLLESLISPDC 
     VLKVVGLPLTGLNTQTQQLLMTVKERKP 
     SLIFLSETWSLKEGREIGVTPASQPGSIIPNSNLDYMFFKFPRMSAAMRTSNTASRQPL* 
 
>NLRP12 
     SAQVLHLYGATYSADGEDRARCSAGAH 
     TLLVQLPERTVLLDAYSEHLAAALCTNP 
     NLIELSLYRNALGSRGVKLLCQGLRHPNC 
     KLQNLRLKRCRISSSACEDLSAALIANK 
     NLTRMDLSGNGVGFPGMMLLCEGLRHPQC 
     RLQMIQLRKCQLESGACQEMASVLGTNP 
     HLVELDLTGNALEDLGLRLLCQGLRHPVC 
     RLRTLWLKICRLTAAACDELASTLSVNQ 
     SLRELDLSLNELGDLGVLLLCEGLRHPTC 
     KLQTLRLGICRLGSAACEGLSVVLQANH 
     NLRELDLSFNDLGDWGLWLLAEGLQHPAC 
     RLQKLWLDSCGLTAKACENLYFTLGINQ 
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     TLTDLYLTNNALGDTGVRLLCKRLSHPGC 
     KLRVLWLFGMDLNKMTHSRLAALRVTKPYLDIGC* 
 
>NLRP13 
     EVDLNILEDEELQASSFC LKHCK 
     RLNKLRLSVSSHILERDLEIL 
          ETSKFDSRMHAWNSICSTLVTNE 
     NLHELDLSNSKLHASSVKGLCLALKNPRC 
     KVQKLTCKS VTPEWVLQDLIIALQGNS 
     KLTHLNFSSNKLGMTV PLILKALRHSAC 
     NLKYLCLEKCNLSAASCQDLALFLTSIQ 
     HVTRLCLGFNRLQDDGIKLLCAALTHPKC 
     ALERLELWFCQLAAPACKHLSDALLQNR 
     SLTHLNLSKNSLRDEGVKFLCEALGRPDG 
     NLQSLNLSGCSFTREGCGELANALSHNH 
     NVKILDLGENDLQDDGVKLLCEALKPHR 
     ALHTLGLAKCNLTTACCQHLFSVLSSSK 
     SLVNLNLLGNELDTDGVKMLCKALKKSTC 
     RLQKLG* 
 
>NLRP14 
VKQLERTFNCKMSLKIKSKLLQCMEVLGNSDYSPS 
     QLGFLELFHCLYETQDKAFISQAMRCFPKVAINICEKIHLLVSSFCLKHCRC 
      LRTIRLSVTVVFEKKILKTSLPTNT 
            WDGDRITHCWQDLCSVLHTNE 
     HLRELDLYHSNLDKSAMNILHHELRHPNC 
     KLQKLLLKFITFPD GCQDISTSLIHNK 
     NLMHLDLKGSDIGDNGVKSLCEALKHPEC 
     KLQTLRLESCNLTVFCCLNISNALIRSQ 
     SLIFLNLSTNNLLDDGVQLLCEALRHPKC 
     YLERLSLESCGLTEAGCEYLSLALISNK 
     RLTHLCLADNVLGDGGVKLMSDALQHAQC 
     TLKSLVLRRCHFTSLSSEYLSTSLLHNK 
     SLTHLDLGSNWLQDNGVKLLCDVFRHPSC 
     NLQDLELMGCVLTNACCLDLASVILNNP 
     NLRSLDLGNNDLQDDGVKILCDALRYPNC 
     NIQRLGLEYCGLTSLCCQDLSSALICNK 
     RLIKMNLTQNTLGYEGIVKLYKVLKSPKC 
     KLQVLGLCKEAFDEEAQKLLEAVGVSNPHLIIKPDCNYHNEEDVSWWWCF* 
 
>NLRC3 
     ALAYLLQVSDACAQEANLSLSLSQGVLQSLLPQLL 
     YCRKLRLDTNQFQDPVMELLGSVLSGKDC 
     RIQKISLAENQISNKGAKALARSLLVNR 
     SLTSLDLRGNSIGPQGAKALADALKINR 
     TLTSLSLQGNTVRDDGARSMAEALASNR 
     TLSMLHLQKNSIGPMGAQRMADALKQNR 
     SLKELMFSSNSIGDGGAKALAEALKVNQ 
     GLESLDLQSNSISDAGVAALMGALCTNQ 
     TLLSLSLRENSISPEGAQAIAHALCANS 
     TLKNLDLTANLLHDQGARAIAVAVRENR 
     TLTSLHLQWNFIQAGAAQALGQALQLNR 
     SLTSLDLQENAIGDDGACAVARALKVNT 
     ALTALYLQVASIGASGAQVLGEALAVNR 
     TLEILDLRGNAIGVAGAKALANALKVNS 
     SLRRLNLQENSLGMDGAICIATALSGNH 
     RLQHINLQGNHIGDSGARMISEAIKTNAPTCTVEM* 
 
>NLRC4 
     GKSLYINSGNIPDYLFDFFEHLPNCASAL 
      DFIKLDFYGGAMASWEKAAEDTGGIHMEEAPETYIPSRAVSLFFNWKQE 
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     FRTLEVTLRDFSKLNKQDIRYLGKIFSS 
     ATSLRLQIKRCAGVAGSLSLVLSTC 
     KNIYSLMVEASPLTIEDERHITSVT 
      NLKTLSIHDLQNQRL PGGLTDSLGNLK 
      NLTKLIMDNIKMNEEDAIKLAEGLKNLK 
      KMCLFHLTHLSDIGEGMDYIVKSLSSEPC 
      DLEEIQLVSCCLSANAVKILAQNLHNLV 
      KLSILDLSENYLEKDGNEALHELIDRMNVLE 
      QLTALMLPWGCDVQGSLSSLLKHLEEVP 
      QLVKLGLKNWRLTDTEIRILGAFFGKNPLK 
      NFQQLNLAGNRVSSDGWLAFMGVFENLK 
      QLVFFDFSTKEFLPDPALVRKLSQVLSKLT 
      FLQEARLVGWQFDDDDLSVITGAFKLVTA* 
 
>NLRC5 
     LPYQLPFHNFPLTCTDLATLTNILEHRE 
    API HLDFDGCPLEPHCPEALVGCG 
     QIENLSFKSRKCGDAFAEALSRSLPTMG 
     RLQMLGLAGSKITARGISHLVKALPLCP 
     QLKEVSFRDNQLSDQVVLNIVEVLPHLP 
     RLRKLDLSSNSICVSTLLCLARVAVTCP 
     TVRMLQAREADLIFLLSPPTETTAELQ 
     RAPDLQESDGQRKGAQSRSLTLRLQKCQLQVHDAEALIALLQEGP 
     HLEEVDLSGNQLEDEGCRLMAEAASQLH 
     IARKLDLSNNGLSVAGVHCVLRAVSACW 
     TLAELHISLQHKTVIFMFAQEPEEQKGPQERAA 
     FLDSLMLQMPSELPLSSRRM 
     RLTHCGLQEKHLEQLCKA LGGSC 
     HLGHLHLDFSGNALGDEGAARLAQLLPGLG 
     ALQSLNLSENGLSLDAVLGLVRCFSTLQ 
     WLFRLDISFESQHILLRGDKTSRDMWATGSLPDFPAAAKFLGFRQRC 
     IPRSLCLSECPLEPPSLTRLCATLKDCP 
     GPLELQLSCEFLSDQSLETLLDCLP 
     QLPQLSLLQLSQTGLSPKSPFLLANTLSLCP 
     RVKKVDLRSLHHATLHFRSNEEEEGVCCGRFTGCSLSQEHVE 
     SLCWLLSKCKDLSQVDLSANLLGDSGLRCLLECLPQVP 
     ISGLLDLSHNSISQESALYLLETLPSCP 
     RVREASVNLGSEQSFRIHFSREDQ 
     AGKTLRLSECSFRPEHVSRLATGLSKSL 
     QLTELTLTQCCLGQKQLAILLSLVGRPA 
     GLFSLRVQEPWADRARVLSLLEVCAQASG 
     SVTEISISETQQQLCVQLEFPRQEENP 
     EAVALRLAHCDLGAHHSLLVGQLMETCA 
     RLQQLSLSQVNLCEDDDASSLLLQSLLLSLS 
     ELKTFRLTSSCVSTEGLAHLASGLGHCH 
     HLEELDLSNNQFDEEGTKALMRALEGKW 
     MLKRLDLSHLLLNSSTLALLTHRLSQMT 
     CLQSLRLNRNSIGDVGCCHLSEALRAAT 
     SLEELDLSHNQIGDAGVQHLATILPGLP 
     ELRKIDLSGNSISSAGGVQLAESLVLCR 
     RLEELMLGCNALGDPTALGLAQELPQ 
     HLRVLHLPFSHLGPGGALSLAQALDGSP 
     HLEEISLAENNLAG GVLRFCMELP 
     LLRQIDLVSCKIDNQTAKLLTSSFTSCP 
     ALEVILLSWNLLGDEAAAELAQVLPQMG 
     RLKRVDLEKNQITALGAWLLAEGLAQGS 
     SIQVIRLWNNPIPCDMAQHLKSQEPRLDFAFFDNQPQAPWGT* 
 
>NOD1 
     RLTVLRLSVNQITDGGVKVLSEELTKYK 
     IVTYLGLYNNQITDVGARYVTKILDECK 
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Figure 12-1 LRR alignments of all NLRs 
LRR exons are highlighted in alternating grey values. Each line represents one leucine-rich repeat 
(LRR). Conserved residues defining the LRR fold are highlighted in bold. 
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     GLTHLKLGKNKITSEGGKYLALAVKNSK 
     SISEVGMWGNQVGDEGAKAFAEALRNHP 
     SLTTLSLASNGISTEGGKSLARALQQNT 
     SLEILWLTQNELNDEVAESLAEMLKVNQ 
     TLKHLWLIQNQITAKGTAQLADALQSNT 
     GITEICLNGNLIKPEEAKVYEDEKRIICF* 
 
>NOD2 
     NVGHLKLTFCSVGPTECAALAFVLQHLR 
     RPVALQLDYNSVGDIGVEQLLPCLG 
     VCKALYLRDNNISDRGICKLIECALHCE 
     QLQKLALFNNKLTDGCAHSMAKLLACRQ 
     NFLALRLGNNYITAAGAQVLAEGLRGNT 
     SLQFLGFWGNRVGDEGAQALAEALGDHQ 
     SLRWLSLVGNNIGSVGAQALALMLAKNV 
     MLEELCLEENHLQDEGVCSLAEGLKKNS 
     SLKILKLSNNCITYLGAEALLQALERND 
     TILEVWLRGNTFSLEEVDKLGCRD 
       TRLLL* 
 
>NLRX1 
     SLRQLNLAGVRMTPVKCTVVAAVLGSGRH 
     ALDEVNLASCQLDPAGLRTLLPVFL 
     RARKLGLQLNSLGPEACKDLRDLLLHDQC 
     QITTLRLSNNPLTAAGVAVLMEGLAGNT 
     SVTHLSLLHTGLGDEGLELLAAQLDRNR 
     QLQELNVAYNGAGDTAALALARAAREHP 
     SLELLHLYFNELSSEGRQVLRDLGGAAE 
     GGARVVVSLTEG 
TAVSEYWSVILSEVQRNLNSWDRARVQRHLELLLRDLEDSRGATLNPWRKAQLLRVEGEVRALLEQLGS
SGS* 
 
>NAIP 
NLDKFLCLKELSVDLEGNINVFSVIPEEFPNFHHMEKLLIQISAEYDPS 
     KLVKLIQNSP 
     NLHVFHLKCNFFSDFGSLMTMLVSCK 
     KLTEIKFSDSFFQAVPFVASLPNFI 
     SLKILNLEGQQFPDEETSEKFAYILGSLS 
     NLEELILPTGDGIYRVAKLIIQQCQ 
     QLHCLRVLSFFKTLNDDSVVEIAKVAISGGFQ 
     KLENLKLSINHKITEEGYRNFFQALDNMP 
     NLQELDISRHFTECIKAQATTVKSLSQC 
     VLRLPRLIRLNMLSWLLDADDIALLNVMKER 
HPQSKYLTILQKWILPFSPIIQK* 
 
CIITA 
     DLKKLEFALGPVSGPQAFPKLVRILTAFS 
     SLQHLDLDALSENKIGDEGVSQLSATFPQLK 
     SLETLNLSQNNITDLGAYKLAEALPSLAA 
     SLLRLSLYNNCICDVGAESLARVLPDMV 
     SLRVMDVQYNKFTAAGAQQLAASLRRCP 
     HVETLAMWTPTIPFSVQEHLQQQDSRISLR* 
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12.2. Mapping statistics of RNAseq reads 
 Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 
Number of input 
reads 
134943073 16097467 154640058 162862993 176498896 
Average input 
read length 
252 252 252 252 252 
Uniquely 
mapped reads 
123424533 146198305 144276036 149360709 163061729 
Uniquely 
mapped reads % 
91.46% 90.82% 93.30% 91.71% 91.71% 
Average 
mapped length 
245.03 245.74 245.49 245.33 244.5 
Mismatch rate 
per base % 
0.44% 0.42% 0.42% 0.43% 0.43% 
Multi-mapping 
reads 
6119358 9613436 4915572 7108225 5922473 
Multi-mapping 
reads % 
4.57% 6.01% 3.21% 4.39% 3.40% 
Un-mapped 
reads % 
3.97% 3.16% 3.50% 3.90% 4.21% 
Table 12-1 Mapping statistics of RNAseq reads for each donor 
Appendix 
135 
12.3. Sashimi plots 
 
Figure 12-2 Sashimi plots of all expressed genes listed in Error! Reference source not 
found. A  
A RNH1, B NLRP1, C NOD2, D CIITA, E NLRP2, F NOD1 and G NLRP12. 
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12.4. Protein sequences of NLRP3 variants 
12.4.1. NLRP3 full-length 
MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFN
GEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEY
LSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQ
ELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTL
YQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAF
DEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEA
KRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTT
TAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVS
AFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLL
ENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPS
QLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMP
KEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLVNSHLTSSFCRGLFSVLSTSQSLTELDLS
DNSLGDPGMRVLCETLQHPGCNIRRLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNAL
GDFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGV
AILCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEG
LLHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQ
SCLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW 
12.4.2. NLRP3 ∆ exon 5 
MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFN
GEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEY
LSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQ
ELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTL
YQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAF
DEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEA
KRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTT
TAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVS
AFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLL
ENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPS
QLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMP
KEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLGRCGLSHECCFDISLVLSSNQKLVELDLS
DNALGDFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALG
DSGVAILCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKL
LCEGLLHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEV
LKQQSCLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW 
12.4.3. NLRP3 2x exon 6 
MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFN
GEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEY
LSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQ
ELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTL
YQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAF
DEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEA
KRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTT
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TAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVS
AFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLL
ENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPS
QLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMP
KEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLGRCGLSHECCFDISLVLSSNQKLVELDLS
DNALGDFGIRLLCVGLKHLLCNLKKLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALGD
FGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAIL
CEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGLL
HPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQSC
LLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW 
12.4.4. NLRP3 exon 5 surface to exon 6 
MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFN
GEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEY
LSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQ
ELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTL
YQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAF
DEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEA
KRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTT
TAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVS
AFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLL
ENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPS
QLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMP
KEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLGRSGLSHEFCFGLSLVLSTSQKLVELDLS
DNALGDFGMRVLCVTLKHPLCNIKKLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALG
DFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAI
LCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGL
LHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQS
CLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW 
12.4.5. NLRP3 2x exon 6 surface rescue 
MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFN
GEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEY
LSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQ
ELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTL
YQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAF
DEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEA
KRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTT
TAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVS
AFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLL
ENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPS
QLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMP
KEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLVNCHLTSSCCRDIFSVLSSNQSLTELDLSD
NSLGDPGIRLLCEGLQHLGCNLRRLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALGD
FGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAIL
CEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGLL
HPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQSC
LLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW 
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12.5. Physico-chemical properties of NLRP3 isoforms 
and artificial variants 
 
full-
length ∆ exon 5 2x exon 6 
exon 5 
with exon 
6 surface 
2x exon 6 
surface 
rescue 
Sizes (bp) 3108 2937 3108 3108 3108 
No. of amino 
acids 1036 979 1036 1036 1036 
Molecular weight 
(Dalton) 
118172.5
8 
111884.4
2 118181.9 
118170.8
6 
118183.6
2 
^No. of − ve 
charged residue 134 129 135 134 135 
No. of + ve 
charged residue 122 118 124 124 122 
Theoretical pI 6.22 6.24 6.28 6.33 6.17 
Instability index 45.6 45.1 43.53 43.89 46 
Aliphatic index 92.88 92.61 94.86 94.01 93.73 
GRAVY -0.203 -0.213 -0.177 -0.182 -0.198 
Table 12-2 Physico-chemical properties of NLRP3 isoforms and artificial variants 
Physico-chemical characteristics of the NLRP3 full-length, ∆ exon 5 and the three artificial hybrids 
containing a doubled exon 6 but no exon 5, a duplication of all exon 6 surface amino acids on to exon 5 
or a rescue of all surface amino acids of exon 5 on the doubled exon 6 backbone. Values were 
calculated with the ExPASy ProtParam tool. 
  
